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Abstract 
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor that originates from 
mesothelial cells of the pleura, a serous membrane that lines and lubricates the lungs and the 
inside of the rib cage. The main risk factor for mesothelioma is prolonged exposure to 
asbestos. Redox stimuli caused by asbestos trigger to a strong and prolonged inflammation, 
which leads to altered gene expression inducing, inter alia, an increase of antioxidant 
enzymes and glutathione (GSH), and to the selection of cells characterized by proficient 
DNA-repair and anti-apoptotic ability. The interplay of all these mechanisms is at the basis of 
the by intrinsic chemoresistance of MPM.  
An extensive meta-analysis indicated cisplatin, a platinum(II) complex, as the most effective 
single agent for MPM treatment, despite an objective response rate of only 23%. The current 
gold-standard protocols are based on cisplatin combined with the antifolate pemetrexed. 
However, this chemotherapy regimen improves the median overall survival for patients with 
MPM of very few months. Furthermore, the tumor recurrence, due to chemoresistance, and 
the cisplatin heavy side effects limit the therapeutic efficacy.  
For this reason, we carried out several research lines in order to discover novel metal- based 
drug candidates.  
We mainly focused our investigations on platinum(IV) complexes aimed to improve the 
selectivity, the antitumoral activity,  and to bypass the pharmacological resistance to 
Pt(II)-based drugs, as cisplatin, oxaliplatin and picoplatin. It is widely believed that 
reduction from Pt(IV) to platinum(II) is essential for the anticancer activity of these 
complexes, that are otherwise rather inert; therefore, they behave as pro-drugs. Moreover,  
they could be functionalized with several bioactive molecules (obtained the so-called bi-
functional drugs), joining the cytotoxic activity of Pt-based drug with a further biological 
property. 
Since MPM arises from a chronic inflammation, the inducible isoform of cyclooxygenase 
(COX-2) represents a good pharmacological target. Therefore, in a further research line we 
investigated a cobalt-based complex (called Co-ASS), derived from a well-know COX-2 
inhibitor, aspirin. The obtained results showed that the biological activity of the candidate 
drug mainly depends on the cellular context, as it acts as CO-releasing molecule (CO-RM), 
which retains a NSAID effect.  
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The second approach aimed to optimize platinum-based combinatorial chemotherapy, in order 
to reduce cisplatin dosage and therefore, its side effects. 
Apoptosis resistance in MPM cells is ascribed to the overexpression of proteins activating key 
pathways, such as c-myc. Thus, we aimed to drop c-myc expression by means of an 
epigenetic agent, JQ1. We analyzed the pharmacological pattern of the cisplatin-JQ1 
association and investigated the better schedule of treatment.  
 
Furthermore, in order to have more reliable results , we developed a protocol to perform drug 
screening on 3D cellular models (spheroids), that more accurately mimic the conditions of 
the  tumor tissue.  
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Introduction 
 
Exploring general pharmacology 
What is pharmacology? 
Pharmacology (from Greek pharmakon, “drug”, and –logos, “knowledge of”) is a branch of 
science that examines the interactions of bioactive molecules (i.e. neurotransmitters, 
hormones, toxins, small molecules) with living systems, their properties and the mechanisms 
of action through which they elicit biological effects. Bioactive molecules are generally 
defined drugs. 
Pharmacological studies dissect the processes at molecular, subcellular and systemic level; 
these investigations are intended for both therapeutic and non-therapeutic purposes (e.g. 
toxicological studies). Pharmacology has evolved over the years, and nowadays is especially 
focused on drug discovery, the process by which novel drug candidates for treatment and 
prevention of a specific disease are synthesized, and then selected on the basis of their activity 
and safety. Within this scenario, pharmacology shares intimate connections with other 
disciplines including chemistry, physiology, biology, medicine and genetics.  
The pharmacological sciences can be further subdivided in several subgroups, depending on 
the discipline of interest (neuropharmacology, cardiovascular pharmacology, chemotherapy, 
molecular pharmacology etc…) 
Characteristics of drug - receptor interactions 
Usually, drugs are designed or to mimic or to block the physiological action of bioactive 
endogenous molecules. To generate a biological effect, a drug has to interact with its target 
defined receptors, i.e.  macromolecules (usually proteins or nucleic acids) located on the cell 
surface or within the cytoplasm.  
In the broad sense, a molecule that binds to a receptor is called ligand. Ligands bind to precise 
receptive macromolecular regions of the target, called recognition sites or binding sites. 
Ligand binding to a receptor alters its conformation  and modulates its functional status 
leading to changes in biochemical processing or chemical signaling that trigger the biological 
response.  
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The interaction between the ligand and its target molecule mainly involves ionic, 
hydrophobic, hydrogen bonds and Van der Waals forces. The combination of this forces leads 
the molecule to reside in a certain position within the complementary binding region. 
Irreversible covalent bonds are rare in biological systems: for this reason, the classical theory 
of drug-receptor interactions assumes reversible binding at 1:1 stoichiometry based on the 
mass action law (Equation 1): 
 
       
   
                                    
                       
where [R],[X] and [RX] represent the molar concentration of receptor, drug, and receptor-
drug adduct (or complex), respectively, and where it is assumed that the reaction components 
are in dynamic equilibrium (that means the rates at which ligand-receptor adduct is formed 
and dissolved are equal). The ligand-receptor interaction is limited by the available binding 
sites, thus, it is saturable. Kon and koff in Equation (1) represent the rate constants for 
association and dissociation of the ligand-receptor complex, respectively.  
The condicio sine qua non a particular drug-target binding occurs in living organisms, where 
several types of ligands and receptors exist, is the attractiveness of a given molecule to a 
receptor, depending on the strength of the chemical forces between the two species; this 
property is defined affinity. 
The affinity constant (Ka) indicates how the equilibrium (1) is shifted towards the complex 
formation; it means that higher the affinity is, the lower the drug concentration required to 
reach receptor saturation is (Equation 2): 
   
   
    
 
    
      
              
However, the binding affinity is usually defined by the Ka reciprocal, the equilibrium constant 
of dissociation (Kd) (Equation 3): 
   
   
    
 
      
    
              
Kd   is inversely proportional to ligand affinity for the receptor [1].  
From equation (3), with appropriate replacements, it is obtained that the concentration of 
bound drug (B) to the maximal available binding sites (Bmax) is: 
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This hyperbolic dependence (Equation 4) is called binding isotherm or Langmuir isotherm 
and expresses the values of fractional receptor occupancy as a function of drug concentration 
and receptor units occupied (Figure 1).  
 
FIGURE 1. Binding isotherm or Langmuir isotherm: concentration of drug-receptor complex as a function of drug 
concentration (concentration-occupation curve) in presence of a limited number of receptive sites. Bmax correspond to 
asymptote value of the curve. Kd stands for the drug concentration that induces half occupancy of total receptors. A. Linear 
plot (arithmetic scale). B. Same data plotted in semi-logarithmic scale [1]. 
 
As shown in Figure 1, the kinetics of binding is initially fast in keeping with the fact that there 
are many unbound sites for the drug; as the occupancy of receptor population occurs, there is 
a reduction of binding until reaching the maximal value of occupied sites.  
Bmax, corresponding to the asymptote value of the curve, stands for the maximal number of 
binding sites available, whereas Kd represents the concentration at half maximal binding 
(binding to 50% of receptor population) occurred. Langmuir isotherm model was adequate to 
depict and quantify affinity of a molecule for a single class of receptors (namely 
homogeneous receptors) [2]. However, in most cases a receptor exists in more subtypes 
(defined as heterogeneous receptors). Scatchard model is obtained through linear 
transformation of equation (4). Graphically, it plots the ratio of unbound ligand to bound 
ligand versus the bound ligand concentration. The plot depicts a straight line of slope, 
corresponding to -1/Kd, which intercept on X axis is Bmax. As depicted in Figure 2, Scatchard 
model loses linearity in presence of multiple binding sites [3]. 
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FIGURE 2. Scatchard plot. In order to construct this plot, the concentrations of both receptor-bound ligand and free ligand 
are measured, and the ratio of bound to free ligand is plotted against the concentration of free ligand. A. Linear fitting of 
data. The point where the line cuts the X axis represent Bmax, while Kd stands for the value of the slope. If all drug molecules 
bind to a single class of receptors with uniform affinity, all data points will fall on a straight line. B If the plotted line is not 
straight, the binding sites (n) are inhomogeneous and vary in affinity [1].  
As shown in Figure 1, if the curves are expressed in the arithmetic form, the data appear 
“compressed” and it would be difficult to correctly estimate fractional binding at various 
ligand concentration. The semi-logarithmic form is preferred because allows better 
extrapolation of the values, especially Kd, in accordance to the fact that places the midpoint in 
a linear portion of the graph. So, linear data regression models are inaccurate because distort 
experimental error and can be misleading; non-linear fitting plots are preferred because 
guarantee better parameter estimation. It is worth to underline that these considerations are 
not only true in this context, but could generalized for all mathematical models used in 
pharmacology. 
 
Ligand binding affinity for particular receptor/s makes interaction selective and specific; 
selectivity is a property of the ligand, while specificity is a property of the receptor. Selective 
ligands bind preferentially few subtypes of receptors, while non-selective ligands bind to 
several types of targets. Selectivity plays an important role in pharmacology, because non-
selective drugs tend to generate heavier side effects. 
Specificity measure the discrimination of a receptor against other for a ligand binding and is 
determined by its spatial geometry. Non-specific drug binding also occurs (i.e. to plasma 
protein molecular sites), preventing the drug from binding to the desired target and prohibits it 
to exert its therapeutic effect [4]. 
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Agonism and antagonism 
Depending on the type of induced response, a drug is labeled with different denomination.  
A molecule that  binds to a receptor, alters its functional state and stimulates a functional 
activity is called an agonist. The bioactive molecule could be a full agonist, which leads to the 
maximal possible response in the system under study (=1), or a partial agonist (0 <  < 1), 
i.e. an agonist that under specified conditions does not elicit an effect as large. Finally, inverse 
agonist is a molecule that may actively reduces basal response. The binding sites for a drug 
may be the same or different from that of an endogenous agonist (hormone or 
neurotransmitter). Agonists that bind to a different site on a receptor are sometimes called 
allosteric agonists. 
 
A compound that reversibly binds to a receptor and preventing binding with its own ligand, is 
called antagonist ( = 0). Consequently, an antagonist inhibits or lowers the full response 
induced by drug.  
There are several forms of antagonisms: competitive, non competitive and uncompetitive. 
 
In competitive antagonism, antagonist “competes” with agonist for common binding site (so-
called orthosteric) placed on the same receptor. Displacement of the agonist from its receptive 
unit lows its potency and, therefore, shifts concentration-response curve to the right. It is also 
known as surmountable antagonism, because if given at higher concentration, agonist will 
increase the number of occupied sites. 
Because simultaneous binding of both ligand it is no possible, classic competitive antagonism 
is defined mutually exclusive. 
At the contrary, non competitive antagonism is called mutually inclusive, because both 
species may interact simultaneously with their respectively receptive sites (known as 
allosteric sites); antagonist interaction prevents conformational changes in receptor, required 
to elicit a response, after agonist binding one its active sites. Unlike competitive antagonism, 
non competitive one depresses the magnitude of maximal response in a non surmountable 
way. 
Lastly, in the uncompetitive antagonism, an antagonist requires receptor activation by agonist 
binding [1] [5]. 
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Relationship between drug-receptor and pharmacological response  
Intrinsic efficacy and affinity 
Binding of a molecule with another receptive molecule is not sufficient to trigger a biological 
response: the interaction of the two species have to be processed in various way through a 
cascade of biochemical reactions ending to an observable functional effect. Indeed, a drug 
bound to a receptor site possesses pharmacological activity only if perturbs processes that 
regulate the physiologic equilibrium of the system by means of stimulation or blockage of the 
target.  
The pharmacological activity of a drug is defined by two parameters: efficacy and potency.  
Efficacy is the degree at which a drug activates receptor and prompts to a cellular response. 
The receptor occupancy model, suggested by A.J. Clark in 1940s [6], was one of the firsts  
attempts to explain the relationship between ligand-receptor interaction and the 
pharmacological response. It argued that the magnitude of the observed effect is directly 
proportional to the grade of receptor occupancy (and therefore, to drug-receptor complex 
concentration) and that the maximal response would be elicited once all receptors were 
occupied at equilibrium. With the introduction of the concept of intrinsic activity () by 
Ariëns in 1960s, the biological effect was expressed as a product of occupancy and intrinsic 
activity of the drug (Equation 5): 
 
                                                       
          
      
  
 
This theory was further revolutionized by Stephenson [7], who introduced the concept of 
intrinsic efficacy     (Equation 6), stating that efficacy is a molecule-related property, 
because different ligands have different capabilities to induce pharmacological effect, with 
various magnitude, trough a biological stimulus (the so-called stimulus-response 
relationship). 
  
          
      
                 
 
This theory explained how a drug can elicit the maximal response without full receptor 
saturation [7]. 
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Lastly, in 1990s Black and Leff introduced the revolutionary operational model, which states 
that the stimulus-cascade response is a hyperbolic relationship, without taking in account any 
intrinsic parameter referred to the drug [8].  
 
The other drug parameter, potency, is the amount of a drug required to elicit an effect of 
given intensity. This parameter is used to compare biological activity of a series of drugs. 
Bioactive molecules differ in potency and maximum efficacy. These are two inter-dependent 
parameters: drugs combing with the same targets could share similar potency but show 
different efficacy (and vice-versa). Potency is indicated by drug concentration (or dose) 
causing 50% inhibition of a biological or biochemical function: in in vitro assay, IC50 or EC50 
(“C” stands for concentration) are used, while in in vivo experiments ED50 (“D” stands for 
dose) is employed [1]. These parameters are calculated by means of concentration-response or 
dose-response curves.  
Hill function and dose-response curves 
The original Hill equation was first introduced by A.V. Hill [9] to describe the equilibrium 
relationship between oxygen tension and the saturation of hemoglobin, indicating y as the 
observed saturation, x as the free ligand concentration and relating K to an equilibrium 
association constant (Equation 7): 
  
   
     
              
The power n designs  the Hill Coefficient, that is a parameter equal to the number of binding 
sites on receptor; it is also called  Hill Coefficient of sigmoicidity, a value that describes the 
slope of the curve. 
The pattern of ligand interaction is called cooperativity. For: 
 n>1, binding of a molecule ligand increases the receptor's apparent affinity, and hence 
increases the chance of another ligand molecule binding (positive cooperativity); 
 n<1, once that one molecule ligand is bound to the target, its affinity for other ligand 
molecules decreases (negative cooperativity); 
 n=1, binding of a molecule ligand  doesn’t influence receptor interaction with another 
ones (non cooperative binding).  
In his experiment, Hill observed that the hemoglobin saturation against oxygen tension gave a 
hyperbolic rectangular concentration-response relation, that resembles positive cooperative. 
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On the rational basis of the receptor occupancy theory, Hill gave the following general 
equation (Equation 8): 
 
     
 
 
   
 
      
              
Where y is the total fractional occupancy, factor ar is the maximal fraction of receptive units 
with a number of r ligands bound, and Kr is the association constant for ligand binding with 
(r-1) ligands already bound. 
Since its first introduction, because its effectiveness in fitting experimental data, Hill’s 
equation was modified and transformed into several equations widely used in order to 
describe the effect derived from several biological processes, such as enzymatic activity, 
cellular growth and the biological response to the drugs, that are non-linear and saturable 
relationships [10]. 
Linearizing Hill equation (Equation 8) by means of logarithmic transformation of both x and y 
parameters, Equation 9 is obtained, also  known as the median-effect equation [11]. It 
describes a straight line having slope of n and a intercept at ordinate axis of nlogK. The term 
“log[y/1-y]” is called the “logit” and linear plots of Equation 9 is called “logit” plot. 
    
 
   
                           
However, this linearization decreases the accuracy of estimation of the parameters, since the 
line is rarely straight and its the slope of is deeply influenced by the extreme values of both 
parameters.  
Usually, the resultant effect (y) is represented as a fraction of maximum effect (i.e.       ) 
or a percentage of maximum effect      (the full range of response that can be affected by 
the drug)[10] [12]. At the same time, if x is substituted by C, the drug concentration at time t, 
the value K, representing the flex of equations 8 and 9, represents is the drug concentration 
corresponding to 50% of maximum effect, namely the      value.        might also be 
log(IC50). Therefore, this equation describes the concentration of drug required to bind a 
receptor to produce a functional effect.  
Therefore,  the previous function is transformed in the follow general Hill equation: 
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When n=1, as in a simple binding isotherm, or a first-order enzyme kinetics, the graphical 
representation of the data is a rectangular hyperbola (Figure 3A). The semi-logarirthmic 
transformation of the x value data (drug concentration, C) yields to  sigmoidal curves with 
symmetric shape. However, when n≠1, high-order of kinetics curves are obtained, described 
by Hill equation (Figure 3C).  
 
 
FIGURE 3. Examples of binding curves. The dependent variable, fractional response (%), is a function of drug concentration 
(independent one). A. “Load” is referred to a general binding isotherm or an enzymatic activity having first-order kinetics. 
Its semi-logarithmic transformation yields to (B) sigmoidal curves with symmetric shape. C:Hill equation is a hyperbolic 
rectangular dose-response relation, that describes the response of a system having multiple binding sites or higher-order of 
kinetics. The different binding sites and described by Hill coefficient n, also called  Hill Coefficient of sigmoicidity  D: Semi-log 
(“logistic”) fitting of Hill curves , that  display sigmoidal curves with symmetric shape [12]. 
Within this context, the most commonly used equation is a semi-log reversed Hill, so-called 
“logistic” function (Equation 11): 
   
 
                  
               
The expression “logistic” stands for logit (semi-log)  plotting of data, because of logarithmic 
transformation of the axis for the independent variable x. Graphically, semi-log fitting of the 
data displays sigmoidal shape curve with slope indicated by n. 
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The function  that describes the biological responses evoked by drugs are known as 
concentration-response (if performed in vitro) or dose-response (if performed in vivo) curves. 
However, often the term “dose” is used to be employed as synonymous of “concentration”, 
although in a improper way. 
Dose-response curves are the basis of pharmacology, since they describe drug activity 
evaluating response observed at molecular, cellular or tissue level as a function of the 
logarithmic dose of an active molecule. In Figure 4, sigmoidal curves with asymmetrical 
shape of the fitting of the data are depicted: a growth curve (Figure 4a) and a dose-response 
curve (Figure 4b). In Figure 4b, the magnitude of maximal asymptote stands for the intrinsic 
efficacy of the molecule, while the location of the curve along the concentration axis 
establishes its potency. IC50, or EC50, (i.e. the half maximal inhibitor concentration), is the 
parameter used to compare the potency of several tested drug and stands for the inflection 
point of the curve. Briefly, while efficacy is a relative measure on the concentration scale, 
efficacy is a relative measure on the response scale.  
 
FIGURE 4. A. Example of a growth curve, that resemble a sigmoidal curve. B. Sigmoidal dose-response curve of a drug that 
affect cell viability [13]. 
Analyzing the pharmacological effect of drugs interactions 
Why drug combination?  
The resultant effect of a  combination of two or more agents may be defined as: 
 additive, if it is the same as the sum of the individual effects; 
 synergistic, if it is greater than the sum of the individual effects; 
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 antagonist, if one drug counteracts the physiological action of the other one, 
diminishing its effect. 
In pharmacology, the most favorable outcome is the synergy, because it offers several 
therapeutic benefits: 
 increasing the efficacy of the therapy; 
 decreasing the dosage, ensuring the same efficacy but minimizing the adverse effects 
of the individual agents; 
 reducing the development of drug resistance. 
 
A plethora of medical conditions is often treated with combination therapy, especially 
infectious diseases and cancer (polychemotherapy). Drug association is necessary when 
therapeutic response after monotherapy is not expected or is not so beneficial. In fact, 
anticancer polychemotherapy is the standard regimen to cure all tumors. 
Therefore, during the past century several mathematical theories were developed to analyze 
the biological effects of combinations of drugs applied simultaneously o sequentially, in order 
to identify the best therapeutic regimen, to optimize the treatment schedule and to define the 
optimal dose ratios.  
The application of these models allowed the optimization of the costs of experiments, to avoid 
useless ones and to minimizing use of laboratory animals.  
Moreover, it should be reminded that the mathematical models solved the problem that the 
pharmacological outcome of a combination is not a simple sum of effects. For example, if 
drug 1 and drug 2 each inhibits 70%, then the combined additive cannot be 140%. 
Unfortunately, mathematical models that analyze the effect resulting from a drugs 
combination per se are unable to explain how and why the underlying mechanisms ascribed to 
pharmacological effects occurs.  
Among the available models, great dissonance exists. It is possible to generate widely 
different conclusions if different methods are applied to the same data set. Moreover, some 
methods are considered questionable and inaccurate.  
To analyze pharmacological effect of drugs combination, additive interaction was 
conventionally established as standard reference in order to discriminate between synergy and 
antagonism.  
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Webb model and Bliss independence criterion   
Webb states that the additive effect for a  combination of drug 1 (dose = 1) and drug 2 (dose = 
2), is given by the product of their fractional activities (Equation 12): 
 
                        
 
Webb model is based on the assumption that the two drugs act in a indipendent way, that 
means that they do not cooperate with each other (i.e. have different modes of action), but 
each one contributes to a common result. However, Webb model does not consider the slope 
of dose-response curves of both drugs combination and single drugs [14]. 
 
Bliss independence model  is based on the idea of probabilistic independence too. It states that 
the combined effect for two drugs was formulated as a sum of the fractional effect for each 
individual agent minus their product. For the combination of drug 1 (dose = 1) and drug 2 
(dose = 2) , the fractional response  f of the combinations is expressed by Equation 13: 
 
                               
 
Positive or negative values from Bliss prediction describe synergistic and antagonistic 
interactions, respectively. 
Graphically, it generates an isobologram called non-interaction surface that defines the 
additivity effect [15]. 
Bliss independence is a simplicist model, derived only from the potency and efficacy 
information obtained from dose-effect relationship. It may be properly applied to mutually 
non-exclusive drugs. Finally, it does not offer a reliable measure of the intensity of interaction 
and often misleads into data analysis. In particular, these model leads to a possible synergy 
overestimation when the dose-response curves are steep (cooperativity coefficient > 2) [16].  
Loewe additivity model 
Loewe additivity model is based on an assumption that is the opposite to the Bliss 
independence criterion: all the drugs in a mixture acts on the same biological target (mutually 
exclusive drugs). Graphical representation of Loewe additivity model is an isobologram, 
which is a cartesian plot having the doses of two drugs as the axis values. The straight and 
parallel lines, connecting the individual  doses of drugs that yield the same and specific effect, 
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are so-called  lines of additivity (or non-interaction surface), or isoboles.  Their linearity is 
based on the assumption of fixed-ratio dose (known also as constant dose ratio, dose 
equivalence or interaction index), that means that the ratios between the equally effective 
doses of the drugs ever gives the same and specific value. So, every dose pairs defines 
exclusively one isobole. Therefore, the general equation of Loewe additivity assumes that, for 
a combination of drug 1 and drug 2: 
 
  
     
  
  
     
                 
 
The  term (Dx) stands for the effect x triggered by the drug D in single treatment, whereas in 
the numerator D indicates the concentration of the drug in the drug combination  that induces 
the same effect. 
Applying the concept of fixed-ratio dose the relative potency of both drugs is kept constant.  
After the determination of additive isobole, it is possible to assess both antagonist and 
synergistic interactions of the mixture. Antagonism (also called  subadditivity) and synergy  
(also defined superadditivity) are indicated when combination data points are located above or 
below the line, respectively [17] (Figure 5).  
 
FIGURE 5. The isobologram plot. Each axis represents the doses of drugs 1 and drug 2 that “alone” induce a specific effect 
(20 and 100, respectively). Matching these intercept points, the additivity line is obtained, which represents all dose pairs 
that, based on drug potencies, should give the same effect. An actual dose pairs denoted as Q is superadditive (or 
synergistic), whereas R is subadditive (or antagonist) [18]. 
It should be noted that Loewe’s isobologram shows a lot of weakness. First, it has limited 
application since it is suitable for mutually exclusive drugs only. Despite of the simple  visual 
display of data,  it is a fallacious and empirical method because it lacks any statistical 
precision, and it offers a rough measure of the type of interaction. It was demonstrated that it 
could give to distorted lines.  
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Combination Index (CI) and dose reduction index (DRI) 
In 1960s Chou, a pharmacology Ph.D graduate student,  derived the Michaelis-Menten 
equation (i.e. the equation that describe the first-order enzyme kinetics). Attracted to the 
complexity of the process substrate-product reactions, he extended the analysis to other 
systems, in particular in the drug-effect context, obtaining several deduction and equations.  
In 1980s, he derived  the median-effect equation, that correlates “dose” and “effect” in a 
simple form [11]. The median-effect function is also called general (or unified) theory of dose 
and effect  because it derives from the principles of mass action law and, by means some 
derivations, it can substitute the Michaelis-Menten equation, the Hill equation, Scatchard-plot  
and the Henderson-Hasselbach equation, chancing fa in  fractional saturation, fraction 
occupancy, fractional binding and fraction ionization, respectively, The Median-effect 
equation is given by Equation (15): 
 
  
  
  
 
  
 
 
                
 
Where D is the dose of a drug, fa  stands for  the fraction affected by D and fu  is the fraction 
unaffected (i.e fu=1- fa ), giving a specific level of effect; since fa  is the ratio of the measured 
parameter affected over the control, its values range from 0 to1. Dm represents the median-
effect dose that inhibits the system under study  by 50% (e.g. IC50), thus, it stands for drug 
potency;  the coefficient m indicates the shape of the dose-effect curves (hyperbolic, 
sigmoidal and flat sigmoidal with m=1, >1, and >1, respectively) (Figure 6).  
Defining x=log(D) and y=log(fa / fu) and plotting y versus x , and rearranging Equation (13), is 
obtained a linear function, the so-called median-effect plot which is the logit linearization, as 
described above (Equation 16): 
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FIGURE 6. Sigmoidal dose-effect curves (a) transformed into the corresponding linear forms (b) by means of the median-
effect plot. The line slopes, indicated with m,  stand for the degree of sigmoicity, and the antilogs of the X-intercepts gives  
the Dm values, which indicate the potency of each drugs [19]. 
The median-effect equation allowed to analyze the a combination of two drugs,  namely  as 
Drug 1 and Drug 2. Based on Equation (16), Chou and Talalay in 1983 derived the 
Combination Index (CI) theorem [11]. 
Assuming that the two agents are mutually exclusive (i.e. share similar mode of action), the CI 
is described by equation 17: 
 
    
       
       
 
   
  
     
     
 
   
  
     
     
 
   
 
    
     
 
    
     
               
 
The term (Dx) stands for the effect x triggered by the drug D in single treatment, whereas in 
the numerator D indicates the concentration of the drug in the mixture that induces the same 
effect. To detect these values,  dose-effect curves for each single drug have to be performed 
and  compared with that one of the combination. 
The assumption of mutually exclusive drugs had been previously proposed by other 
researchers; Chou and co-workers introduced the condition of non mutually exclusive drugs,  
postulating that the two agents are mutually non-exclusive or inclusive (i.e. act trough 
mechanisms know or supposed to be different):  a further term was added to equation (17) 
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equation because the combination mixture of the two agents is regarded as a third component, 
obtaining Equation (18): 
 
   
    
     
 
    
     
 
        
          
               
 
CI is a a-dimensional value that allows to discriminate additive effect from antagonism and 
synergism (with CI=1, CI > 1, CI < 1 respectively). Equation (17) and (18) may be expressed 
in the following general form, in the case of two drugs that show x% effect: 
     
   
    
     
 
   
               
Where      
  is the combination index for n drug at x% effect.  
When drugs in combination are in fixed- constant ratio classic isobologram is constructed 
(Figure 7a); conversely, if the agents are in non constant ratio, plotting of data yield to 
normalized isobologram (Figure 7b). In the  latter procedure, doses in combination are 
normalized with their ED50 “alone”. Normalized isobologram is adopted in order to 
determine the optimal combination ratio for maximum synergy [19].  
 
FIGURE 7. The ED50 (or IC50) isobologram for two drugs. When CI=1, combination data points fall on the hypotenuse drug-
interaction result in additivity. If combination data points fall on the lower left, synergism is indicated (C < 1). Finally, their 
presence in the upper right indicates antagonism (C > 1). a. Classic isobologram, where the drugs in combination are in 
constant dose ratio (equipotency ratio). On X- and Y-axis are indicated the equipotency mutual doses that prokove a 
specific effect in the mixture. b. Normalized isobologram for two agents, at non-constant combination ratios, whose doses 
in combination are normalized with their ED50 “alone”.  Classic isoblogram is suitable for mutally exclusive drugs, whereas 
normalized isobologram is adopted for mutually nonexclusive ones [19]. 
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So, proposing the median-effect principle and the CI theorem,  Chou and Talalay gave 
theoretical basis to isobologram model, that was absent in Loewe’s one.  
 
In addition to isobologram, Chou and Talalay introduced a novel approach for drug-
interaction analysis based on the same mathematical bases. It consists of a Fa-CI plot (Figure 
8), where the CI values are expressed as a function of the effect levels.  Whereas isobologram 
is a dose-oriented graphic, the Fa-CI plot could be regarded as an effect-oriented graphic.  
Use of Fa-CI is preferred for a lot of reasons. First, because the isobologram is a bi-
dimensional system, is indicated only for two-drugs combinations. Also, if it is constructed 
for a lot of effects, lines overlap and graph becomes too messy to read. Conversely, Fa-CI plot 
shows all fa simultaneously, whatever the number of drug tested in association. Between the 
plethora of models available, Fa-CI based methods is the most popular for drug combination 
studies, because is the most accurate and offer a quantitative estimation of the extent of 
synergy and antagonism.  
 
 
FIGURE 8. Fa-CI plot for n drugs combination given at fixed dose ratio. Experimental data closely fit those predicted by 
means of computer simulation using CompuSyn, a software performed by Chou and Martin [19].    
 
For clinical purposes, high effect levels of synergy mean  therapeutically promising mixtures. 
Moreover, it is worth to keep in mind how these theories are simplified models of the more 
complex cell system, and  the whole organism, consequently, synergy  depends on the 
context; for example, selective synergy is relevant against the target but antagonism is desired 
 20 
 
towards the off-targets in order  to minimize  side effects. Therefore, synergy is not a property 
merely of a drug combination: it relies on ratio of the mixture constituents. 
One of the major advantages of having a synergistic drug combination is the possibility to 
reduce the dose of the drug used, maintaining the same efficacy with reduced toxicity. 
The dose-reduction index (DRI) is the reciprocal of CI terms and is a measure of how many-
fold the dose of each drug in a synergistic combination could be reduced exerting the same 
effect (Equation 20). 
 
   
    
     
 
    
     
 
 
      
 
 
      
               
 
In Figure 9, Fa-DRI plot expressed DRI as a function of the effect levels. 
 
 
FIGURE 9.  Fa-DRI plot for n drugs combination given at fixed dose ratio. At the same effect levels, computer simulation (by 
CompuSyn, software ideated by Chou and Martin) does not predict with precision experimental data [19]. 
   
However, it should be noted that DRI is not a parameter for synergy and antagonism [19] 
[11]. 
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Polygonogram 
It is a graphical representation of multidrug combinations that shows the pharmacological 
effect of each drug pairs (Figure 10). It as merely a tool of practical utility, because it allows 
an overall visualization of the outcomes by means of colorful lines; usually; synergism is 
presented by a solid line and antagonism is depicted by a dashed one and their thickness 
reflects the strength of observed effect [19]. 
FIGURE 10. Sample illustration of polygonograms. a) Heptagonal polygonogram for 7 anti-HIV agents using two drug-
combination in vitro, for which are 120 possible combinations. Synergism and antagonism are depicted with different 
colour lines (solid red-tone  and broken blue-tone line, respectively). The thickness of the line represents the degree of 
interaction effect. b) Polygonogram for 5 anticancer drugs with different mechanism of action [19].  
Response surface modeling  
The effects of a combination could be plotted against the dose pairs in a three-dimensional 
coordinate system generating  a surface in the plane, the so-called response surface. 
Graphically, the doses are scaled in the X-Y axis, while the effect is plotted as the vertical 
distance above the planar point (Z-axis). They are built by means of mathematical equations 
represent surface of isoboles in three-dimensions, integrating all the doses, all the effects 
given by single treatments, and the effects given by the mixture (Figure 11). The simplest 
model is based on Loewe additivity response surface analysis. The surface created stands for 
the additive interactions and become the reference to discriminate the experimentally  
determined effects. If the combination data fall in the area above this surface, they indicate 
synergism, whereas if they drop below mean an antagonist response.  
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FIGURE 11. Loewe aditivity response surface: Illustration of dose-response curves for two drugs with their surface plot and 
related isobologram for simple competitive additivity.  (A) A 3-D surface plane with the related dose-response curve for 
increasing concentration of both drugs in a fixed ratio (1:1), (B) its related contour plot that drops under the 3-D surface 
[12].  
 
In addition to Loewe additivity response surface, during the last decades further theoretical 
approaches  have been proposed. Greco et al., Machado, Plummer and Carter introduced 
equations with a single interaction parameter that summary the nature and the magnitude of 
the pharmacological effect. Otherwise, Minto and Kong introduced  differents approach using 
a polynomial function [20] [21]. 
However, these models do could generate biases: indeed,  if applied to the same data set they 
are likely to generate widely different conclusions. 
However, the response surface analysis is not largely employed because it is a complicated 
procedure. A reliable fitting of response surface to combination  data is often not possible 
because of an inappropriate experimental design or simply because of the poor number of 
available data.  
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Antitumoral pharmacology 
The tumorigenesis  
In physiological conditions, the balance between cell proliferation and cell death is preserved 
and strictly regulated to maintain normal tissue homeostasis. However, in some circumstances 
this order is disrupted and tumorigenesis occurs. Most cancers do not rise from a single event: 
tumorigenesis is a complex and multistep process in which acquisition of multiple abnormal 
functions are required to evolve through a series of premalignant stages into an invasive 
cancer. These changes are the result of hereditary mutations or of lesions induced by 
exogenous factors as UV light, X-rays, chemicals and viruses.  
The efficiency of repair of premalignant lesions of DNA is one of the most critical events in 
cancerogenesis. If they can’t be corrected, cells undergo cell suicide (i.e apoptosis, that is 
described in the next paragraphs). However, some cells may survive to uncompleted or 
uncorrected DNA lesions in key genes, i.e. proto-oncogenes,  accumulating mutations and/or 
and genomic instability. These alterations give to mutant cells a selective advantage that 
allows them to duplicate out of control, that is the hallmark of the tumor. During this process, 
cells gain new characteristics which  consequently are given to descendent cells. Growth and 
selection of  first transformed cells is a process so-called clonal selection.  
Several theories were proposed about the origin and the behavior of tumor-initiating cells, that 
are not still well understood. It was argued that stem cells acts as progenitors for tumor 
initiation because of their inherent capacity for self-renewal and their longevity, which 
promote the sequential accumulation of mutations. However, this thesis remains to be proven. 
It is compatible with observations obtained from some tumors, while it is elusive for other 
cancer types [22]. 
Relevant abnormalities that lead to tumorigenesis result from mutations in protein-encoding 
genes that regulate cell division and growth, which can be broadly classified into two groups: 
proto-oncogenes and tumor suppressor genes. Proto-oncogenes encode proteins that promote 
cell growth enhancing cell division (such as tyrosine kinase receptors, kinases, GTPase 
regulators, transcription factors extracellular and growth factors). Their mutated forms are 
called oncogenes. On the other hand, tumor suppressor genes encode for proteins that control 
and stop cell division or induce cell death. Therefore, mutations that produce oncogenes favor 
growth while those that affect tumor suppressor genes hold back ability to inhibit cell growth. 
In both circumstances, uncontrolled proliferation occurs. Consequently, cancer cells acquire 
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defects on regulatory circuits that rule tissue homeostasis [23] [24]. Generally speaking, 
malignant cells exhibit the follow capabilities: 
 aberrant and unchecked growth; 
 loss of capacity for senescence and limitless replicative potential; 
 evasion of cell death, in particular apoptosis; 
 sustained angiogenesis; 
 tissue invasion and metastasis; 
 altered mechanism of DNA damage repair; 
 conversion from aerobic to anaerobic metabolism (the so-called Warburg effect). 
Cell growth control 
Cellular replication is ruled by cell cycle, that is a series of unidirectional, repetitive and 
tightly regulated events. It is composed of four stages: G1, S, G2 (which form the interfase) 
and finally, M. Upon receipting the mitogenic stimulus, cell enters the cell cycle in G1 phase: 
the cell becomes actively a rise in cell metabolism and in the expression of proteins and 
organelles creates the conditions needed for the next stage, i.e. the S (synthesis) phase, 
characterized by DNA replication. In the G2  phase, the accuracy of DNA replication is 
checked and proteins needed for the imminent cell division are then synthesized. During the 
M (mitosis) phase, the chromosomes separate in the nucleus and finally the cytokinesis, the 
division of the cytoplasm, occurs (Figure 12). The cell cycle can be arrested in checkpoints, 
close to critical events, to control the accuracy of the preceding processes and to prevent the 
progression of cell cycle in case of abnormalities. This block allows the cell to restore  the 
normal conditions and, if it is not possible, to induce apoptosis in the damaged cells . So, 
checkpoints prevent the transmission of aberrant traits to daughter cells. Loss of this 
regulation is an hallmark of cancer [25]. 
 
 
 
 
 
FIGURE 12. The events of cell cycle. The checkpoints, shown in yellow boxes, act as a central control system in order to 
regulate progression of cell cycle [26].  
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Cell cycle control system is based on two key families of proteins. The first is the family of 
cyclin-dependent protein kinases (CdKs); the second is a family of activating proteins, called 
cyclins. Cyclins bind to CdKs and control their ability to phosphorilate  appropriate target 
proteins. There are different  classes of cyclins and CdKs, each one defined by the stage of the 
cell-cycle at which they are assembly (Table 1). 
 
TABLE 1.  The main classes of cyclins and CdK molecules are listed, referred to  vertebrates (middle column) and budding 
yeast (such as Saccharomyces cerevisiae, that is a popular ”model” organism) (right column). A specific cyclin-Cdk complex 
is activated at the entry point of each cell-cycle phase [25].  
Some somatic cells (as neurons, muscle cells) do not undergo cell division and persist in a 
quiescent state, out of the cell cycle, called G0. Other normal adult cells can duplicate, under 
the stimulation of external growth signals, as growth factors and hormones, in restricted cases 
only. Furthermore, they can replicate for a limited number of times, known as the Hayflick 
limit, that is about 60-70 doublings, given by the gradual erosion of telomeres, (the ending of 
chromosomes, whose role is maintaining integrity of inner part), that become shorten after 
every cell cycle. Eroded chromosomes can lead to a permanent escape from the cell cycle, in  
G0, called senescence, or can trigged apoptotic cell death.  
Adult stem cells as those of the derma, the hematopoietic progenitors and cells of the 
germinal lines actively proliferate to solve their physiological role, under a fine-tuned 
stimulation. 
On the contrary, cancer cells proliferate under misleading stimulation, which can be also 
generated by themselves (autocrine stimulation), reducing their dependence on external 
stimulation and control [25]. 
Tumor suppressors 
Regulatory circuits of cell cycle are controlled by two critical tumor supressors frequently 
mutated, that are P53 and RB (for sake of clarity, in according to HUGO gene nomenclature, 
genes are named in italicized). P53 is a transcription factor that triggers the cell cycle arrest, 
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apoptosis and senescence. Since its crucial role in the maintenance of genomic stability, it was 
called “the guardian of genome”. Indeed, p53 functional inactivation has been observed in 
more than 50% of tumors. If DNA damage is so extensive that it cannot be repaired, P53 leads 
the cell to suicide eliciting apoptosis. p53 functional inactivation leads to failure of this 
machinery, that may be worsen by defective bcl-2, a proto-oncogene that counteracts 
programmed cell death [27]. Along with p53, another tumor suppressor, the product of RB 
gene, RB, is mutated in several cancers. Its functional inactivation has a central role in 
retinoblastoma, that is a children-affecting tumor. If hypophosphorylated, RB prevents the 
proliferation by sequestering and altering the function of E2F transcription factor, that 
controls the expression of genes fundamental for progression from G1 into S phase. So, 
defective RB is persistently iperphosphorilated  and promotes cell proliferation. Similarly, 
oncogenes activation, stress inputs or DNA damage, trigger the transcription of a protein 
called p21. It blocks the activity of CdK required for progression through G1, giving the 
chance to repair the DNA before it undergoes duplication. 
Oncogenes and signal transduction 
Tyrosine kinase receptors 
Proto-oncogenes encode proteins that belong to an interwined network of cascade signals 
(pathways) involved in the processing and amplification of the mitogenic signals. So, it is 
intuitive that the acquisition of multiple defective products fosters aberrant cell behavior. 
This could be envisaged in the context of tyrosine kinase receptors (RTKs) pathways, which 
are frequently mutated in cancer. RTKs are cell-surface receptors that play a key role in cell 
proliferation, differentiation, survival, metabolism and migration. The RTK family includes  
20 subfamilies; some example of members are the epidermal growth factor receptor (EGFR), 
the vascular endothelial growth factor receptor (VEGFR), the platelet growth factor receptor 
(PDGF), the fibroblast growth factor receptor (FGFR) and the insulin receptor. Because their 
activity depends on the binding of growth factors, are also know as growth factors receptors. 
Aberrant growth factor receptors activity in cancer is mediated by four main mechanisms: 
autocrine activation, RTK overexpression, gain-of-function mutations that make the receptor 
constitutively active, or chromosomal translocations [28]. RTKs activation prompts to a series 
of  downstream events transmitted to the nucleus, generally leading to cells division (Figure 
13). Many proto-oncogenes take part to these signal transductions pathways. They consist of 
two groups: non-receptor tyrosine kinases  (TKs), such as abl and src, and guanosine 
triphosphate (GTP)-ase (e.g. ras) [29]. 
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Abl is a cytosolic tyrosine kinase. The mutated form of its proto-oncogene ABL results from 
chromosome 9 and 22 translocation, that yields to an hybrid chromosome, called Philadelphia 
Chromosome, and to the BCR-ABL oncogenes, coding for a fusion protein BCR-ABL that is 
constitutively active, yielding to uncontrolled cell cycle. This translocations occurs in many 
cases of chronic leukemia [30]. 
The oncogene coding for the GTP-ase RAS  is one of the most common sites of mutation in 
the array of cancer types. The SOS-Ras-Raf-MAP kinase (MAPK, mitogen activated protein 
kinase) cascade is stimulated by a lot of stimuli (as cytokines, growth factors, oxidative 
stress). The MAPK family includes three subfamilies: ERK, JNK and P38. This signaling 
cascade cross-talks with other molecular pathways, such as PI3K-AKT cascade, promoting 
the transmission of pro-survival signals (Figure 13).  
Moreover, growth factor receptors and non-receptors tyrosine kinases interplay with the Janus 
Kinase/ signals transducers and activators of  transcription  (JAK/STAT) pathway, that 
contributes to cancerogenesis stimulating cell proliferation and preventing apoptosis. JAK 
belongs to a family of non-receptor protein tyrosine kinase that, after activation, recruits and 
activates STAT proteins inducing their dimerization, nuclear translocation and DNA-
transcriptional activity [31].  
 
FIGURE 13.  RTKs  have a characteristics structure consisting of 
three principal domains: the extracellular ligand-binding domain, 
the transmembrane domain and finally, the intracellular catalytic 
domain. They are activated by ligand-induced oligomerization 
(mainly dimerization), that thus induces autophosphorilation of 
the tyrosine located on catalytic domain.  After RTKs activation, 
Grb2 binds SOS, that interchange GDP bound to Ras, with GTP. It  
triggers a complex network of downstream signals.  Several 
proteins are involved, ultimately activating one or more 
transcription factors, stimulating the expression of the genes that 
are under their control [28].  
 
 
Transcription factors 
Transcription factors  (TF) are nuclear proteins that regulate the expression of target genes by 
means binding to specific DNA sequences, called responsive elements, which can be found in 
regulatory parts upstream and/or downstream the target genes, the  promoters and the 
enhancers, respectively. The mechanism of actions of TF involves binding to other proteins, 
forming homo- and/or heterodimeric complexes.  
The signaling of the TF Nuclear factor-kB (NF-kB) has a central role in cancer. It exerts a 
pleiotropic effect that is context-dependent, ranging from tumor promoting actions (such as 
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triggering proliferation, mestastasis, inflammatory response, angiogenesis, pro-survival 
signals) to tumor suppressor activities (as inducing apoptosis, senescence and promoting 
DNA repair). It should be noted that NF-kB aberrant activity is not due to oncogenic 
mutations in the genes itself, but is mainly a consequence of its induction by “upstream” 
oncogenic signals [32]. 
There are five subunits that belong to the mammalian NF-kB family, which all share a related 
DNA-binding and dimerization domain, termed the REL domain. The subunits RelA (also 
known as p65), RELB and REL contains domain that mediates gene transcription, while the 
subunits p50 and p52 modulate DNA-binding. 
NF-kB resides, in the cytosol as a dimer, bound to an inhibitor called IkB.  NF-kB activation 
requires phsphorilation of  IkB by IkB kinase (IKK), which thus becomes ubiquinated and 
destroyed by proteasomes. This event allows NF-kB to translocate into the nucleus where acts 
as a transcription factor, ruling the expression of  many genes [33]. 
FOS, JUN, c-MYC are some examples of oncogenic transcription factors that regulate many 
crucial genes involved in tumor initiation. 
C-MYC is broadly involved in many human malignancies and its functional alteration was 
found in up to 70% of human cancer, resulting from both its deregulation and overexpression. 
It harbors a central role in many cellular processes such as the cell cycle, energy metabolism, 
stem cells differentiation and apoptosis [34].  
 
 
FIGURE 14.  MYC oncogenes receives downstream growth promoting signals, elicited by many receptors, that regulate its 
expression. In turn, c-myc dimerizes with Max, which by binding to E-box consensus recognition elements  may rule genes 
transcription [35]. 
The c-myc transcriptional activity is modulated by epigenetic modifications (defined  as 
chromatin changes that alter its conformation and so, its transcriptional state, without 
modifying its genic information [36], as displayed in Figure 15) through MYC-MAX/ MYC-
MAD dimerization (Figure 14). The dimer c-myc-max cooperates with histone acetylases 
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(HATs), that catalyze the acetylation of histones (the proteins around whose chromatin is 
wrapped). Their acetylation stabilize expanded chromatin conformation, promoting DNA 
transcription [35]. Conversely, c-MYC activity is counteracted by MAD which, after binding 
MAD, recruits histone deacetylases (HDACs) and promote transcriptional repression [37].   
 
 
 
FIGURE 15. The image shows an overview of epigenetic regulation of chromatine. Epigenetic modifications include post-
translational modification of histone proteins by acetylation (Ac), methylation (Me), phosphorilation (P). Lysine acetylation 
and DNA methylation play a key role in regulating gene expression by modulation of wrapping/unwrapping of the 
chromatin around protein spools called histones. Lysine acetylation is mediated by histone acetylase enzymes (HATs), that 
stabilize DNA in the expanse and transcriptional active state (called euchromatine) rendering the DNA more accessible to 
the transcriptional machinery. At the contrary, histone deacetylases (HDACs) remove the acetyl groups from histones and 
maintain DNA into a compact state (known as eterochromatine) not favorable to DNA transcription (gene silencing). DNA 
methyltransferases (DNMT), though histone methylation, stabilize eterochromatine too [36]. 
 
In addition, transcriptional regulation of c-MYC is under tight control  of the transcriptional 
regulators FUSE-FBP-FIR system. The far upstream element (FUSE) is a DNA region that 
become single-strand during C-MYC transcription, while return to double-strand 
conformation if is not being expressed. During c-MYC transcription, the FUSE-binding 
protein (FBR) is bound to FUSE, whereas the interaction of FBP-interacting repressor (FIR) 
with FBP returns c-MYC transcription to basal levels [38].   
Epigenetic regulation has a crucial role in cancer progression, since modulate genes 
transcription. For this reason, in the last decades it was  regarded as a good target for 
antitumoral therapy.  
Cell death 
In order to eradicate tumors, antitumor drugs mainly aim to induce cell death in neoplastic 
cells only. Several types of cell death can be distinguished according to morphological and 
biochemical parameters; they co-exist within the same tumor, and are strictly interconnected, 
thus, it is often difficult to discriminate them [39].  
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However, only apoptosis and necrosis are lethal mechanisms in the strict sense of the term. As 
depicted in Figure 16, the others can be, in some cases, intermediate steps towards the   
apoptosis or necrosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 16. Antitumor agents  lead to interconnected signals transduction cascade, that lead to different cellular fates.  
Understanding how these pathway crosstalk and interfere is essential for the rationale design of  chemotherapeutic drugs 
[40]. 
 
Apoptosis is also known as programmed cell death type I (PCD). The term apoptosis comes 
from Greek and means the falling off of leaves from trees. Indeed, as this natural event, 
apoptosis plays a central role in several processes involved in the organism homeostasis, such 
as embryonic development and tissues turnover. Thus,  apoptosis deregulation leads to 
pathogenesis: suppression of apoptosis plays a key role in cancer development.  
Apoptosis can be triggered by a variety of signals, as oxidative stress, chemicals, radiation, 
tumor-necrosis factor-alpha (TNF-) and it is elicited through  two main pathways: the 
extrinsic one, mainly activated by cell-membrane receptors in the presence of extracellular 
stimuli, and the intrinsic one, that integrates intracellular signals such as DNA damage and 
involves mitochondria membrane depolarization (Figure 17). Both pathways are characterized 
by the activation of a particular class of cysteine-proteases, caspases, which are divided into  
initiators caspases (caspase 8 and 9, respectively, having autocatalytic activity), which 
activate by proteolytic cleavage the  downstream effectors, the executioners (caspase 3 and 7). 
Effector caspases initiate other proteolytic cascades that lead to the DNA fragmentation and to 
progressively disassembling of  the cell into apoptotic bodies.  
Unlikely to intrinsic pathway, extrinsic circuitry does not involve mitochondria and is initiates 
by extracellular stimuli that activate transmembrane receptors [41]. 
 31 
 
It was suggested that extrinsic pathway is correlate to cell-membrane receptors clustering 
within lipid rafts, that are large and dynamic assemblies enriched in colestherol, 
sphingomyelins and sphingolipids that float freely within the cellular membrane bilayer [42]. 
 
 
FIGURE 17. Sequence of events of apoptosis at cellular (left) and molecular (right) level. (Left) Apoptosis is characterized by 
a series of morphological events as cell shrinkage, disruption of membrane of organelles, nucleus condensation, chromatin 
cleavage and finally, cell fragmentation into apoptotic corps engulfed by macrophages (if the cells is not phagocytosed, they 
will undergo degradation in a process called secondary necrosis). (Right) These processes reflect the activation of molecular 
pathways, of whose caspases are the principal drivers. The extrinsic pathway involves the activation of death receptors (as 
TNF or FAS receptors) that, after binding with adapter proteins, induce activation of caspase-8. The intrinsic pathway is 
regulated by anti- (as Bcl-2, IAP): upon intracellular stimuli, the activation of pro-apoptotic proteins (as Bax, Bad, Bid) leads 
to the opening of the mitochondrial membrane transition pore (MOMP), resulting in loss of the mitochondrial 
transmembrane potential, and  to  cytocrome c  release; within the cytosol, it binds and activates both apaf-1 and caspase-
9, forming the apoptosome, with the consequent caspase 9 activation. Both the initiator caspases activate the effector 
caspases 3 and 7 [41]. 
Autophagy is another example of programmed cell death (PCD type II). It represents a 
physiological and adaptative response induced by cell stress as nutrient deficiency, cytokynes, 
damaged organelles or genomic instability. As shown in Figure 18, autophagic cells undergo 
auto-cannibalism to sustain viability, simply  recycling some non-essential components as 
energy source [43].   
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FIGURE 18. Autophagy is characterized by the formation of intracellular vesicles with double membranes, termed 
autophagosomes. After swallowing cellular organelles (e.g. ribosomes, mitochondria), they fuse with lysosomes. 
Degradation of the content occurs and the resulting metabolites  are thus recycled and used for biosynthesis and energy 
metabolism. Beclin 1, a protein essential for autophagy, is also an oncogene [44].  
Necrosis, unlike apoptosis, is an energy-independent process. It usually arises after a 
traumatic injury that perturbs cellular homeostasis. Morphological changes of necrotic cells 
include cell swelling,  disruption of membranes and rupture of organelles. Loss of integrity of 
the plasmatic membrane results in the release of the cellular content into the surrounding 
tissue microenvironment, acting as a chemotatic signals that eventually recruit inflammatory 
cells [45].  
The mitotic catastrophe occurs in case of  failed mitosis and it is characterized by 
morphological alterations as multiple- and micronucleation. It mainly derives from erroneous 
nuclei separation during cytokinesis [46]. 
Cell senescence is a non-proliferative but viable state during which cells do not proliferate. It 
is a physiological destiny of normal cells that has a finite capacity for growth. As previously 
stated, senescence can occur following a period of cellular proliferation (replicative 
senescence) or in response to acute stress (stress-induced premature senescence) , such as 
DNA damage, telomeres shortening, excessive oncogenes signaling. As depicted in Figure 19, 
the senescence program is regulated by p53 and p16-pRb pathways [47]. 
FIGURE 19. P53 and pRb are  central activating 
pathways of senescence. The p53 protein, after 
activation, proceeds to activate its transcriptional 
target p21, which arrests the cell-cycle. p53 could 
be activated by several stimuli, such as DNA-lesions 
detected by the DNA-damage sensors ATM and 
ATR. P53 is inhibited by Mdm2. Senescent cells 
express p16
INK4a
 an upstream activator of pRB. 
Active pRb, binds to the E2F protein family 
members to repress their transcriptional target 
required for cell-cycle progression [47]. 
 33 
 
The role of autophagy, necrosis and senescence in antitumor chemotherapy is still under 
debate, because they can play a dual role in tumor progression, acting both as a cancer 
promoters and suppressors [48]. Indeed, autophagy may either act as a defense mechanism 
involved in the development of a resistant phenotype either lead to cell death [49]. Also 
necrotic cells, albeit not viable, promote tumor progression by means of the release  of pro-
inflammatory signals that recruit inflammatory cells, producing growth factors and 
eicosanoids which can stimulate tumor growth as well. Lastly, senescence on one hand may 
represent a protective barrier to neoplastic expansion, counteracting aberrant cell proliferation 
fostered by oncogenes (Figure 20), on the other hand it might be detrimental  since senescent 
cells cooperate with tumor progression, by means of the secretions of mitogenic factors, i.e. 
the  senescence-associated secretory phenotype (SASP) [50] [51]. 
 
FIGURE 20. Elevated activation of oncogene signalling  (as 
Ras, myc) in vivo may promote both cell proliferation and 
cellular senescence. However, mutations that disable cellular 
senescence cooperate with the initiating lesion to promote 
cell progression  [52]. 
 
 
 
 
Senescent cells have large and flattened morphology , absence of proliferation markers, 
heterochromatic foci and expression of senescence-induced -galactosidase enzyme. 
Senescent cells are displayed in blue because of X-Gal, a chemical is converted into a blue 
product by -galactosidase. 
DNA damage response 
Most anticancer drugs are DNA-damaging agents (genotoxic agents). The efficiency of the 
DNA damage response have a crucial impact on cell fate; indeed, a nonfunctional repair 
machinery leads to genomic instability that promotes cancerogenesis and can affect the 
responses to DNA-damaging anticancer therapy. DNA damage activates a complex network 
of molecular mechanisms that involve several players (Figure 21), depending on the nature of 
the lesions and cell cycle checkpoint at which DNA defects is detected [53].  
Lesions can affect or one DNA strand (intrastand lesions) or double strands (interstrand 
lesions). The former may repaired by three mechanisms: base- excision repair (BER), 
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nucleotide excision repair (NER) and lastly, the mismatch repair (MMR). Among them, NER 
has a crucial role in cancer chemotherapy. The excision repair cross-complementation group 1 
(ERCC1) endonuclease is a critical component of the is a multienzimatic complex NER: 
bound  to XPF product, the resulting heterodimer has endonuclease activity on both intrastand 
and interstrand cross links (ICLs). The latter ones are the most toxic lesions, since they induce 
a helix distortion and hinder their separation that is essential for DNA replication and 
transcription.  
Accumulation of ICLs activate different signals, depending on the cell cycle checkpoints at 
which they are detected, mainly during the DNA replication, stalled replication forks. ICLs 
are resolved by means of a  cleavage on the damaged filament and so converted into a double 
strand breaks (DSBs). DSB are detected by sensors as Poly (ADP-ribose) polymerase 
(PARP), which activate the signalling by means of ATM and/or ATR, that in turn activate 
p53 and other downstream signalling cascades [54] [55]. DBSs can be repaired by two 
mechanisms: homologous recombination (HR) or non homologous end joining (NHEJ). ICLs 
repair proficiency depends on the ERCC-1/XPF activity and other enzymes belonging to the 
MMR system. Examples of diseases associated to inefficient ability to repair ICLs are the 
Fanconi anemia and breast cancer associated to mutation of a critical component of HR 
system, the tumor suppressor BRCA1/BRCA2 [56][57]. 
DNA polymerases have an important role in DNA damage repair. 15 different mammalian 
DNA polymerases have been identified: some of them are specialized in DNA synthesis (such 
as DNA Pol  and ), others participate in repair or tolerance of DNA damage (as Pol , Pol 
; Pol , Pol , Pol , Pol ). The DNA damage tolerance process, that allow the DNA 
replication bypassing the damaged sites, is called translesion synthesis [58]. 
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FIGURE 21. 
MECHANISMS OF DNA 
REPAIR. (a) Base excision 
repair (BER) is 
responsible for repair 
DNA adducts generated 
by ROS and alkylating 
agents. Damaged base is 
removed by a specific 
DNA glycosylase and the 
resulting abasic site is 
excised by an AP 
endonuclease (APEX1). 
The 5’-deoxyribose-
phosphate is removed, 
leaving one nucleotide 
gap that is filled by DNA 
polymerase and joined 
by  a ligase. XRCC1 and 
Poly(ADP-ribose) (PARP) 
polymerase facilitate the 
repair. (b) Nucleotide 
excision repair (NER) 
removes helix-distorting 
adducts  induced by UV 
radiations, polycyclic 
aromatic compounds 
and chemotherapic 
agents as cisplatin. It 
contributes to the repair 
of intrastrand and 
interstrand  crosslinks 
(ICLs). Defects in NER 
components are 
associated with some cancer predispositions, as xeroderma pigmentous. The distorted region is removed by ERCC1-XPG 
and after filled by Pol orc Mismatch repair (MMR) is a process that removes mismatched bases. If double strand 
breaks (DBS)  arise in DNA induced by interstrand crosslinks (ICLs),  (d) non-homologous end hoining (NHEI) or (e) 
homologous recombination (HR) processes occurs. HR operates in late S or G2 phase of the cell cycle, when as a sister 
chromatid operates as a template for the broken strand. Some enzymes of the NER system cooperates with HR. NHEJ 
introduce deletions, which can be further tumor-promoting lesions [58].  
The role of extracellular microenvironment 
Cancer must not be conceived as an homogeneous entity of proliferating cells. It is a complex 
tissue where tumor cells coexist with several normal cells, classified as stromal cells.  
Cancerous population is driven and sustained by both heterotypic signalling from stromal 
cells and by the interaction with components of extracellular matrix (ECM). ECM is a tight 
network of collagen, fibronectin, proteoglycans fibers and other structural proteins. ECM 
gives tissue their mechanical properties and help to organize communication between cells 
embedded within the matrix. The extracellular milieu has to be regarded as a  dynamic 
context, because it gradually evolves supporting the malignant growth, aggressiveness  and 
metastasis. Attachment of the cells to matrix is essential for survival and migration and lose of 
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contact yields to a particular type of cell death called anoikis. Anchoring is mediated by cell-
surface adhesion molecules (e.g. cadherins and integrins) [59].  
Oxygen and nutrient supply are essential for cell function and survival, obligating all cells in a 
tissue to reside within 100-150 m of a capillary blood vessel. At longer distance, oxygen 
concentration falls to zero. So, secretion of angiogenic regulators (e.g. FGF, VEGF, PDGF) 
occurs promoting neovascularitation in tumor mass. Inflammatory cells help the “angiogenic 
switch” and in turn, cancer cells secrete chemoattracts that recuit proinvasive inflammatory 
cells. It should be noted that, since some tumor areas are distant to vascular supply, they are 
deprived of oxygen and cancer cells  adapt to survive in hypoxic condition [60] [61].  
 
FIGURE 22. (Upper) Cancer as a 
complex system, sustained by cell-
matrix and cell-cell communication 
trough autocrine and paracrine 
signalling. In the autocrine signalling, 
a cell secretes a chemical messenger 
that binds to a receptor located on 
the same cell, while in the paracrine 
signaling a cell produces a signal that 
induce changes in nearby cells. 
 Adjacent non-malignant cells as 
fibroblasts, inflammatory cells, 
endothelial cells, cancer stem cells 
participate in tumor development and 
progression through secretion of 
several factors. (Lower) If altered cells 
remain in their original location and 
do not spread to other tissues, they  
are considered benign, otherwise if 
they become invasive, they are 
regarded as malignant. Malignant 
cells could penetrate the walls of 
lymphatic and/or boold vessels, 
extravase and then migrate to 
distants sites [24].  
 
The anticancer chemotherapy 
In the past, the term chemotherapy indicated the treatment used against pathogenic hosts 
invading the body (bacteria as well as cancer cells) by means of chemical compounds (both of 
natural and synthesis origin).  
Conventional anticancer chemotherapy aims to arrest the proliferation of malignant cells 
and/or induce them to die. Thus, they mainly interfere, directly or indirectly, with the 
mechanism responsible for the cell duplication: the cell cycle (Figure 23). 
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FIGURE 23. The relationship between cell cycle and tumor drugs action. Based on their mechanism of action,  antitumor 
drugs should be divided in two main groups: specific- and non specific- cell cycle phase [62]. 
 
 
The words cytostatic and cytotoxic describes the way some anti cancer drugs work. The word 
cytotoxic means that drugs that are used to treat cancer kill the cancer cells by apoptosis 
induction. This is the primary mechanisms of action of many anticancer drugs, including 
alkylating agents, platinum compounds, topoisomerase inhibitors and the antimetabolites [63] 
[64]. Because in many cases the DNA synthesis machinery is involved in this cytotoxicity, 
some evidences indicated that S-phase cells are sensitive to these agents. Therefore, cytotoxic 
agents cannot distinguish between normal and malignant cells, since they act on all proliferant 
cells. [65].   
 At the contrary, cytostatic drugs work by stopping the cancer cells from multiplying;  so, they 
stop the cancer growing. For example, hormone therapies used to treat breast cancer could 
also be called cytostatic therapy. They work by blocking particular receptors of the cancer 
cells that transmit mitogenic signals. So, by blocking them, the treatment is stopping the 
cancer from growing [62].  
However, we would note that  cytostasis or cytotoxicity often depends on the in vitro and in 
vivo assay conditions, such as doses, times, and schedules of exposure [66]. For example, 
with the topoisomerase II inhibitor daunorubicin, differential effects have been reported 
depending on the doses: cytostatic and G2-M arrest at low concentration and cytotoxicity and 
G1 and S arrest at high concentrations [67]  
Similarly, cytostatic drugs could trigger cell death when damage can be resolved, as observed 
with microtubule-targeting agents [68]. By interfering with microtubule dynamics, these 
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agents arrest cells in mitosis and induce cytostasis. Since mitosis arrest is poorly tolerated, it 
could lead to cell death [69].  
Inhibitors of  Mitogenic stimuli : anti-hormones and targeted therapy 
This class of drugs acts inhibiting the receptor or, in general, the pathway responsible for the 
proliferative stimulus.  
For example, when estrogen binds to the estrogen receptor (ER) inside cells, the resulting 
hormone-receptor complex activates the expression of specific genes, involved in cell growth 
and proliferation; breast cancer cells that express these receptors (ER-positive breast cancer 
cells) are an effectively treated by molecules that interfere with estrogen’s ability to stimulate 
the growth  (antihormones). Several drugs have been approved by the FDA for the treatment 
of ER-positive breast cancer. Selective estrogen receptor modulators (SERMs), 
including tamoxifen, bind to the ER and prevent estrogen binding [70], while aromatase 
inhibitors (AIs) are another class of drugs that hinder  the production of  estrogen by means of 
blocking the activity of aromatase, and  are actually used for the treatment of ER-positive 
breast cancer [71].  
Targeted therapy, or Molecularly targeted therapy, aims to inhibit of the cancer mitogenic 
stimuli mainly coming from growth factors. Targeted therapy interferes with specific targets 
as receptors and/or enzymes specifically expressed by  in a type of tumor cell and which are 
involved in tumor growth. Thus, targeted therapy is aimed to reduce the proliferation on a 
specific subset of cells (the tumor) rather than interfere with the growth of any diving cell, as 
the traditional chemotherapy does.  
Targeted therapy drugs are small molecules, small molecule drug conjugates and monoclonal 
antibodies. Small-molecules are tyrosine-kynase inhibitors, such as Imatinib mesilate 
(Gleveec
TM
), a kinase inhibitor, that has inhibitor activity against  the chimeric Bcr-Abl fusion 
protein. In particular, Gleveec emerged as a successful drug in the treatment of chronic 
myelogenous leukemia, which pathogenesis is ascribed to ABL oncoprotein [72]. 
Nevertheless, targeted therapies have some limitations, further than the insurgence of 
resistance; the high selectivity limits their efficacy on cancer types specifically due to that 
single deregulation; for instance, transtuzumab (Herceptin
TM
), a recombinant humanized 
monoclonal antibody direct against the HER-2 (also known as ERBB-2) protein, is only 
efficacy against HER-2 positive cancer. Indeed, a lack of response to  Transtuzumab was 
observed when mutations on her-2 gene occurred [73] [74]. Similarly, Gefitinib (Iressa
TM
), a 
EGFR kinase inhibitor, cause tumor regression only if its target is expressed and not mutated 
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[75]. It is for this reason that targeted therapies may work best in combination, either with 
other targeted therapies or with more traditional therapies. 
 Antimetabolites 
Antimetabolites represent a class of drugs that interferes with the synthesis of DNA and RNA, 
thus, these agents selectively damage cells during the S phase. They are commonly used to 
treat leukemias, cancers of the breast, ovary, and the intestinal tract, as well as other types of 
cancer. 
Metotrexate is the progenitor of folic acid antagonists class. It is an inhibitor of dihydrofolate 
reductase (DHFR), the enzyme that reduces dihydrofolic to tetrahydrofolic acid. 
Tetrahydrofolate is essential for proliferating cells, since participates in purine and 
thymidylate synthesis. Another antifolate is pemetrexed  acting not only on DHFR, but also 
by inhiting thymidylate synthase (TS). TS is involved in de novo synthesis of  
deoxynucleoside triphosphates (dNTPs) precursors, the substrates needed for DNA 
polymerase DNA strand elongation [76].  
Purines (6-mercaptopurine, 6-Tioguanine, Gemcitabine) and pirimidine analogues (5-
Fluorouracil, Citosine Arabinoside), mimic the structure of endogenous nitrogen bases 
(Figure 24), but with some modification on the 5’ position of the sugar ring. Since DNA 
synthesis  proceeds in a 5' to 3' direction, these nucleotide analogues are incorporated into the 
DNA backbone but do not allow further stand elongation. 
Furthermore, they can act on other enzymes involved in nucleotide biosinthesis: for instance, 
5-Fluorouracil is a TS inhibitor. 
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FIGURE 24. Chemical structure of the four bases that become incorporate into DNA are showed, as well as the various 
modification introduced in pyrimidines and purines analogs that function as cytotoxic chemoterapeutic agents [62]. 
Alkylating agents 
The cytotoxic properties of sulfur mustard was serendipitously discovered  during the World 
War I; later, early clinical experiments highlighted that these molecules were able to induce 
tumor regression trough DNA alkylation. This event started  the discovery of novel antitumor 
agents and gave rise to the era of modern cancer chemotherapy. 
Alkylating agents directly damage DNA to prevent the proliferation of cancer cells. As a class 
of drugs, these agents are not phase-specific; in other words, they work in all phases of the 
cell cycle. Their cytotoxic effect is primarily exerted on rapidly proliferating tissues, as bone 
narrow cells, intestinal epithelium and, hair follicles, lacking of  selectivity towards malignant 
cells. 
Alkylating agents are used to treat many different cancer type, including leukemia, 
lymphoma, Hodgkin disease, multiple myeloma, and sarcoma, as well as cancers of the lung, 
breast, and ovary [62].  
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They interact with the nucleophilic centers of the target forming reactive electrophilic 
products by means of or first-order nucleophilic substitution (SN1) or  second-order 
nucleophilic substitution (SN2) mechanisms, that are illustrated in Figure 25. In the former 
case, the rate determining step is the formation of a carbocation intermediate or related 
transition complexes. These reactive intermediate form a covalent bond with nucleophilic 
sites, such as the imidazole groups of purine bases. Conversely, in SN2  the carbocation is not 
formed. As final result,  alkyl groups are added to  DNA.  
 
 
FIGURE 25. Example of first-order substitution (SN1) or  second-order nucleophilic substitution (SN2) [65]. 
 
 
DNA-adducts induced by alkylating agents are detected by the DNA-control machinery, that 
triggers cell-cycle arrest at G1/S or G2/M checkpoints.  
Alkylating agents are classified into five groups: 
 the nitrogen mustards, which include mechlorethamine, chlorambucil, 
cyclophosphamide, ciclofosfamide, and melphalan, acting as shown in Figure 26; 
 aziridine, such as tiotepa, form intermediates similar to those generated by nitrogen 
mustards; 
 the alkyl sulfonates, as busolfan, alkylate DNA through the release of methyl 
radicals;  
 nitrosoureas, (such as carmustine and lomustine) give rise to extremely reactive 
intermediates that could induce both intra- and inter-strands cross-links. Thanks to 
their lipophilicity, they can cross the blood-brain barrier, thus, they are commonly 
employed in the treatment of brain tumors; 
 triazenes, which account for dacarbazine and temozolomide, are considered as pro-
drugs since their metabolite methylates DNA. 
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FIGURE 26. Mechanism of action of mechlorethamine, a nitrogen mustard (A) By a SN1 cyclization, a quaternary carbocation 
intermediate is formed. (B) Since it is very unstable, avidly bind N7  of guanine residues in DNA [62].  
Platinating agents 
Cisplatin 
Cisplatin, [cis-diamminedichloro platinum (II)] or CDDP, is a square-planar complex of 
platinum composed of  two ammonia as carrier groups (that are stable ligands that are not 
replaced by substitution reactions)  and two chloride atoms as leaving groups (which are 
ligands that are displaced by water molecules). 
Cisplatin is a Pt(II) complex, that means that metal is the oxidation state +2.  
It was synthesized for the first time in 1844 by Peyrone (thus assuming the name of 
Peyrone’chloride), but its anticancer properties were serendipitously discovered in the 1960s, 
when Rosenberg studied the effect of an electric field on Escherichia coli growth. He 
observed a stop of cell division that was non ascribable to the electric field, but was attribute 
to platinum complexes generated by the electrolysis of platinum electrodes in contact with the 
NH4Cl
- 
 buffer in which bacteria were growing. Exactly, cis-[Pt(II)(NH3)2Cl2) was identified 
as the bioactive species, i.e. cisplatin [77] [78]. This observation  showed that since  this 
compound was able to stop the cellular division of bacteria, it might also be able to stop 
proliferation of cancer cells. After few years of clinical trials, this hypothesis was validated 
and in 1979 the FDA approved cisplatin as anticancer agents. Since then, cisplatin represented 
the cornerstone in the treatment of a wide variety of solid tumors, such as  testis and ovarian 
cancer (giving cancer cure in 95% cases), and  bladder, head, neck, mesothelioma and small 
cell lung [79]. Passive diffusion was believed to be the main mechanism trough which 
cisplatin moves across the membrane; however, active transporter as copper transporter 1 
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(Ctr1) and organic cationic transporters are implicated in cisplatin cellular uptake [80] [81]. In 
the bloodstream, where the chloride concentration is about 100 mM, cisplatin remains intact. 
Once inside the cell, the chloride concentration drops to 2-10 mM, allowing cisplatin undergo 
aquation by means of water substitution of  its chloride groups  (Figure 27). The rate of 
aquation of cisplatin in water (or buffer, pH=7, 37 °C) was measured, and the half life for 
formation of monoaquo species is around 120 min [82]. 
 
 
FIGURE 27. Schematic representation of cisplatin aquation. Upon entering cells, the low of chloride ion concentration 
causes the platinum compounds (1) to undergo aquation reactions, which means that water molecules replace one or both 
chloride leaving groups. The result is the formation of mono and diaquo  species (2 and 3, respectively ). 2 intermediates is 
the most reactive  towards nucleophiles sites [80].  
 
 
The active metabolites of cisplatin, namely the highly reactive mono-and bi-aquated species ( 
cis-[Pt(H2O)Cl(NH3)2]
+ 
and cis-[Pt(H2O)2(NH3)2]
2+ 
, avidly bind DNA, in particular, the N7 
atoms of purine bases located in the major groove, inducing a double helix  distortion that 
inhibits DNA transcription and replication. Cisplatin forms either monofunctional adducts, 
either bifunctional protein-DNA cross-links,  intrastrand (involving adjacent bases as 1,2-
d(GpG), 1,2-d(GpA) and 1,3-d(GpG) , are the most frequent lesions) and interstrand DNA 
cross-links. (ICLs). Although the latter ones are less frequent (5-10%), they are the most 
lethal lesions, since they are processed by means of DSB formation, as described above. The 
main mechanisms responsible for cisplatin-DNA adducts repair are NER, MMR and DSBs 
repair. NER is involved  in repair of intrastrands Pt-DNA cross-links, while repair of Pt-DNA 
ICLs requires components of both NER and recombination repair machinery [83].  In the 
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attempt to remove Pt-adducts and restore DNA integrity , the cell cycle is arrested in G2 phase 
[53] [55].  
HMG-domain proteins are damage-recognition elements that identify and bind Pt-DNA 
adducts (especially 1,2-intrastrand crosslinks). Within this context, they have a controversial 
role. On one hand, they recruit the repair machinery to the damage site, on the other hand, it 
was postulated that they may protect Pt-adducts from recognition by DNA repair enzymes 
preventing NER activity and allowing the lesion to persist [84].  
The persistence of DNA-adducts and the failure of DNA-repair prompt to cell death 
pathways [85]. Actually, it has been observed that high concentration of cisplatin lead to 
apoptosis or necrosis, while lower concentration induce cell cycle arrest/senescence [86] 
(Figure 28). 
 
 
 
 
 
 
 
 
 
 
FIGURE 28. Schematic summary of cisplatin-induced damaging signalling. Initially, DNA damage activate the sensor kinases 
ATM and ATR.  Activation of p21 an p53 prompt to cell cycle arrest, DNA repair or to intrinsic apoptosis.  An extrinsic 
circuitry may be initiated by DNA damage. Importantly, it has been reported that cisplatin could induce apoptosis in the 
absence of DNA damage, through reticulum endoplasmatic (ER) stress.  The fate of cancer cells following cisplatin 
treatment is determined both by the relative intensity of the damage and by the crosstalk between these signalling 
pathways [87].  
 
In addition to genomic DNA, cisplatin could also bind mitochondrial DNA (mtDNA). These 
interaction drastically alter mitochondrial functionality, because mitochondria lack of mtDNA 
repair. Moreover, cisplatin interacts with the voltage- dependent anion channel (VDAC), 
inducing mitochondrial membrane permealization. It was argued that all these damages 
mediated cisplatin oto- and nephrotoxicity [88].Cisplatin not only reacts with DNA, but also it 
form covalent adducts with other many biological molecules. Obviously, it also covalently 
binds mRNA nucleotides [89]. Moreover, cisplatin reacts with endogenous nucleophils 
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containing sulphur functionalities, such as reduced glutathione (GSH), methionine, cysteine-
rich proteins as metallothioneins. GSH is plays a relevant role in cisplatin detoxification. 
Intriguingly, it has been reported that cisplatin also interacts with membrane phospholipids, 
inducing changes in membrane fluidity, modification in membrane cholesterol contents and 
FAS receptor aggregation [90]. 
 
 
FIGURE 29. (Upper) The activated aquo platinum species covalently binds to DNA. Several types of adducts are formed, 
including 1,2-intrastrand cross-links  and interstrand cross-links. (Lower) Basis of the insurgence of cisplatin resistance. The 
main removal pathway for DNA adducts is the NER system, and its increased activity can occur in tumors leading to 
platinum drug resistance. In addition, resistance can occurs through increased tolerance to platinum-DNA adducts, 
involving or loss of MMR  or translesion synthesis that bypass the adducts. Lastly, downregulation of apoptotic cascade is 
observed [91]. 
 
Several toxicities associated with clinical treatment of cisplatin were found, with 
nephrotoxicity, ototoxicity and peripheral neurotoxicity being the most serious. 
Nephrotoxicity is primarily due to uptake of the drugs by the proximal tubule cells of the 
nephron; this side effect has largely been controlled by diuretics and pre-hydration of patients 
[79].  
In addition to its toxic side effects, a major limitation of clinical use of cisplatin-based 
chemotherapy is chemoresistance. It can be inherent, if the drug is ineffective from the 
beginning of treatment,  or acquired, when the drug is initially efficient but lose activity over 
time. Resistance to cisplatin is considered a multifactorial phenomenon, orchestrated by a 
plethora of events, as displayed in Figure 29 [92]: 
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1) first of all, chemoresistance processes may precede the interaction with DNA 
obstaculating target binding. It accounts for two main mechanisms. The first one  
involves reduced accumulation (low levels of CTR1) or increased efflux  by means of 
copper-transporting P-type adenosine triphosphate (ATP7A and ATP7B) and  
MRP1/MRP2 isoforms  [93] [94]. The second mechanisms is ascribed to sequestration 
by citoplasmatic scavengers containing thiols, as GSH, that prevent reaching of the 
target DNA. High levels of GSH, and/or GST, have been observed in vitro in case of 
cisplatin resistance [95] [96] [97] [98]; 
2) a second type of events is directly related to target interaction. It includes both 
increased repair of DNA-Pt adducts and increased tolerance to DNA lesions, as 
showed in Figure 29. The NER system plays a relevant role, since a correlation 
between NER proficiency and cisplatin resistance has been widely reported. Increased 
tolerance to platinum-induced DNA damage can occurs trough loss of function of 
MMR [99];  
3) moreover, resistance mechanisms may concern defective apoptosis due to of Bcl-2, X-
linked Inhibitor of apoptosis (XIAP), overexpression [100]or mutated p53. It has been 
reported that the p53 mutated cancer cells tolerate the formation of DNA adducts 
induced by cisplatin and cannot activate the apoptotic machinery [101];  
4) overexpression of several factor transcription (such as TATA-binding protein (TBP), 
c-fos, c-myc and NF-kB) contribute to cisplatin resistance [102] [87]; 
5) Recently,  it has been pointed out that epigenetic changes (as DNA-methylation and 
acetylation of histones) represent a dynamic survival strategy that contributes to 
cisplatin-resistant phenotype [103]. 
 
Development of new platinum anti-cancer drugs 
Although cisplatin is a successful cancer treatment, it is not an ideal drug. It does not 
selectively act towards malignant cells, causing a plethora of side effects, it cannot be 
administered orally and patients can show or inherent or acquired resistance. 
So, in the later decades, further platinum(II) complexes  have been developed in order to 
improve cisplatin. These efforts led to a second-generation platinum compound, the 
carboplatin, [cis-diammine (cyclobutane-1,1-dycarboxilate-O,O’)platinum(II)]. The 
substitution of the chloride leaving groups with a chelated carboxylate in the former one has 
contributed to decrease nephro- and neurotoxicity maintaining the same efficacy.  Carboplatin  
shares the same carrier groups as cisplatin, thus, and after aquation, forms the same adducts. 
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Accordingly, both compounds exhibit cross-resistance. However, carboplatin aquation occurs 
with a slower kinetics because the dicarboxylate dianion dissociates more slowly than the 
chloride ligands. In fact, the half-life  for aquation of carboplatin is around 100 fold higher 
than that of cisplatin [82].  
Later, a third-generation platinum complex, oxaliplatin,[(1R,2R)-cyclohexane-1,2-
diamine)(ethanedioato)-O,O’)platinum(II)] extended Pt-based therapy to intrinsic resistant 
tumors,  as colorectal cancer, modifying also the carrier groups. Distinct pharmacological 
profiles of oxaliplatin are ascribed to the different carrier groups, the bidentate ligand 1R,2R-
diaminocyclohexane (1R,2R-DACH), in place of two monodentate ammine ligands of 
cisplatin. With respect to cisplatin-derived DNA lesions, oxaliplatin-induced DNA adducts 
are recognized less efficiently by MMR system [104] [105] and HMG domain proteins [106], 
because the bulkier and more hydrophobic carrier group distort in a different way the 
conformation of double helix and consequently are less efficiently repaired  [107]. 
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FIGURE 30.  Pt(II) complex currently used in clinic 
 
Cisplatin, carboplatin and oxaliplatin are worldwide approved drugs. Other compounds have 
only approved locally, like Lobaplatin [1,2-di(aminomethyl)cyclobutanelactatoplatinum(II)] 
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and Nedaplatin (cis-diamminoglycolatoplatinum(II)) and Heptaplatin [propanedioato(2-)-
0,0’)[2-(1-methylethyl)-1,3-dioxolane-4,5-dimethanamine-N,N’]platinum(II), in China, Japan 
and Korea respectively [108] (Figure 30).  
The search for new Pt(II) drugs able to overcome GSH-related cisplatin resistance led to the 
discovery of Picoplatin, also known as AMD473 or ZD0473 (Figure 31). It has been 
investigated in several clinical trials against a wide spectrum of platinum-resistant tumors as 
second line therapy, and it has been regarded as a promising drug candidate for the treatment 
of small cell lung cancer, receiving orphan drug designation in 2007, but unfortunately it 
seems not to be considerably effective [109].  
 
 
FIGURE 31.  Picoplatin 
 
As an alternative to mononuclear platinum compounds, several polynuclear platinum 
complexes have been synthesize by Farrell and co-workers, based on the rational that they 
may form a different variety of DNA adducts (mainly interstrand). Some of them entered 
clinical trials, but didn’t go beyond the phase II because of their high toxicity [110].  
Leading to Pt(IV) complexes 
All Pt complexes used in clinic are administrated intravenously, by means of long and 
debilitating perfusion cycles. Therefore, in the last decades attention was devoted to the 
development of orally-administrable compounds, based on platinum at oxidation state +4, i.e. 
Pt(IV) complexes. These molecules have an octahedral coordination geometry, are inert to 
substitution by with biological nucleophiles. These  features increase their lifetime in the 
bloodstream, raising their chances of reaching the tumor intact. Since their inertness, the 
conventional assumption is that Pt(IV) complexes are prodrugs. Pt(IV) prodrugs can be 
reduced by low molecular antioxidants, such as ascorbate and GSH, to their more reactive 
squanar-planar Pt(II) counterparts that are able to bind DNA (Figure 32). Pt(IV) reduction 
acts by the loss of the two axial ligands, which  requires two-electron transfer process. 
However, ascorbate and GSH contained in the low molecular weight fraction of cell lisates 
inefficiently reduce Pt(IV) complexes, while the high molecular weight fraction is highly 
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efficient,  independently on the amount of intracellular GSH; furthermore, metalloproteins can 
reduce Pt(IV) complexes in the presence of NADH [111]. 
 
The activation of the Pt(IV) depends on two critical parameters:  the reduction potential (Ep) 
and lipophilicity. Both of them depend on the nature of the axial and equatorial ligands. 
Ep determinates the ease of reduction of the complex and consequently is stability under 
biological conditions to reach the tumor target and exerts its biological activity. Considering 
complexes with the same set of equatorial ligands, the most easily reduced are those with 
chloride axial ligands, the most difficult to reduce are complexes with hydroxide axial 
ligands. The substitution of axial ligands with carboxylate chains lead to a complex with 
intermediate potential of reduction.[112]. 
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FIGURE 32.  Activation of the inert Pt(IV) prodrugs. In the cell, the octahedral Pt(IV) complex undergoes a 2 electron 
reduction, mainly by ascorbate or GSH, yielding to their squanar-planar Pt(II) analogs.  
 
 
A interesting work was performed by Hall et al. using the X-ray absorbition near edge 
spectroscopy (XANES), that investigated the reduction kinetics of a series of 
diaminedichloroplatinum(IV) complexes with different axial ligands, on A2780 human 
ovarian carcinoma cell line. They stated that Pt(IV) are reduced within few hours to Pt(II) 
after entering the cells, with a kinetics in agreement with their previous reported Ep calculated 
by means of cyclic voltammetry [113]. 
 
Moreover, axial ligands offer the opportunity to modulate the lipophilicity of the compounds.  
Lipophilicity affects the ability to enter tumor cells by passive diffusion and the propensity to 
be absorbed by the gastro-intestinal tract. A moderately lipophilic complex can be better 
absorbed and more accumulated allowing to overcome one of the main resistant mechanisms 
ascribed to cisplatin, the limited intracellular accumulation. Kelland and al. investigated the in 
vitro antitumor activity of a series of platinum(IV) complexes, and stated that a clear 
relationship exists between the number of carbons on the axial ligand and citotoxicity and that 
compounds with longer axial chains were significantly more cytotoxic and selective than 
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cisplatin [114]. In according to Kelland et al., Gramatica et al. showed that the cytotoxicity of 
platinum complexes is correlated with the length of axial ligands. Notably, they developed a 
predictive and robust quantitative structure-activity relationship (QSAR) model able to 
evaluate the relationship between structural features and in vitro citotoxicity of platinum 
complexes, using a lipophilic descriptor (LogPo/w) and an electronic descriptor (Ep) [115]. 
 
Up to now, some Pt(IV) complexes reached clinical trials but none of them has not yet 
obtained the approval. Iproplatin entered phase II clinical trials, but with limited success. The 
oral administrable Satraplatin, (OC-6-43)-
bis(acetato)amminedichloro(cyclohexylamine)platinum or JM216 (Figure 33), ended phase 
III, in combination with prednisone, for hormone refractory prostate cancer management 
[116].  
 
 
 
 
 
 
 
 
FIGURE 33. Iproplatin and Satraplatin 
 
In recent years, drug delivery approaches have been developed to improve the selectivity of 
platinum complexes towards tumor cells. These efforts accounted for to several strategies, 
such as liposomal-based (Lipoplatin) or co-polymer based products (Prolindac) [117]. 
Topoisomerase inhibitors 
Movement of the growing fork during DNA replication induces formation of positive 
supercoils; in order to extensive DNA synthesis to proceed, the supercoils must be removed. 
The overwinding of DNA is regulated by topoisomerases, that are enzymes that exist in two 
isoform, called I and II. Topoisomerase I cleaves only one strand of DNA duplex and then 
reseals it removing both positive and negative supercoils. Topoisomerase II enzymes have the 
ability to cut both strands of DNA molecule, pass another portion of the duplex through the 
cut, and reseal the cut [25]. 
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The former class is inhibited by campotecines (which include irinotecan and topotecan), 
whereas the latter class is the target of antracyclines (as doxorubicine) and antibiotics (such as 
Actinomycin, Mitomycin C and Bleomycin) [62]. 
Moreover, doxorubin acts as an intercalating agent, as far as its planar structure prompts to a 
distortion of the double helix. 
Mitotic spindle inhibitors 
These drugs block the formation of functional mitotic spindle in M phase, preventing cell 
division. The mitotic spindle is composed of  microtubular  fibers, formed by tubulin, at 
which duplicated DNA chromosomes are grasped. They ensure that, after cell division, each 
new cell gets a full set of chromosomes.  
Vinca alkaloids ( such as Vincristine, Vinblastine), bind tubulin, preventing its 
polymerization, and the formation of spindles and cell division. Conversely, taxanes 
(Paclitaxel, Docetaxel) stabilize the assembled tubulin filaments, hindering the separation of 
the daughter cell [118].  
Epigenetic modulators 
Epigenetic modifications include heritable and reversible changes modulating a variety of 
mechanisms such as RNA elongation, mitosis, DNA replications and repair, all of them 
influenced on the state of chromatin. By affecting gene activity, epigenetics also plays a major 
role during tumorigenesis. Therefore, the development of drugs acting as epigenetics 
regulators attracted considerable interest. Their general mechanism of action is simplified in 
Figure 34. 
 
 
FIGURE 34. Epigenetic control systems generally involve three types of proteins: writers (such as HATs), erasers (such as 
HDACs) and readers as BRD4. (+)-JQ1 prevents it from reading the acetyl-lysine residues of histones and modulating gene 
transcription by disruption of chromatin-dependent signal transduction [119]. 
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Epigenetic modulators inhibit enzymes that convert chromatin to the open-active 
conformation, i.e. histone deacetylase (HDAC) and DNA methyl transferase (DNMT) 
inhibitors, or prevent the inactive-acetylated chromatin to be read, as BET inhibitors. Several 
HDACs and DNMT inhibitors have been tested in vitro and are currently evaluated clinically 
[120] [121].  
HDAC inhibitors belong to different structural families that includes hydroxamates 
(vorinsotat and  suberoylanilide hydroxamic acid, or SAHA) , cyclic peptide (trapoxin B), and 
short-chain fatty acids (valproic acid, sodium butyrate). HDACs inhibitors induce apoptosis 
by activating both extrinsic and intrinsic pathways, and prompt cells to senescence [122].  
Despite promising in vitro observations, clinical trials using HDCA or DNMT inhibitors 
alone are frequently deluding, whereas given in combination show a modest antitumor effect 
[121] [123].  
The role of BRD4 in c-myc expression and NF-kB activity 
Bromodomain and extraterminal (BET) family of acetyl-lysine recognition motifs act as 
chromatin regulators. The BET family orchestrates the expression of genes that regulate both 
inflammation processes and proliferation. Notably, BRD4, highly expressed in a broad range 
of tumors, plays a key role in driving gene expression in M/G1 mitotic chromatin and ruling, 
inter alia, c-Myc and FOS-L1 expression [124], and, indirectly, NF-kB [20] [125].  
Transcriptional activation is associated with chromatin acetylation, which prompts to BRD4 
recruitment. Then, BRD4  forms a complex with two transcription cofactors: the Mediator and 
the positive transcription elongation factor b (P-TEFb), a kinase that facilitates  RNA 
polymerase II-dependent transcription [126]. This complex not only occupies the enhancers, 
but also the super-enhancers (larger complexes of transcription factors responsive elements 
recognized by TF and coactivator), that work through cooperative and synergistic interplay. 
Super-enhancers are correlated with tumor progression, since their clusters are usually 
generated near oncogenes in cancer cells [127]  Super-enhancer activity depends on the 
recruitment of BRD4, thus, its inhibition leads to their disruption. In multiple myeloma, the 
association between super-enhancers and oncogenes transcription has been demonstrated 
[128]. Recently, BRD4 was proposed as good target by means modulate c-myc transcriptional 
function. 
In the last years, the emerging drug candidate (+)-JQ1 (Figure 35), a tieno-tiazolo-1,4-
diazepine, has attracted great interest. It is a potent and high specific inhibitor of BET family. 
 53 
 
(+)-JQ1 displaces BET proteins from chromatin by competitively binding to the acetyl-lysine 
recognition pocket, modulating gene transcription. (+)-JQ1 shows high binding activity for 
BRD4; on the contrary, the (−)-JQ1 stereoisomer has no appreciable affinity to BET 
bromodomains. 
 
 
FIGURE 35. Skecth of (+)-JQ1 and (-)-JQ1 
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Antitumoral drug discovery in vitro 
Hit-to-lead phase: design and screening 
The process of drug discovery is a very long way.  It generally follows the following path that 
includes the following stages: 
target validation (TV) → assay development → high-throughput screening → hit to lead 
(H2L) → lead optimization (LO) → preclinical drug development → clinical drug 
development. 
Hit to lead (H2L), also known as lead generation, is a stage in early drug discovery where 
primary active agents (namely hit compounds) are evaluated from a high throughtput 
screening (HTS), and then undergo limited optimization to identify new analogues with 
improved potency, called lead compounds [129]. Lead and hit compounds share the same 
pharmacophore,  i.e.  the set of various functional groups spatially orientated in a specific 
way or of features necessary for activity trough a biomolecular target, that is defined by 
quantitative structure-activity relationship (QSAR) studies. Further chemical modifications 
are introduced during lead optimization phase to refine flaws of each series [130]. 
Early screening of investigated molecules is performed in  the attempt to establish the degree 
of their potency and selectivity and so, to identify the compounds with better pharmacological 
profiles that deserve to be addressed to future investigations. In a second step, drugs 
mechanism of action is elucidated at molecular or cellular level. In the last years, the drug 
discovery process has relied on system biology to better understand the cellular response of to 
bioactive agents. Its introduction has allowed to move from a “target approach” to a “system 
approach” and so, to connect biological activity of bioactive molecule to an increased 
biological space [1] [129]. 
In vitro processes of identification of bioactive molecules involves high troughput screening 
(HTS). HTS are assay performed by micro-plates, usually formatted of 96 or 384 wells, that 
allow to test simultaneously several compounds using small volumes.  
Two factors are crucial: first, the choice of a reliable, rapid, sensible and reproducible HTS 
method; second, suitable biological model that resemble the features of the disease against 
which you wish intervene. For anticancer drug screening, cell lines are mainly employed. A 
cell line derives from a specimen of the same site of origin/tissue, thus, it composed by cells 
that share the same genetic and morphological characteristics. In the field of anticancer drug 
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discovery, tumor cell lines are employed as experimental model and the effort are focused on 
cytotoxic or cytostatic compounds that cause tumor regression. Cell lines of hematological 
tumors growth in suspension, while those of solid tumors growth attached to a solid support 
as monolayer. They are maintained in a growth medium that mimic bloodstream. 
Unfortunately, advances in the process of anticancer drug discovery are not so fast. This 
drawback lie mainly  on the limits harbored by in vitro tumor models available. 
In vitro solid tumors models 
Cell monolayer model 
The most commonly used cell model for in vitro study is the monolayer of cells  growing on a 
sterile, tissue culture treated, plastics substrate. Once the available surface is covered by cells, 
they reach confluence and growth stops (Figure 36). Therefore, in order to  keep the cells 
actively growing, they have to be sub-cultured at regular intervals.  However, 2-D models 
harbor some intrinsic limitations and are unrepresentative of solid tumor tissue and the 
associated microenvironment. They do not replicate the molecular patterns, gene expression  
and further genetic and epigenetic changes accumulated during cell replication in the body. 
Moreover, they do not simulate both the heterogeneity of tumor niche and cell-cell and cell-
matrix interactions [131]. So, drug research based on 2-D models may not accurately predict a 
drug’s effects in the body, leading to a high rate of false positives  of promising drugs 
candidate.  
 
FIGURE 36. Monolayers growth of an in vitro cell line attached to surface of a Petri dish treated for cell culture (TC, the 
surface has to be hydrophilic and negatively charged). Once available surface is covered by cells, they reach confluence and 
growth stops. 
Although the 2-D culture model offered an important contribution to drug research, a lot of 
efforts were done to develop in vitro models that resemble in vivo tumor tissues. In the last 
years, these efforts prompted to the implementation of 3-D tumor models in antitumor drug 
discovery. 
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Multicellular tumor spheroid models 
3-D tumor models includes [132]: 
 hollow fibers reactors: cells are seeded into hollow fiber to form solid mass; it is a 
discouraged procedure because fiber all both holds back cells growth;    
 multicellular layer model: cells are seeded into semi-permeable support membrane; it 
is used to measure drug diffusion trough the membrane that stands for a barrier 
between extracellular environment and cells layer. The information obtained is be 
questionable, since it does not reflect in vivo cell arrangement. Also, it’s not 
compatible with not long-term culture;  
 multicellular tumor spheroids. 
 
Multicellular tumor spheroids (MCTS) are spherical cell aggregates having diameters of 
around 350-400 M . They are formed by an outer shell of proliferating cells (reflecting the in 
vivo situation of cells adjacent to blood vessels), by a inner ring of quiescent cells and finally, 
by a necrotic/hypoxic core. Spheroids develop a concentration gradient of oxygen, nutrients, 
catabolites and drugs. 
MCTS accurately simulate the conditions of native tumors as volume growth kinetic, 
cytoarchitecture and cellular communication (Figure 37); cell-cell and cell-matrix contacts are 
similar to those of  avascular nodules,  intervascular regions of large solid tumors and 
micrometastasis.  
MCTS are less sensitive than their 2-D system counterpart to the same treatments [133]. Thus, 
they reproduce some physiological characteristics that are crucial for therapeutic efficacy and 
provide a more realistic prediction of in vivo drug responses. The ability to generate 
spontaneously MCTS is given by the presence of a peculiar sub-populations, as cancer stem 
cells [134]. Unfortunately, not all primary tumor cells or all established cell lines 
spontaneously form spheroids; it is a intrinsic ability independent of the culture technique 
[135]. Sometimes, cancer cells have to grow in stem cell medium, rich in growth factors,  to 
generate MCTS [136]. Ivascu and co-worker analyzed the spontaneous generation of several 
cell lines, representative of different tumors, and assessed that some of them give rise to 
simple cellular aggregates [137]. 
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FIGURE 37.  Tumor spheroids exhibit a  concentric organization of proliferating, quiescent and dead cells. Moreover, they 
simulate the diffusion gradient of drugs, O2 and nutrients. Molecules diffuse until a distance of 150-200 m the outer layer 
[138]. 
 
Spheroids represent a useful tool since they could be used for long-term drug studies and 
allow to discriminate the cytostatic and  cytotoxic activity of an anticancer agent. 
Furthermore, they could be co-cultured with different cell types, as endothelial or immune 
cells [138]. Lastly, MCTS allow to reduce the use of animal models (Figure 38).  
 
 
FIGURE 38. Since MCTS models approximate some features of in vivo tumors, they can fill the gap between conventional 2D 
assays and the in vivo screenings in animal models. So,  they allow to reduce employment of animal test systems [139].  
 
Several techniques have been proposed to generate MCTS, including spinning flasks, liquid 
overlay, microscaffolds, and the hanging drop method to shape the  cell aggregation  [140]. In 
spinner flask, cells are growth in dynamic suspension of culture medium yielding a high 
number of very different spheroids. In the second one, cells are seeded into culture dishes 
coated with agarose. The former couple of procedures are not reliable since are not able to 
control spheroids size, while the latter two and require specific and expensive tools.  
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However, in a drug screening perspective since, microplate-based methods  are the best ones. 
In literature many methods to avoid cell adhesion have been reported, based on well surface 
coating, for instance by an hydrophobic polymer, i.e. poly (2-hydroxyethil metacrylate) or 
poly-HEMA, or by Matrigel® (that is a basement membrane extract that resembles ECM 
components)  [137].  
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Malignant Pleural Mesothelioma 
What is asbestos? 
Asbestos refers to a naturally occurring family of hydrated mineral silicate fibers. It is 
conventionally classified in two distinct groups: 
 The amphiboles, which include crocidolite (“blue asbestos”), amosite (“brown 
asbestos”),  anthophyllite, tremolite and actinolite; 
 chrysotile, or “white asbestos”. 
The former fibers are needle-like, while the latter fibers have a curled,  “serpentine” shape. 
In the 20
th
 century, asbestos (especially crocidolite and amosite fibers)  had a widespread 
commercial diffusion because of its ideal advantages, represented by durability, fire-
resistance, and cheapness. Indeed, the term  asbestos comes from ancient Greek and means 
inextinguishable. It was employed in building as insulation material (e.g. brake lining, ship 
building, ceiling, pool tiles), also mixed with cement, and for other disparate uses (e.g. 
cigarette filters, theatre curtains, tablemat, crayons). 
Asbestos was regarded as the best available material for these applications until, in 1960s, 
many evidences highlighted its pitfall: carcinogenicity. Asbestos fibers, once inhaled, can lead 
to pleural plaques, to a chronic pleural and lung fibrosis (called asbestosis) and/or act as a 
tumor promoter or co-carcinogenic, giving rise to, broncogenic carcinoma(lung cancer)  and 
pleural and peritoneal malignant mesotheliomas [141] [142] (Figure 39). 
 
 
FIGURE 39. Diagram showing the situation of the types of pathology caused by asbestos fibers [142]. 
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Asbestos carcinogenicity relies on its fibrous structure: the fiber surface area, size, solubility 
and their chemical composition all play a role in its mechanism of action.  Needle-like fibers 
are by far more potent than curly fibers in causing MMs because they deeply penetrate into 
the lower respiratory tract and they are cleared less rapidly from the lungs. This phenomenon 
is enhanced for longer (> 2 m) and less soluble fibers. 
Notably, among the asbestos types, crocidolite and amosite are characterized by the highest 
iron content, which is involved in tissue injury, since the ferrous ions integrated into asbestos 
fibers are oxidated by hydrogen peroxide to ferric ions (Fenton reaction) leading to the 
production of hydroxide anion (OH
-
) and hydroxyl radicals (HO
•
). In turn, ferric ions can be 
reduced to ferrous ions by superoxide anion (O2
-
), as well as other biological reductants, 
making a  chain of reactions that fuel the genesis of other damaging oxygen species (ROS), 
such as  hydrogen peroxide (H202) and alkoxyl radicals  (RO
•
) [143]. 
In addition crocidolite fibers has the finest fiber diameter; thus this type of asbestos is 
regarded as the most oncogenic one [144]. 
 
Malignant pleural mesothelioma and asbestos 
Malignant  mesotheliomas (MMs) are fatal tumors arising from mesothelial membranes that 
line the pleural, peritoneum and pericardium cavities. The primary function of mesothelial 
cells is to form a protective monolayer around inner organs that facilitates their movement  by 
means of the secretion of a lubricant (consisting of glycosaminoglycans and 
phosphatidylcholine) that supports the  lubrification of their serosal surface [145].  
The association between asbestos exposure and mesothelioma was established in 1960s, when 
Wagner et al. [146] published a paper that described 33 cases of MMs, observed in African 
miners exposed to Caper Blue Asbestos. Two years later, Wagner confirmed this thesis 
producing MPM in laboratory animal models by direct exposure to asbestos dust. 
Since then, a lot of extensive epidemiological data have been accumulated and the scientific 
community widely accepted that even a low-level exposure of asbestos is able to induce 
mesotheliomas [147]. 
MMs are considered occupational malignancies, because they mainly occured in male 
workers exposed to asbestos fibers.  However, many cases have been observed in family 
members of asbestos workers and in the people living in proximity of asbestos mines and 
factories due to environmental pollution by asbestos mineral fibers [148]. 
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MM most commonly occurs in the pleura: the so-called malignant pleural mesothelioma 
(MPM) stands for up to 80% of all cases [149].  
MPM tumor cells can assume three histological subtypes, namely: 
 Epithelioid, which is the most common and with better prognosis; 
 Sarcomatous, with spindle-like cells; 
 mixed or biphasic, with both epitheliod and sarcomatoid components. 
MPM has a very poor prognosis: the median survival is less than 12 months from the 
diagnosis. 
The malignancy develops after a long period of latency, that may be in the order of about 40  
years after initial asbestos fiber inhalation [150]. In the past, MPM was considered an 
extremely rare tumor. However, MPM risk has been climbing more and more and its peak of 
incidence is coming in the next decades as a result of past widespread use of asbestos (Figure 
40). 
 
FIGURE 40.  Incidence rate of MPM (age-standardized rates, ASR), observed in the past and predicted for the next decades. 
It mainly affect the male population arising from occupational exposure [151]. 
 
 
Nowadays,  only few countries  banned the employment of asbestos; it  still can be mined and 
exported in Russia (which is the largest producer), Brazil, South Africa, China, India, 
Kazakistan and Canada, where it is often handled without adequate precautions. USA and 
Japan did not ban the use of asbestos but restricted its usage only. Italy banned the use of 
asbestos in 1992, but the hazards is still there, since huge amounts of asbestos derivates still 
remain in public and private buildings. Many rules to avoid the risk of accidental asbestos 
inhalation have been adopted and some attempts to force asbestos decontamination in industry 
and housing are ongoing [148].  
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It should be noted that asbestos represents a potential hazard in case of natural disasters or 
explosions, because it can become airborne from building and the air could be contaminated 
with its small fibers. One emblematic example is the fall of the twin towers, in 2001: the 
buildings was made of about 400 tons of  asbestos and after their collapse to the ground, there 
was a release of ultra-fine asbestos fibers. Rescue workers and local population were exposed 
to asbestos from the air and have a high risk to develop MPM or asbestos-related diseases in 
the next future. [152]. 
In addition, in some Western countries (i.e. Greece, Cyprus and Turkey) there are volcanic 
rocks containing asbestiform minerals, that have been used by inhabitants to build houses.  
So, this malignancy is not going to disappear rapidly but, on the contrary, it will represent for 
a long time a worldwide threat. 
Analysis of mesothelioma mortality recorded in WHO database between 1994 and 2008 
yielded a death rate of 6.2 cases per million population and estimated that 125 million people 
worldwide are currently exposed to asbestos in workplace [153].  
MPM epidemiological patterns closely reflects  the geography and history of asbestos  
exposure. Disease incidence varies between countries and the burden of MPM death cases are 
relevant in Australia, Belgium and Great Britain [147] (Table 2).   
 
 
TABLE 2. Disease incidence of MPM varies markedly between geographic area but the highest annual rates are reported in 
specific countries [154]. 
 
 
Italy shows one of the highest incidence rates of MPM (in the period  2003-2009,  5184 
deaths per year occurred) and exhibits the highest mortality rates in Liguria, Piemonte, Friuli-
Venezia Giulia and Lombardia regions, mirroring the occupational, and the 
cobsequentenvironmental asbestos exposure (Figure 41). The greatest mortality cluster have 
been observed  in Casale Monferrato (AL) and its surrounding area, where, the factory Eternit 
was active in the production of asbestos-cement until 1986. 
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FIGURE 41. (Left): In Italy, MPM 
mortality has high regional 
variability. The acronym SMR 
stands for standardized mortality 
relative, since the mortality was 
standardized with number of 
resident population. MPM death 
cases are concentrated in specific 
sites (red spots),  
corresponding to municipalities 
where asbestos manufacturing 
and use was hugely employed in 
large asbestos-cement factories, 
in shipyards and close to quarries. 
(Right): Mortality cluster in North 
West area for men (upper) and 
women (lower) are depicted. Two 
main clusters was found in both 
gender, corresponding to the 
area with major asbestos-cement 
industries: Casale  Monferrato  
(AL) and Broni (PV) [155]. 
 
 
Mechanisms underlying asbestos carcinogenecity 
A huge number of evidences showed that asbestos is a complete carcinogen, since after its 
inhalation, the fibers reach the pleura and initiate a cascade of events in mesothelial and not-
mesothelial cells that reshape the cellular milieu. However, hitherto it is still not completely 
understood the mechanism of malignant transformation. It seems that the molecular 
pathogenesis of MPM is a multifactorial process involving multiple phenomena (Figure 42). 
Three hypothesis have been reported since now [156] [142]: 
1) the chromosome tangling theory: asbestos fibers are engulfed by mesothelial cells. 
The uptaken fibers physically interfere with mitotic spindles during cell division, 
resulting in incorrect chromosomes segregation, chromosomal structural abnormalities 
and aneuploidy ; 
2) the adsorbition theory: in vivo, the positive and negative charges on mineral surface 
of asbestos fibers catalyze the deposition of proteins and/or hazardous chemicals; 
3) the so-called oxidative stress theory: asbestos fibers generate ROS both outside and 
inside the cells, triggering oxidative stress. After phagocytes (i.e. alveolar 
macrophages and leukocytes) engulf  the asbestos fibers, they produce large amounts 
of free radicals to eliminate them, without success and (the so “frustrated 
phagocytosis”). The iron contained in asbestos, catalyzes the generation of reactive 
oxygen species on mineral fibers surface by itself and amplifies the ROS cascade. 
 64 
 
 
FIGURE 42. Pleural malignant transformation. Asbestos trigger ROS generation and the release of inflammation mediators. 
In addition, asbestos interfere with mitotic spindle during chromosomes segregation. These events allows genetic 
alterations to accumulate within mesothelial cells and sustain asbestos-induced DNA-damage, leading to the initiation of 
mesothelioma [149]. 
 
ROS generated by asbestos fibers  have two main consequences that both have a crucial 
influence on pleural malignant transformation: 
1)  insurgence of DNA damage; since hydroxyl radicals are added to DNA bases 
forming DNA adducts that induces conformational changes of double helix. In 
particular, it was reported that 8-oxo-2’ deoxyguanosine has a major role in 
carcinogenesis. Reduced repair of oxidized DNA bases will results in elevated genetic 
and epigenetic lesions and consequently, their predispose changes in expression of 
several genes correlated with protein metabolism, cell transformation, survival, 
proliferation and motility [157]; 
2) chronic inflammation; asbestos-killed cells and the frustrated phagocytosis induce 
the recruitment of many inflammatory cells by means of the  secretion of many 
cytokines and growth factors, as tumor necrosis factor-alpha (TNF-, interleukins 
(such as IL-1, IL-6, IL-8); HMGB1, and VEGF. The prolonged state of 
inflammation also enhances the expression of inducible enzymes causing, interalia, 
up-regulation of cyclooxigenase-2 (COX-2) [158]. It is known that prostaglandin E2 
(PGE2), the main COX-2 metabolite,  impacts several pathways involved in 
carcinogenesis. 
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Because of  these signalling are persistently activated, chronic inflammation occurs. 
This events induce a reshaping of cellular microenvironment. 
 
Because of the crucial role of oxidative stress in MPM pathogenesis, this malignancy is 
regarded as a “reactive-oxygen driven tumours”. 
All these perturbations induce  mesothelial cells to die. However, in some of them, a 
compensatory mechanism is activated to inhibit asbestos-induced cytotoxicity. The high 
concentration of growth factors and cytokines promotes a cascade of pro-survival pathways, 
stimulating cell proliferation, neoplastic transformation and tumor progression. In fact, is well 
known that chronic inflammation promote carcinogenesis [159] (Figure 42). 
 
It seems that genetic factors predispose specific individuals to MPM. Individual differences in 
genes involved in detoxification, might partly explain the difference in susceptibility to MPM. 
However, their role  need to be further elucidated [160]. Furthermore, a possible role of the 
viruses has been proposed. It was hypothesized  that the oncogenic Simian Virus-40 (SV-40)  
is a potential cancerogenic factor in MPM pathogenesis and that could increase the risk of its 
occurrence among people exposed to asbestos. SV-40 is a monkey virus which is thought to 
have infected humans via contaminated polio vaccines used in 1950s and 1960s [161]. 
However, the evidences are controversial and it is unlikely that SV-40 play a role in the onset 
of this malignancy [162]. 
 
Molecular alterations in MPM 
MPM progression is a long multi-stage process, therefore, protracted  oxidative stress  
signalling provokes  persistent  DNA damages.  
Consequently, a lot of deregulated pathways   in MPM contribute to tumor development and  
chemoresistance [163]. The oncogenic cascade of events include: 
 activation of NF-kB pathway and NF-kB dependent genes, as  c-myc and c-Jun 
oncogenes; 
 activation of the epidermal growth factor receptor (EGFR). This event is correlated 
with the activation of extracellular downstream signal-regulated kinases (ERKs) (i.e. 
ERK 1/2); ERKs modulates transcriptional activity of several proto-oncogenes as c-
fos and c-jun; 
 promotion of antiapoptotic genes as Bcl-xl; 
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 upregulation of anti-oxidant enzymes, such as manganese superoxide dismutase 
(MnSOD) and GST  [164], and increase of GSH metabolism [165] [166]; 
 overexpression of genes involved in each DNA repair system, especially genes related 
to double-strand break repair (Figure 43) [167]. 
 
FIGURE 43.  Schematic representation of genes overexpressed in malignant pleural mesothelioma related to DNA repair 
(green).  They account for both the chemo- and radio-resistance. In particular, defects on MMR (by MSH6 overexpression) 
and NER (by GTF2H2/p44) confer to platinum resistance  [167]. 
 
MPM Chemotherapic treatment: the state of art 
MPM is highly refractory to most of the available conventional therapies. When the disease is 
diagnosed in advanced stage and surgical approaches are not suitable, chemotherapy is the 
cornerstone of the treatment  and platinum-based regimens represent the gold-standard. In a 
meta-analysis of phase II trials conducted between 1995-2001, cisplatin was the most active 
single agent for the treatment of unresectable MPM [168]. 
First-line chemotherapic treatment combined cisplatin with gemcitabine. In 2003, a phase III 
randomized trial compared cisplatin alone versus cisplatin plus pemetrexed in untreated 
MPM. The combination gave a response rate  of 41.3% compared to 16.7% for cisplatin alone 
and improved the median overall survival for patients of very few months (12.1 versus 9.3 
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months with cisplatin alone) [169] [170]. Despite association of cisplatin and gemcitabine 
shows similar benefits [171], gemcitabine is not still employed in clinical regimens.   
A second-line therapy still lacks and need to be developed. Vinorelbine was evaluated in 
monotherapy for this purpose, but obtained a response rate of 16% and a median survival of 
9.6 months. With the combination of vinorelbine and cisplatin, the response rate was 30%, 
two fold higher, and the median survival was 16.8 months [172]. 
 
The way of  selectivity of targeted therapies was explored on the basis of markers 
differentially expressed by tumor cells with respect to  non-malignant cells. Indeed, 
mesotelioma cells secrete and express several angiogenic factors (such as EGF, VEGF, 
PDGF) that sustain angiogenesis and increase vessel density, which is correlated with poor 
outcome. Consequently, a plethora of tyrosine kinase inhibitors of their receptors were 
investigated. They showed  strong activity against in vitro MPM models, but were proved 
ineffective, both in monotherapy and in associations, in a lot of phase II/III clinical studies. 
Similarly, cell cycle pathway inhibitors were evaluated and failed to improve the survival. So, 
these evidences are damping down the enthusiasm for molecular targeted drugs as standard 
treatment for MPM [173].  
In addition, epigenetic drugs were also evaluated, but without giving promising results [174] 
[175].  
The failure of MPM management is due to two main reasons: first, because is often diagnosed 
in the late stages when the disease is too advanced for current therapies; second, because 
sometimes it is misdiagnosed with other malignancies (benign pleural disease, metastatic 
cancer, adenocarcinoma). A lot of efforts have been devoted to identify an serum biomarker, 
which had to guarantee selectivity, early diagnosis, and treatment outcome prediction. 
Among several potential biomarkers, over-expressed in MPM cells, that have been evaluated, 
the most promising are the following: 
 soluble mesothelin-related peptide (SMRP), a glycoprotein that plays a role in cell 
adhesion and cell-to-cell recognition and signaling over-expressed on mesothelioma 
cells; 
 osteopontin, a tumor-associated glycoprotein that regulates cell-matrix interactions 
and cellular signaling; 
 megakaryocyte potentiating factor (MPF), is a sialoprotein involved mainly in bone 
matrix formation and tumor invasion. 
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However, each biomarkers listed above have some limitations: osteopontin lacks of 
specificity for mesothelioma, while both SMRP and MPF show poor sensitivity for detecting 
non-epithelial subtypes [163].  So, further efforts are needed to discover better prognostic and 
detection tools for MPM. 
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Materials and methods 
Unless specified, all reagents were purchased from Fisher Scientifics. 
Unless specified, absorbance, fluorescence and luminescence values were recorded  with a 
Tecan Infinite F200 plate reader. 
Cell culture 
MPM cell lines derived from pleural effusion of previously untreated patients suffering from 
MPM, called BR95 (epithelioid histotype), MG06 (mixed histotype, with epithelial 
predominance), MM98 (sarcomatoid histotype), and MM98R. The latter is a cisplatin-
resistant cell line derived from wild-type MM98 by exposure to sub-lethal concentration of 
cisplatin for several months [176].  
A human mesothelial cell (HMC) lines was employed to check the selectivity of drugs 
candidate investigated. HMC were isolated by gentle scraping of the peritoneum of the inner 
wall of uncomplicated congenital hernia sacs surgically excised from premature babies. This 
local environment is usually devoid of significant inflammatory stimuli in the absence of 
complications and therefore the peritoneum remains thin and almost transparent and the 
uninjured HMCs are mostly in a normal (resting) state with a pavement-like appearance. All 
cell lines were obtained from the bio-bank of the hospital of Alessandria (Pathology Unit). 
Their phenotypes are shown in Figure 44. 
 
FIGURE 44. The MPM cell lines (a) BR95,epitheliod; b) MG06,mixed; c) MM98, sarcomatoid) and the human mesothelial cell 
(d) HMC) line were employed in this study. The epitheliod cells show a regular shape, while the sarcomatoid are spindle-
shaped. MGO6 mixed phenotype cells shows a predominance of epitheliod component. HMC cells show  intermediate 
morphological characteristics between them. 
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HMCs, epithelioid and mixed cells were growth in F10 Ham’s medium, whereas Dulbecco’s 
modified Eagles’ s medium was used for sarcomatoid ones.  
The A2780human ovarian carcinoma , the HCT-116 human colon carcinoma cell line and  the 
MCF-7 breast cancer cell lines were purchased from ECACC (European Collection of Cell 
Cultures, UK) and were growth in RPMI -1640,McCoy’s 5A and MEM supplemented with 
non-essential amino acids, respectively. 
The human lung cancer cell line A549 was a kind gift of Dr. S. Bonetta (Avogadro 
University) and was grown in RPMI 1640.The acute leukemia HL-60 cells was a kind gift of 
Dr. S. Martinotti (Avogadro University) and was growth in RPMI-1640. 
Media were supplemented with L-glutamine (2mM), penicillin (100 IU mL
-1
), and 10% fetal 
bovine serum (FBS)  to give the complete medium. FBS is commonly used as a supplement to 
cell culture media since it supports cell growth and product formation proving a broad 
spectrum of macromolecules, attachment factors, nutrients, hormones and growth factors.  
Media and supplements were purchased from Sigma-Aldrich, Lonza Biosciences and Life 
Technologies. 
Cells manipulation was performed in a laminar flow cabinet, in sterile conditions, to prevent 
contamination.  
Cells were routinely grown in sterile polystyrene TC Petri dishes with a diameter of 10 cm at 
37 °C in a 5 % CO2 humidified chamber (Thermo Scientific, Model 370). In order to  keep the 
cells actively growing and avoiding that they reached confluence), they were sub-cultured at 
around twice a week. 
Briefly, medium was aspirated from the cell culture Petri dish, cells were washed once with 
sterile PBS (phosphate buffer saline containing 50 mM sodium phosphate, 150 mM sodium 
chloride, pH 7.2) and then, a trypsin-EDTA solution (0.05% and 0.2%, respectively, Hyclone) 
was added. Once the cells detached from the plate, serum-containing medium was added to 
inhibit trypsin. Harvested cells were collected into an appropriately sized centrifuge tube and 
centrifuged for 5 minutes at 1100 rpm. Following centrifugation, the supernatant was 
removed, and the cell pellet was resuspended in complete medium. Thus, cells were counted  
by means of an hemocytometer  and an adequate cell number was re-seeded. 
To perform the routine determination of the IC50 values, 2000-5000 cells were seeded into 
sterile tissue-culture-treated 96-well plates and allowed to attach 24h before drug treatment. 
Then, they were challenged with drugs for 72 h continuous treatment (CT) at various 
concentration. 
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For cell senescence cells (2104) were seeded in 24-wells plates the day before treatment.  
  
For clonogenic assay, 200 cells well
-1
 (BR95) or 100 cells well
-1
 (MM98) were seeded in 6-
well plates the day before the treatment. 
Compounds and drug candidates 
Unless specified, compounds were synthesized in Osella’s laboratory. Platinum complexes 
investigated are shown in Figure 45.  
Figure 45a display cisplatin, carboplatin, ethacrynic acid and the bi-functional complexes 1 
(cis,cis,trans-diamminodichloridobis(ethacrynato)platinum(IV)) and 2 (cis,cis,trans-
diamminodichloridobis(ethacrynato)platinum(IV)).  
In Figure 45b, picoplatin and its Pt(IV) analogues 3 (cis,cis,trans-
[PtCl2(mpy)NH3(CH3COO)2), 4 (cis,cis,trans-[PtCl2(mpy)NH3(CH3CH2COO)2) and 5 
(cis,cis,trans-[PtCl2(mpy)NH3(CH3CH2 CH2COO)2) are reported. Platinum(IV) complexes 
with linear carboxilate chains as axial ligands, are 6 (cis,cis, trans-diaminedichlorobisacetate-
platinum(IV)), 7 (cis,cis, trans-diaminedichlorobisbutanoate-platinum(IV)), 8 (cis,cis, trans-
diaminedichlorobisesanoate-platinum(IV)), 9 (cis,cis, trans-diaminedichlorobisoctanoate-
platinum(IV)), as shown in Figure 45c. 
Lastly, Pt(IV) complexes with carboxylate aromatic axial ligands are reported (Figure 45d). 
10 (trans,cis,cis-[Pt(C6H5COO)2Cl2(NH3)2]), 11 (trans,cis,cis-[Pt(C6H5CH2COO)2Cl2(NH3)2]) 
and 12 trans,cis,cis-[Pt(C6H5(CH2)2COO)2Cl2(NH3)2]) share cisplatin as Pt(II) counterpart; 
while 13 (cis,trans,cis-(1R,2R-DACH)[Pt(C6H5COO)2Cl2]), 14 (cis,trans,cis-(1R,2R-DACH 
[Pt(C6H5CH2COO)2Cl2]) and 15 (cis,trans,cis-(1R,2R-DACH) [Pt(C6H5(CH2)2COO)2Cl2]) 
share 1R,2R-DACH-Cl2 as Pt(II) analogue. 
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FIGURE 45. Sketch of platinum complexes investigated  
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Compounds preparation (solvent used, final stock concentration and storage) was summarized  
in Table 3.  
 
Complex Final Stock 
concentration 
Solvent Storage 
Cisplatin 
(Sigma-Aldrich) 
1 mM aqueous solution of 
NaCl (0.9 % w/v) 
brought to pH 3 with 
HCl 
 –70 °C.  
 
Carboplatin  
(Strem Chemicals) 
25 mM ultrapure water (Milli-
Q) 
Prepared immediately  
before the experiment. 
Ethacrinic acid (EA) 
(Sigma-Aldrich) 
0.1 M DMSO Prepared immediately  
before the experiment. 
1 20 mM DMSO –70 °C.  
2 10 mM DMSO Prepared immediately  
before the experiment. 
Picoplatin 5 mM DMSO –20 °C. 
3 5 mM DMSO –20 °C 
4 2.5 mM DMSO –20 °C 
5 2.5 mM DMSO –20 °C 
6 5 mM NaCl 0.9 % –70 °C 
7 5 mM NaCl 0.9 % –70 °C 
8 5 mM absolute ethanol –70 °C 
9 2.5 mM absolute ethanol –70 °C 
10 10 mM DMSO –70 °C 
11 10 mM DMSO –70 °C 
12 10 mM DMSO –70 °C 
13 10 mM DMSO –70 °C 
14 10 mM DMSO –70 °C 
15 10 mM DMSO –70 °C 
1R, 2R-DACH-Cl2 5 mM DMSO Prepared immediately  
before the experiment. 
Oxaliplatin 5 mM L-(+)-Lactic acid  dissolved over night 
(O.N.) the day before 
the treatment 
 
TABLE 3. Solvent used, final stock concentration and storage of each platinum compound under investigation are listed. 
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(+)-JQ1 and (-)-JQ1 (Figure 46) were dissolved in DMSO to final concentration 10 mM and 
stored at -20 °C until used. Both compounds were kindly supplied by Prof. S. Knapp 
(University of Oxford, UK). 
 
FIGURE 46. Sketch of (+)-JQ1 and (-)-JQ1 
 
Co-ASS [2-acetoxy-(2-propynyl)benzoate]hexacarbonyldicobalt (Co-Co), Co-EPM 
hexacarbonyl[-(2-ethylphenyl)-methanol]dicobalt (Co-Co) and acetylsalicylic acid (ASA) 
(Sigma) were dissolved in absolute ethanol, to final concentration of 20 mM, 10 mM and 1 
M, respectively (Figure 47). Cobalt complexes were stored at 4 °C, while ASA was prepared 
immediately  before the experiment. Co-ASS was kindly supplied by Prof. R Gust (University 
of Innsbruck, Austria). 
 
FIGURE 47. Sketch of Co-Ass, Co-EPM and ASA. 
 
 
Compound stock solutions were diluted in complete medium to the required concentration 
ranges. In the case of co-solvent, the co-solvent concentration never exceeded 0.5 % (these 
concentration was found to be nontoxic to all the cells tested). 
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Determination of solubility and lipophilicity 
Complexes 6-9 
The water solubility of the Pt(IV) complexes 6-9 was determined preparing their saturated 
solutions in water, which were stirred in the dark at 25 °C. After 24 h the solid residue of each 
sample was filtered off (0.20 μm regenerated cellulose filters) and the Pt content of the 
solutions was determined by means of ICP-OES. 
The lipophilicity of a molecule is usually represented by the logarithm of its n-octanol/water 
partition coefficient (log Po/w). The classic method to measure log Po/w is the flask-shaking, 
based on the partition of the analyte into a mixture of n-octanol and water. 
A  solution ([C]init.water) of compounds 6-8 in n-octanol-saturated water (Vwater) was prepared 
and shaken with water-saturated n-octanol (Voct.). The mixture was shaken for 30 min and 
centrifuged for 30 min at 4000 rpm. The platinum content of the initial and final aqueous 
phase ([C]fin.water) was determinated by means of ICP-OES. This method was used to 
determine the log Po/w values of complexes 6-8 but it was not efficient in the case of the 
extremely lipophilic complex 9.  
In most cases the volumes of octanol and water are equal, but for compounds with extreme 
logP values like Pt-complexes different volumes must be used. The logPo/w value can be 
calculated with the following formula logPo/w = log  
                          
           
  
      
     
 . 
Moreover, the lipophilicity of the complexes was evaluated by means of RP-HPLC.  
Among the alternative experimental methods developed to measure the lipophilicity, the 
retention parameters in RP-HPLC (where n-octanol is ideally replaced by the C18 chains 
functionalizing silica as stationary phase, while the mobile phase consists of various mixtures 
of water and an organic co-solvent) are often used [177]. 
Since RP-HPLC retention is due to partitioning between (polar) mobile and (apolar) 
stationary phases, there is a straightforward correlation between the partition coefficient and 
the HPLC capacity factor k’ (k’ = (tR – t0) / t0, where t0 is the retention time for an unretained 
compound and tR is the retention time of the analyte). The log k0 (k’0 is the HPLC capacity 
factor extrapolated to 0% co-solvent) values of compounds with known log Po/w can be used 
to create a calibration curve (log Po/w = a log k'0 + b) to evaluate partition coefficients of new 
compounds from chromatographic data. 
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However, owing to the very different lipophilicity of the studied complexes it was not 
possible to find a range of % of methanol (organic modifier of the aqueous mobile phase) to 
perform the logk’ measurements and then the estrapolation of logk0. Therefore, one only 
chromatographic condition (90% methanol/ 10% HCOOH 15mM) was used to get logk90 
values for complexes 6-9. 
To determinate logk’90 , solutions of the platinum complexes 0.5mM were prepared. KCl was 
the internal reference to determine the column dead-time (t0). 
Cisplatin and complex 10 
 As far as chromatographic condition concerned, a solution of methanol and HCOOH 15mM 
was used as eluent. The lipophilicity index is derived from the log of the capacity factor k’ (k’ 
= (tR – t0) / t0, where t0 is the retention time for an unretained compound and tR is the retention 
time of the analyte, extrapolated to 100% HCOOH (log k0).  
To determinate log k0, solutions of the platinum complexes 0.25 mM were prepared. 
KCl was the internal reference to determine the column dead-time (t0). 
 
Determination of the IC50 values 
Unless specified, cell treatment was performed for 72h continuous treatment (CT). At the end 
of the period, the activity of the candidate drug or mixture was determined.  
For sake of clarity, it should be pointed out that the activity of an antitumoral drug mainly 
resides in the inhibition of cell growth  (IC50 value) that  could be determined by means of 
two approaches: i)  trough cell viability assays that reveals the amount of the remaining alive 
cells or ii) detecting the amount of dead cells by means of cytotoxic assays. 
Based on their mechanisms of action, cell viability assays assess two main features of cell 
viability: 
 adherence on the support: the cellular residual biomass  is revealed by means of 
cationic dyes (such as methylene blue, BM, or Crystal Violet, CV)  or anionic 
colorants (as sulphorodamine B), that bind to acid or basic intracellular sites (such as 
those of proteins and nucleic acids), respectively;  
 metabolic activity: by direct detection of the adenosine tri-phosphate (ATP) amount or 
by means of the activity of enzymes that lye on mitochondria of living cells, 
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specifically the mitochondrial dehydrogenases. This group of assay includes the [3-
(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2-2H-
tetrazolium] inner salt   (MTS) assay, resazurin (shown in Figure 48); 
 Cell proliferation: i) measuring incorporation of labeled DNA precursors (as 3H-
thimidine or bromodeoxyuridine, BrdU, a thimine analogues) that are incorporated 
into newly synthesized DNA strands of actively proliferating cells,  or by means of ii) 
clonogenic assay, which evaluate the ability of a single cell to grow into a colony. 
 
 
FIGURE 48. In cell metabolically active, (left) the colorless tetrazolium salt is converted to yellow formazan [178], whereas 
(right) resazurin is converted to resorufin, a fluorescent product, by mitochondrial enzymes [179]. 
 
Cytotoxicity tests point out dead or damaged cells (which have holes in their membrane) by 
means of dye exclusion, which means that live cells (due of intact membrane) will not take up 
any dye and will appear unstained, or by means of the detection of membrane leakage of 
typical intracellular markers, i.e. the lactate dehydrogenase. 
As far as our experimental procedure concerned, in a first step we decided to evaluate 
residual cell viability by means of colorimetric tests more suitable for automation analyses: 
methylene blue (BM) staining or MTS assay. 
Methylene blue (BM) staining 
For BM staining test, cells were fixed and stained were fixed and stained at 4°C by 1 h 
incubation with 2 g L
-1
 methylene blue in 50% methanol-50% water, allowed to dry, washed, 
and eluted with 200 L well-1 of 50% ethanol-50% 0.1 M HCl. Absorbance was recorded at 
620/405 nm [180].  
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MTS assay 
The MTS assay was based on a commercial kit (CellTiter Aqueous Solution, Promega, Milan, 
Italy), according to the manufacturer’s instructions. Briefly, the reagent was added to cells in 
complete medium, and incubated for 1-4 h. The absorbance values of the product were 
recorded at 490/620 nm. 
Resazurin reduction assay 
In a second step, viability experiments were repeated using the more sensitive resazurin 
reduction assay [181] to confirm the preliminary data, since resazurin method is a nontoxic, 
rapid and sensitive procedure. Resazurin assay is provided of a wide dynamic linear range 
(50-50000 cells), as shown in Figure 49, that is wider than absorbance-based methods (such 
as BM and MTS) but similar to luminescence-based ones (as ATP) [182]. 
 
FIGURE 49. Correlation between signal-cell number is reported for resazurin assay  
Resazurin (10 g*mL-1; Acros Chemicals, France) was added to cells (seeded in black plates, 
in order to limit cross-talk between the different well) in fresh medium for 1 h at 37 °C. The 
amount of reduced product, resorufin, was measured by mean of fluorescence intensity using 
an excitation wavelength of 550 nm and an emission wavelength of 585 nm. 
The absorbance/fluorescence values of eight wells containing medium without cells were used 
as blank.  
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Clonogenic assay 
In order to performed this experiment, cells are challenged with the drug, then the drug is 
removed and fresh medium is added (recovery), replacing it twice a week. Lastly, colonies 
number is evaluated. So, the clonogenic assay allows to assess the antiproliferative ability of a 
drug by means of clonal growth evaluation: if a drug acts as a cytostatic, its effect is lost upon 
its removal and cells resume proliferation; on the contrary,  if a drug acts as a cytotoxic agent, 
triggers cell death and cells lose clonal growth ability. 
 Clonogenic assay method was performed as described by Franken et al [183]. Briefly, 200 
cells well
-1
 (BR95) or 100 cells well
-1
 (MM98) were seeded in 6-well plates and allowed to 
attach 24h before drug treatment. Then, they were challenged by drug candidates from day 0 
to day 3, and then allowed to recover in fresh medium, changed every 3 days, until day 10, 
when colonies were stained with methylene blue. Experiments were performed three times in 
triplicate. Colonies were counted manually and reported as percentage of the control. 
Data analysis:IC50 determination 
The final IC50 was calculated from at least three independent replicates of the same 
experiment each carried out in triplicate. 
Data were normalized to 100 % cell viability for non-treated cells, and IC50 were obtained 
from the dose-response sigmoidal curve using Origin Pro (version 8, Microcal Software Inc., 
Northampton, MA, USA). 
Combination experiments 
Combination experiments were performed using fixed-dose-ratio concentrations. For 
simultaneous administration, drugs was co-diluted and the resulting stock solution was 
serially diluted and tested for cell viability. 
Combination index (CI) values were calculated for non-mutually exclusive drugs, according 
to Chou and Talalay Equation (16) [184]. 
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Other cell-based investigations 
Senescent cell staining 
Senescent cells remain viable, metabolically active and differ from  quiescent cells that are in 
a temporary state of growth arrest; senescent-associated phenotype cells tend to be 
morphologically enlarged, flattened, and display cytoplasmatic granularity, chromatin foci 
and eventually, elevated activity of senescence–associated -galactosidase (SA--Gal). The 
latter feature represent the rational of the -galactosidase staining.  
In order to carry out the assay, HMC, BR95, MG06, MM98 and MM98R cells (2104) were 
seeded in 24-wells plates the day before treatment.  At the end of the treatment, cells were 
washed twice with PBS, fixed in 3% formaldehyde for 30 min at 4°C, and washed again with 
PBS. Then, the -galactosidase staining was performed. Cells were incubated with a 
chromogenic substrate for -galactosidase, that converts it to a rich blue product [185]. Cells 
were washed and at least three different 10X microscopic fields were photographed with a 
Leica EC3 camera mounted on a Leica DMIL LED microscope. The Cell Counter plug-in of 
ImageJ 1.45s was used to count the total number of cells and the blue ones. The cell count 
was performed independently, on different experimental repetitions, by two different 
operators. 
Treatment with cobalt complexes, cisplatin and ASA 
Cells were challenged with increasing concentrations of drugs. The treatments were renewed 
the third day, and left until the seventh day, when -galactosidase staining was performed as 
previously describes. 
 
Treatment with cisplatin-JQ1combination 
HMC, BR95 and MG06 were treated with 0.5, 1 and 2.5 M (+)-JQ1, and/or with cisplatin at 
molar ratio 1:3, while MM98 and MM98R were treated with 0.05, 0.1 and 0.25 M (+)-JQ1 
and/or with cisplatin at molar ratio 1:10. After three days of incubation, a set of experiments 
was stopped, while drug-free fresh medium was given to a parallel set, and left until the 
seventh day. 
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Cellular accumulation: uptake  
The whole cell accumulation of the platinum drug, here defined as uptake, was determined 
from A2780 and HCT 116 cells treated for 4 h with 10 µM cisplatin and complex 10. Cells 
were washed three times with PBS, detached from the Petri dishes using 1 ml 0.25 % Trypsin-
EDTAand harvested in fresh complete medium.  An automatic cell counting device (Countess 
®, Life Technologies), was used to measure the cell number and the mean diameter from 
every cell count. About 5x 10
6
 cells were transferred into a glass tube and centrifuged at 1100 
rpm for 5’ at room temperature. The supernatant was carefully removed by aspiration; in 
order to limit the cellular loss, about 200 µL of  the supernatant were left. Cellular pellets 
were stored at -80°C until mineralized. After defrosting, all tubes were weighted, in order to 
retrieve the actual volume from each sample by difference with the empty tube. Then, 70% 
HNO3 was added and left 1 h at 60°C in an ultrasonic bath. Before the measurement, the 
HNO3 is diluted to 3%. Platinum determination was performed with an ICP-MS. Instrumental 
settings were optimized in order to yield maximum sensitivity for platinum. For quantitative 
determination, the most abundant isotopes of platinum and indium (used as internal standard) 
were measured at m/z 195 and 115, respectively.  
The amount of Pt found into the cells after the treatment is usually reported as ng of Pt. Thus, 
if the actual cell number, expressed in terms of 10
6 
cells, platinum uptake is expressed by 
Equation 21: 
                
     
         
               
Spheroids treatment with drug candidates 
Cells were seeded in U-shaped wells of polypropylene plates, put on an orbital mixer 
(Rotamax 120, Heidolph Instruments) in a CO2 incubator.  After 4 days, BR95 and HCT-116 
cells gave 300-400 m diameter spheroids from an initial seed of 104 cells/well and 750 
cells/well, respectively.  
Before drug challenging, spheroid morphology was assessed and pictures of at least three 
spheroids per conditions were taken at 4X magnification. 
Treatment with Pt(IV) complexes  
The spheroids (after medium removal by gentle aspiration) were challenged with drug-
containing medium (200 L/well) for 72h, then drug-free medium was replaced twice a week 
until the control reached the maximal growth or the experiment was stopped. At the same 
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time points,  pictures of at least three spheroids per each experimental condition were taken at 
4X magnification.  
Sequential treatment with cisplatin and JQ1 
Cisplatin was given for 24h, and then spheroids were treated with JQ1 for further three days, 
and re-treated with the same concentrations for further three days. Control experiments were 
performed in drug-free medium. The 4
rd
 and the 7
th
 days of treatment (corresponding to the 8
th
 
and the 11
th
 from cell seeding), pictures of at least three spheroids per condition were taken at 
4X magnification.  
Data analysis 
Dimensions of spheroids were assessed using CellProfiler
TM 
2.0. Spheroids dimensions were  
confirmed using the native Leica Application Suite software (version 2.0, Leica 
Microsystems). Data were exported to a spreadsheet and filtered for solidity ≥0.8 and 
diameter ≥ 150 pixel, converted to m by means of the microscope calibration. The spheroid 
volume was calculated from the mean diameter, and reported as fold change with respect to 
the time zero of the treatment (4
th
 day after cell seeding). 
Spheroids validation 
Spheroids were fixed in 4% formaldehyde in 0.15 M phosphate buffer (pH 7.2) for 1 hr. Then 
they were post-fixed in tetroxide osmium for 1 hr in the same buffer. After dehydration in a 
graded series of ethanol solutions, specimens were embedded in Epon araldite. Semi-thin 
sections for light microscopy (0.5µm) were cut with an ultramicrotome (Leica Ultracut UCT), 
using a glass or a diamond knife, and stained with Toluidine blue. At least ten semi-thin 
sections per treatment were observed under a light microscope (Zeiss, Axioscop 2). 
Biochemical assays 
BCA 
Protein concentration was determined  by means of the bicinchoninic acid (BCA) colorimetric 
assay. This method is based on the reduction of Cu 
2+
 to Cu
1+ 
 by protein in alkaline medium; 
the chelation of two molecules of BCA with one cuprous ion gives a purple-colored product. 
The macromolecular structure of protein, the number of peptide bonds and the presence of 
four particular amino acids (cysteine, cystine, tryptophan and tyrosine) are reported to be 
responsible for color formation with BCA [186].  
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Microplate protocol was performed and bovine albumin serum (BSA) was used as standard;  
series of dilutions of known concentration of BSA were prepared (working range of protein 
concentration was 20-2000µg/mL). Following manufacturer’s instructions, 25µL of each 
standard or unknown sample were added to  175 µL  of reagent  in a microplate well.  Plate 
was incubate at 37°C for 30 minutes.  
The absorbance at 562 nm was measured at or near 562nm. The concentration of each 
unknown sample was determined based on the standard curve. 
GST activity inhibition 
Glutathione-S-transferase activity was recorded as the rate of conjugation of the thiol group of 
GSH to 1-chloro-2,4-dinitrobenzene (CDNB), that lead to an increase in the absorbance at 
340 nm [187]. The assays were performed in the presence of GSH (2 mM) and CDNB (1 
mM) in 100 mM phosphate buffer, pH 6.8 at 25 °C in microplate (final volume 200 L), 
recording points every 30 s for a total time course of 5 min. The slope of the increase in 
absorbance at 340 nm (Abs340 min
-1
) was determined by linear fitting. The slope of the blank 
was subtracted from all samples, and GST specific activity was determined by Equation 22:  
 
             
           
           
 
     
      
                 
    
      
            
 
The human GST (from placenta, Sigma-Aldrich) was used as positive control and tested for 
the enzyme inhibition assay. The enzyme was dissolved in 100 mM phosphate buffer pH 6.8 
containing 10% glycerol to obtain a stock solution of 0.25 mg mL
-1
, and used in final 
concentration of 0.5 g mL-1. The mother solutions of cisplatin, EA, 1 and 2 (see previous 
paragraph) were serially diluted in phosphate buffer and immediately used to test the GST 
activity.  
Residual GST activity from cells was measured after a short treatment (4 h, 24 h) with EA, 
cisplatin, 1 and 2 at sub-toxic concentrations (near to the IC25 values of the compounds at 72h) 
or after a longer treatment (72h), both with low-toxic concentrations (near to the IC25) and 
with toxic concentrations (near to the IC50 values of the compounds at 72h). After the 
treatment, cells were washed by PBS, harvested with a cell scraper in 100 mM phosphate 
buffer containing 2 mM EDTA (pH 7) and sonicated on ice. The cell lysate was immediately 
used to measure the GST activity as described above or stored at -80°C until measured. GST 
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activity was normalized on the protein concentration, determined by means of the BCA assay 
(see previous paragraph).  
GSH quantification 
Intracellular GSH quantification was based on a fluorometric method. 
. 
Briefly, cells were 
seeded in Petri dishes, and left one day before treatment. After treatment, cells were washed 
by PBS, trypsinized, counted with an automatic device (Countess, Invitrogen Life Science, S. 
Giuliano Milanese, Italy), and lysed in 0.1 M phosphate buffer pH 6.8, containing 0.1% 
Triton®-X-100. Lysates were immediately deproneinized by ultrafiltration (Amicon ultra®, 
10 kDa cutoff, Millipore, Milan) in order to exclude endogen GST activity. Filtrates were 
stored at –80°C until measured. The fluorescent GST substrate monochlorobimane was used 
at 0.5 mM (saturating condition, KM =74 M) to determine sample GSH concentration using 5 
g ml-1 human placenta GST at 37°C in 0.1 M phosphate buffer pH 6.8. Fluorescence was 
read after 1h at 360/405 nm in a 96-well black plate (Nunc, Fisher Scientifics, France). A 
standard curve of GSH from 0.1 M to 50 M was used to extrapolate GSH concentration, 
then normalised on filtrate volume and cell number to obtain nmol GSH 10
-6
 cell. To obtain 
the intracellular concentration, the cell volume was calculated from cell diameters given by 
the cell counter (1.44 pL for MM98 and MM98R, 1.77 pL for BR95 and MG06). 
PGE2 detection 
MM98 and BR95 cells  were treated for 24 h with concentrations corresponding to the 
respective IC50 values of Co-ASS, Co-EPM and ASA (namely, for MM98: 2 M Co-ASS, 25 
M Co-EPM and 5 mM ASA; for BR95: 15 M Co-ASS, 25 M Co-EPM and 1 mM ASA). 
At the end of the treatment, arachidonic acid (Cayman Chemicals, Cabru, Arcore) was added 
to the culture medium up to final concentration 10 M. After 1 h, an amount of 100 L of the 
supernatant was immediately assayed by means of the Human PGE2 ELISA (Life 
Technologies, S. Giuliano Milanese, Italy) following manufacturer’s instructions. 
Apoptosis induction 
Cells were treated for 24 h with increasing concentrations of Co-ASS. Caspase-3 activity was 
measured from the cell lysates using the Caspase-3 fluorometic kit (Cayman Chemicals, 
Cabru, Arcore) following manufacturer’s instructions. 
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Mitochondrial potential gradient 
The mitochondrial potential gradient () was assayed in living cells in black-walled, clear 
bottom, tissue culture treated, sterile 96 wells plates (ViewPlate 96 F, Perkin-Elmer, Milan) 
by means of the mitochondria staining kit (Sigma-Aldrich, Milan), following manufacturer’s 
instructions. This method is based on a fluorescent probe, JC-1 ((5,5’,6,6’-tetrachloro- 
1,1’,3,3’-tetraethylbenzimidazolocarbocyanine iodide), that forms red fluorescent aggregates 
when it concentrates in the mitochondrial matrix (due to the electrochemical potential 
gradient), whereas it forms green fluorescent monomers dispersed throughout the entire cell 
after dissipation of the mitochondrial membrane potential. The red fluorescent aggregates 
were recorded using an excitation wavelength of 525 nm and an emission wavelength of 590 
nm; the green fluorescent monomers were recorded using an excitation wavelength of 490 nm 
and an emission wavelength of 530 nm. Valinomycin was used as positive control.  
In order to perform this experiment, cells were challenged with increasing concentration of 
Co-ASS (ranging from 5 M to 50 M and from 0.5 M to 20 M for BR95 and MM98, 
respectively) for 24 h. 
Oxidative stress detection 
The 2′,7′-dichlorofluorescein diacetate (H2DCF-DA, Sigma-Aldrich) dye was used to detect 
reactive oxygen species (ROS) levels. After diffusion into the cell, H2DCF-DA is 
deacetylated by cellular esterases to a non-fluorescent cell-impermeable compound, and later 
oxidized by ROS/NOS into the green fluorescent product 2’, 7’ –dichlorofluorescin (DCF).  
 Cells were seeded in white walled, clear bottom, tissue culture treated, sterile 96-well plates 
the day before treatment, performed in triplicate. Then, cells were treated 2 h with equitoxic 
concentration of the complexes under study (for MM98: 10 M Co-ASS, 50 M Co-EPM, 10 
mM ASA; for BR95: 30 M Co-ASS, 50 M Co-EPM, 2 mM ASA. Moreover CoCl2 500 
M was used as positive cobalt-salt containing control). Parallel tests with 1 h pre-incubation 
with 1 mM N-acetylcysteine (NAC), a well known anti-oxidant were also performed. At the 
end of the treatment, the culture medium was replaced by 100 M of H2DCF-DA in medium 
without serum and the plates were incubated for 30 min, in the dark, at 37°C. After 2 washes 
by PBS, the cells were given fresh medium without serum, having 500 M of H2O2 in 
positive control wells. Oxidized DCF fluorescence was measured at an excitation wavelength 
of 485 nm, and an emission wavelength of 535 nm. 
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NF-kB activity 
2106 BR95 cells were plated in Petri dishes and 4x106 MM98 cells were plated in 175 cm2 
flasks 24h before treatment. Then, cells were treated  with equitoxic concentration of the 
complexes under study (for MM98: 10 M Co-ASS, 50 M Co-EPM, 10 mM ASA; for 
BR95: 30 M Co-ASS, 50 M Co-EPM, 2 mM ASA. Then, cells were washed, trypsinized, 
and nuclear extracts were obtained following the manufacturer’s instruction of a commercial 
kit (NE-PER
®
, Pierce, Thermo Fisher). Protein content was quantified by means of the BCA 
assay (Pierce, Thermo Fisher). NF-κB activity was tested on 5 g of nuclear extracts using a 
chemiluminescent assay kit (NF kappa B p65 Transcription Factor Assay Kit, Pierce, Thermo 
Fisher), following manufacturer’s instructions. Briefly, the kit contains two streptavidin-
coated 96-well plates with the bound biotinylated-consensus sequence that can be bound only 
by the active forms of the target transcription factor. The captured active transcription factor 
is then detected with a specific primary (NF-κB p65) and a secondary HRP conjugated 
antibody. The nuclear extract of HeLa cells TNF- activated was tested as positive control, 
while the competitor consensus DNA duplex was added in some wells as negative control 
(specific binding). A chemiluminescent substrate was then added to the wells, allowing 
quantitative measurement with the plate reader.  
Statistical analysis 
Statistical analysis was performed by means of the t-test or one-way ANOVA. The statistic 
significance values (p) are referred to control values (*p < 0.05, **p < 0.01, ***p < 0.001). 
Data are expressed as the means of ± standard deviation of at least 3 replicates. 
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Results and discussion 
 
Generation of multicellular tumor spheroids (MCTS): 
optimization  of microplate-based method 
MCTS represent a reliable model in the prospective of screening of drug candidates against 
MPM, since it has been previously reported that MPM cells resist anoikis as quiescent 
pluricellular aggregates [188] and that tumor cells obtained from pleural fluid of MPM 
patient' present well-organized aggregates like spheroids [189].   
MPM spheroids have been previously generated, as: i) tumor fragment spheroids that grew in 
agar-coated plates [190] and ii) small spheroids (d = 100 m)  that grew in poly-HEMA 
coated plates within and a short time of culture [191]. 
 
In order to design our microplate-based method, we combined the rational of spinner flask 
and rotation procedures with the prerequisite of absence of cell attachment to the substrate.  
Since the hydrophobic surface of polypropylene does not allow cell adhesion and many sterile 
polypropylene plates are commercially available, we experimented  polypropylene tubes and 
plates in order to develop a plastics coating free method to obtain MCTS. 
We started with using sterile conical tubes made of polypropylene; 0,2 ml (PCR tube), 1,5 ml, 
2 ml conical tubes and 15 ml both conical and round-bottom tubes. 500x 10
3
 cell ml
-1
 were 
seeded in tubes of and spun 10 min at 1000 x g , according to Ivascu’s method [137], then 
placed in a CO2 humidified incubator. We obtained  compact spheroids from the MM98 and 
MM98R sarcomatoid MPM cell lines, MG06 mixed phenotype and BR95 epithelioid cell 
lines. 
Then, we scaled-up the procedure seeding the same number of cells in 96-wells PCR 
polypropylene plates sterilised under UV light, sealed with an adhesive film (BrathSela, 
Greiner BioOne). MM98 and MM98R gave compact spheroid within 24h, but many satellite 
objects could be observed, and sometimes spheroids attached to the bottom of the well, 
starting surface colonization. Furthermore, the small volume of medium was reduced due to 
massive evaporation, as any lid could not be adapted to the plate. We also tried to use 
Matrigel® to allow cell aggregation, according to the method reported by Ivascu et al. [137]. 
 90 
 
Unfortunately, we obtained a flat and floating dish which entrapped cells but did not evolved 
to a spheroid-like architecture. 
After the failure of the firsts approaches, we tested a sterile low cell binding 96-wells plate, 
round bottomed, with lid, sold for Embryoid Body Formation. Also this attempt reveled 
unsuccessful, since MM98 spheroids managed to colonized the surface of the well again. 
Eventually, we tried cheaper polypropylene sterile microplates, U-bottom, with lids. Apart 
from MPM cell lines, in this step we introduced other cell lines, previously reported to 
generate spheroids, as HCT-116,  or cell aggregates in some conditions, as A549, MCF-7 and 
A2780. In addition, we introduced the non-tumor HMC cell line.  
As the previous procedure, we spun cells 10 min at 1000 x g. The centrifugation protocol gave 
optimal results with MG06 and  BR95 only, whereas MM98 adhered on the well’s surface. 
We hypothesized that centrifugation was not the optimal method to allow cellular aggregation 
so, we moved to a milder method: thus, we put the microplates on an orbital mixer, with 
continuous shaking at 200 rpm in a CO2 incubator. This method was optimal both for MG06 
and BR95, while unfortunately MM98, MM98R, A549 and  MCF-7 continued to colonize the 
well’s bottom surface and A2780 formed simply aggregates, as shown in Figure 50. 
 
FIGURE 50. Image of MCTS of BR95 cell lines (left), and A2780 cellular aggregates (right). In BR95 spheroids, a outer 
translucent shell is observed, corresponding to proliferant cells. 
 
However, orbital shaking let us obtain spheroids even from HCT-116.  
Then, we performed growth kinetics to assess if spheroids able to grow in an exponential 
manner [192] [193]. 
In order to evaluate the relationship between the cell number per well and the propensity to 
generate spheroids, we seeded an increasing number of cells of each line. Medium was 
carefully replaced twice a week until compact spheroids were observed, or until the growth 
plateau was reached. 
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We toke in account only spheroids showing at least a diameter of 400 mm, that is the critical 
size to obtain a necrotic core and a gradient of proliferating cells had formed.  
As depicted in Figure 51, only HCT-116 and BR95 cell lines gave growing spheroids.  
 
HCT-116 cells gave 300-400 m diameter spheroids after an initial seed of 750 cells/well, as 
previously reported [135], while as far as BR95 cell lines concerned it occurred after an initial 
seed of 10000 cells/well. 
It should be noted that  a minimal time lapse (at least 4-5 days)  is needed to obtain mature 
spheroids, in order to allow cells aggregation and compaction  under agitation. 
MM98 and MM98R continued to compact until about 5
th
-6
th
 day decreasing their dimension. 
We then tried to seed them in the presence of 20% FBS, but they were not actively growing.  
A some growth was observed in MG06 cells, but too limited drug screening purposes. 
The non-tumor HMC cells   formed non-proliferant spheroids, according to  their non-
malignant nature.  
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FIGURE 51. Growth kinetics of MM98, MM98R, HMC, MG06, BR95 and HCT-116 cells until until the growth plateau was 
reached. 
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For sake of clarity, Table 4 shows the overall characteristics and experimental conditions of 
cell lines investigated in order to generate MTCS: 
 
Cell line Type Spheroid 
Type 
Growth Medium FBS 
(10%) 
BR95 MPM (epitheliod) non-adherent 
Spheroids 
exponential Ham's F10 10 
MG06 MPM 
(Epitheliod/Mixed) 
non-adherent 
Spheroids 
exponential Ham's F10 10 
MM98 MPM 
(Sarcomatoid) 
plate-adherent 
Spheroids 
stable 
dimensions 
DMEM  20 
MM98 MPM 
(Sarcomatoid) 
plate-adherent 
Spheroids 
decreasing 
dimensions 
DMEM  10 
MM98R MPM 
(Sarcomatoid) 
plate-adherent 
Spheroids 
stable 
dimensions 
DMEM  20 
MM98R MPM 
(Sarcomatoid) 
plate-adherent 
Spheroids 
decreasing 
dimensions 
DMEM  10 
HMC Mesothelium non-adherent 
Spheroids 
stable 
dimensions 
Ham's F10 10 
HCT-116 Human colon 
carcinoma 
non-adherent 
Spheroids 
exponential McCoy's 5A 10 
MCF-7 Human  breast 
adenocarcinoma 
cell aggregates / EMEM+NEAA 10 
A2780 Human ovarian 
carcinoma 
cell aggregates / RPMI 1640 10 
A549 Human  lung 
carcinoma 
cell aggregates / RPMI 1640 10 
 
TABLE 4. Morphology and growth profile are listed for each cell lines investigated to assess their propensity to generate 
proliferant MCTS. 
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In the perspective to use MTCS as tools for antitumor drugs screening, we thus expressed 
growth kinetics of BR95 and HCT-116 MTCS as a function of the spheroid mean volume, 
similarly to the in vivo evaluation of tumor mass regression after antineoplastic treatment 
(Figure 52). 
 
 
 
FIGURE 52. Growth kinetics of BR95 (left) and HCT-116 (right) cells, expressed as a function of volume. The growth plateau 
was reached after about 15 days and 20 days, respectively. 
 
 
BR95 morphology was assessed by means toluidine blue staining of spheroid section, which 
confirm the presence of a necrotic core, as shown in Figure 53. 
 
 
 
FIGURE 53.  Toluidine blue staining of BR95 spheroid section after 4 days from seeding. 
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Pt(IV) complexes designed to circumvent cisplatin 
chemoresistance due to GSH/ GST system 
As previously described, MPM is a malignancy characterized by strong intrinsic 
chemoresistance associated to anti-oxidant enzymes and GSH metabolism.  
The conjugation between GSH and cisplatin occurs spontaneously but can also be mediated 
by the enzyme glutathione –S-transferase-pi (GST-pi). The conjugate (NH3)2Pt-(SG)2 is 
extruded by cells via GS-X pumps, a member of the multi drug resistance-associated protein 
(MRP) family.   
GST is also involved in the regulation of survival / cell death by interacting with the protein 
JNK (c-Jun N-terminal kinase) [194]. Therefore, by inhibiting GST could reduce both its 
detoxifying action, both pro-apoptotic signal to activate JNK. 
Moreover GST enzymes, responsible for cisplatin conjugation with GSH, results in some 
circumstances overexpressed in MPM [195]. Therefore, we focused in the study of molecules 
able to bypass this chemoresistance mechanism and at the same time to exert a cytotoxic 
effect on tumor cells. We tried to reach this goal by means of two strategies, that will be 
discussed herafter. 
 
Bi-functional platinum complexes as GST inhibitors 
Interestingly, studies on human bladder cancer cells showed that the in vitro cisplatin 
resistance is partially overcome by buthionine sulfoximine (BSO) treatment, which 
counteracts the enzyme involved in GSH biosynthesis, as well as by ethacrynic acid (EA), a 
diuretic drugs, that inhibits GST [196].   
So, our first study was focused on the investigation of complex 1, cis,cis,trans-
diamminodichloridobis(ethacrynate)platinum(IV); that is a Pt(IV) complex having cisplatin as 
precursor and  functionalized with two molecules of (EA) in order to join cytotoxic activity of 
Pt-based drugs with lowered chemoresistance. Complex 1 was previously synthesized by 
Dyson and co-workers, called as ethacraplatin, that reported that it is strong GST inhibitor per 
se [197].  
In order to better understand the role of EA on the pharmacological effects of Pt-drugs, the 
pharmacological properties of 1 were compared with those of a Pt(II), the cis-
diamminobis(ethacrynate)platinum(II) or complex 2. We assumed that both complex 1 (after 
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reduction and hydrolysis) and 2 (after only hydrolysis) lead to the formation of the same 
active molecule [Pt(H2O2)2(NH3)2]
2+
.  
First of all, 1 and 2 were tested on the MPM cancer cell lines; then the antiproliferative effects 
of 1 and 2 bi-functional complexes were compared with the respective individual precursors. 
We observed that compound 1 was more active than 2 and it seemed to overcome the 
resistance to cisplatin and that. However, 1 and 2 complexes showed a lower activity (i.e, 
higher IC50 values) compared to the reference compound, cisplatin, that showed the best 
performance. In addition, cells were challenged  with a combination of cisplatin and EA 
(given simultaneously in a molar ratio 1:2), in order to mimic the biological effect of the two 
bioactive constituents after their release. Interestingly, we noticed that the resistant factor (RF,  
i.e. IC50 MM98R) / (IC50 MM98)  obtained for 2 was identical to that obtained for the co-
treatment with the mixture of cisplatin and EA. These results suggest that the bi-functional 
molecule 2 explicates its activity merely releasing the two EA moieties and by generating the 
aquo complexes (Table 5). 
 
 Cisplatin Carboplatin 1 2 EA Cisplatin 
(+ 2 EA) 
MG06 4.1±1.5 40.0±8.0 17.6±2.3 26.9±6.3 47.5±9.6 7.3±1.6 
BR95 6.2±0.9 33.1±7.6 10.9±1.2 29.4±7.6 33.6±6.6 7.6±3.3 
MM98 3.2±1.0 57.5±11.5 11.8±3.5 20.7±6.5 45.8±6.5 4.8±0.1 
MM98R 19.4±2.8 70.8±14.9 17.3±3.4 60.5±8.2 69.4±11.9 13.7±4.3 
RF 6.1 1.2 1.5 2.9 1.5 2.9 
 
TABLE 5. IC50 (M) values  calculated after 72 h of treatment, are listed. 
Resistance factor (RF) = (IC50 MM98R) / (IC50 MM98).  
 
Assuming that the Pt(IV) complex is reduced to Pt(II) within the cell and releases a molecule 
of cisplatin and two equivalents of EA, the pharmacological effect of 1 was compared with 
that of the association cisplatin + EA. On the contrary, the complex 2 was compared with the 
combination of carboplatin + EA, as it has been assumed that the leaving groups of 2 and 
carboplatin possess a similar hydrolysis kinetics. Thus, compounds 1 and 2 were considered 
as an intra-molecular fixed-dose-ratio combination of their building blocks: two equivalents 
of EA and cisplatin for 1 and two equivalents of EA and carboplatin for 2. 
Any combination did not show a synergistic effect (CI > 1), as pointed out in Figure 54. It 
should be noted that CI profile of the co-treatment with cisplatin and EA coincides with that 
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of 2. This evidence, in according with their RF, supports our hypothesis that this bi-functional 
molecule exerts its activity by means of the simple release of two EA moieties, generating the 
active metabolite [Pt(NH3)2(H2O)2]
2+
.  Complex 1 gave the highest CI value. All this body of 
evidence indicates that compound 1 behaves differently than 2 and so, it should acts as a GST 
inhibitor per se. 
FIGURE 54. Combination Index (CI) vs Fraction affected (FA) plots for the combination of EA + cisplatin 72 h (white squares), 
1 vs cisplatin and EA (black trangles), 2 vs. EA and carboplatin (black circles, except for MM98R). a) MM98; b) MM98R; c) 
BR95; d) MG06. The dotted line at CI=1 (additivity) stands for the limit between antagonism (over 1) and synergism (below 
1). 
Consequently, we determined the residual GST activity following candidate drugs exposure 
after 4, 24 and 72 h CT (drugs given at sub-lethal concentrations corresponding to their IC25) 
and after 72 h CT of drug given at concentrations corresponding to their IC50. Surprisingly, 
both bi-functional complexes and the cisplatin and EA combination did not result in the 
inhibition of cellular GST, as listed in Table 6 and Table 7. Moreover, GST activity seemed 
not to be related to acquired resistance since MM98 and MM98R share the same basal GST 
levels, which did not change after treatment. 
 
 
 98 
 
 NT EA Cisplatin 1 2 
4 h treatment      
MG06 12015 11111 12413 10411 10615 
BR95 989 9113 9820 10739 8311 
MM98 4013 379 4613 449 449 
MM98R 539 419 519 5211 409 
24h treatment      
MG06 10749 11059 13055 11546 12932 
BR95 11932 13540 1199 14646 11424 
MM98 8031 6526 7417 5314 519 
MM98R 5820 6112 5313 6715 7416 
72 h treatment      
MG06 798 776 725 7510 939 
BR95 8911 9512 1018 8911 11016 
MM98 781 679 7311 818 758 
MM98R 6511 697 5810 7514 646 
TABLE 6. Residual specific GST activity  (mol min
-1
 g
-1
) from from MG06, BR95, MM98 and MM98R cells treated for 4, 24 
and 72 h with concentrations corresponding to their IC25: 20 M EA, 5 M 1, 10 M 2, 1 M cisplatin (5 M for MM98R). Data 
are normalized upon protein concentration and are not statistically different from the control (one-way ANOVA, p > 0.05). 
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72 h treatment NT EA Cisplatin 1 2 
MG06 8110 10531 8830 8211 10734 
BR95 7718 751 774 7713 817 
MM98 476 476 252 6621 6818 
MM98R 488 5515 383 362 331 
TABLE 7. GST specific activity (mol min
-1
 g
-1
) from cells after exposure to complexes. Residual specific GST activity from 
MG06, BR95, MM98 and MM98R cells treated for 72 h with concentrations corresponding to their IC50: 20 M EA, 5 M 1, 
10 M 2, 1 M cisplatin (5 M for MM98R). Data are normalized upon protein concentration and are not statistically 
different (one-way ANOVA, p > 0.05), except for MM98 treated with cisplatin (p < 0.005). 
The complexes were then tested to assess their ability to inhibit the purified enzyme. In 
accordance with data reported by Dyson et al., complex 1 exhibited a strong GST inhibition, 
much higher than that of 2, whereas cisplatin showed no substantial GST inhibition (Figure 
55). Complex 1 was as active as EA in GST inhibition , supporting our hypothesis that this bi-
functional complex might be regarded as simple intracellular combination of a platinum(II) 
complex and EA. 
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FIGURE 55. Residual % GST activity of the purified enzyme in presence of increasing concentrations of EA, 1, 2, and the 
relative sigmoidal curves (Hill equation) for the extrapolation of the IC50 values (in terms of enzyme inhibition). For cisplatin 
a dotted-line plot is reported, indicating no GST inhibition.  
Previous studies showed that EA increases GSH levels in some tumor cell lines [194]. It was 
reported that the conjugate ethacrynic acid-GSH (EA-SG) is a sevenfold more potent GST 
inhibitor than  free EA. Whereas EA induces GST inhibition trough a non-competitive way, 
EA-SG inhibits GSH by competitive mechanism [198]. In other words, the inhibition of GST 
induced by EA-SG should be overcome through a raise in GSH intracellular concentration. 
Therefore, we detected intracellular levels of GSH. 
We observed a jump in intracellular levels of GSH after platinum complexes exposure, except 
for the epitheliod cell lines challenged with cisplatin. In addition, the cisplatin resistant cell 
line MM98R showed the highest raise of intracellular GSH (Figure 56).Thus, we deduced that 
this cellular phenomenon is responsible for the antagonist effect of platinum complexes, 
because counteracts their pharmacological action. 
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FIGURE 56. Intracellular GSH levels from a) MG06, b) BR95, c) MM98 and d) MM98R cell lines treated for 72h with 20 mM 
EA, 5 mM 1, 10 mM 2, 1 mM cisplatin (5 mM MM98R). The intracellular levels of GSH determined and normalized to cell 
volume, resulting in a basal value of around 5 mM. Statistical analysis was performed by unpaired t-test (with respect to 
control: *p < 0.05, **p < 0.01, ***p < 0.001. 
In conclusion, the attempt to decrease MPM intrinsic resistance targeting GST with EA-bi-
functional conjugates is not a useful strategy for chemotherapy [199]. 
 
Pt(IV) analogues of picoplatin 
The second strategy aimed to circumvent cisplatin resistance started from a different chemical 
rationale. 
 It is well known that picoplatin, or cis-amminedichlorido(2-methylpyridine)platinum(II), is 
able to bypass GSH-related cisplatin resistance because it is composed of a bulky 2-
methylpyrimidine as a carrier group: the steric hindrance created by this substituent is able to 
hinder the conjugation of GSH with the metal complex. On the other hand, it is generally 
accepted that the reduction of Pt(IV) complexes can be carried out by intracellular reductants 
as GSH. Pt(IV) compounds are believed to be reduced to their active Pt(II) metabolites, 
which, in turn, will be activated by hydrolysis and bind DNA[200] [201]. Thus, the insertion 
of the picoplatin square-planar structure in a Pt(IV) octahedral scaffold should give an ideal 
pro-drug candidate. 
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Furthermore, it is important to recall that picoplatin entered in a phase II trial as a second-line 
therapy in mesothelioma, showing a manageable tolerability profile [202]. 
Thus, a series of complex Pt (IV), having axial carboxilate chains of increasing length and  
picoplatin as common precursor, was investigated the four cell lines of MPM, on the 
cisplatin-sensitive ovarian A2780 cell line and on a non-malignant cell lines (HMC) and their 
antiproliferative activity was compared. Unfortunately, we could not challenge HMC cells 
with picoplatin. 
 As showed in Table 8, Pt(IV) congeners of picoplatin showed good activity on both ovarian 
and MPM cell lines. All of them were more active than picoplatin; 3 was the least potent 
molecule whereas 5 had similar activity than cisplatin. We observed that the longer the axial 
chain is, the more active and selective the Pt(IV) complex is, confirming the relationship 
between activity and length reported in literature. Indeed, previous studies showed a strict 
correlation between antiproliferative activity and length of the carbon chain was observed for 
other Pt(IV) complexes in vitro [114] [115] and in vivo tumor models [203].  
According to our hypothesis, these compounds bypassed the resistance to cisplatin, as showed 
the  much lower resistance factor (RF) values.   
As stated above, the cisplatin-resistant cell line MM9R shows a higher increase in 
intracellular GSH (when treated with platinum derivatives at sub-lethal concentrations) with 
respect to the wild counterpart MM98, event that could partially explain the acquired 
resistance. For this reason, the observed low RF for compounds 3-5 may be related to a 
generally low inactivation of Pt(IV) complexes under investigation. 
 Cisplatin Picoplatin 3 4 5 
A2780 1.2  0.4 1.6  0.3 7.4  1.9 2.4  1.3 0.40  0.04 
BR95 6.2  0.9 42.9  4.7 17.5  4.9 15.2  2.1 5.6  0.2 
MG06 4.1  1.5 42.8  2.6 13.2  4 11.1  0.6 7.2  0.8 
MM98 3.2  1.0 30.2  4.6 12.7  3 10.1  2.6 5.6  0.5 
MM98R 19.4  2.8 34.4  4.7 12.1  1.9 13.2  2.3 9.4  0.9 
HMC 6.7  1.2 / 22.8  2.0 21.3  1.9 18.9  3.1 
RF
a
 6.1 / 1.0 1.3 1.7 
SI
b
 1.5 / 1.6 1.8 3.1 
TABLE 8. IC50 values calculated after 72 h continuous treatment. 
a 
Resistance factor (RF)= IC50 (MM98R)/IC50 (MM98). 
b 
Selectivity Index (SI)= IC50 (HMC)/ mean IC50 (BR95, MG06, MM98). 
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Reduction of complexes 3-5 by GSH was verified. The formation of the corresponding Pt(II) 
counterparts has nearly similar t ½ , ranging from 25 and 32 min [204], and became almost 
complete after 4 h, supporting the assumption of the “activation by reduction” mechanism.  
 
Based on these findings, we could declare that these Pt(IV) analogues of picoplatin  are quite 
promising candidates for MPM treatment. 
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Pt(IV) axial dicarboxylate complexes as anticancer drug 
candidates  
Pt(IV) complexes with linear carboxylate chains as axial ligands 
We studied a series of dicarboxylate-platinum(IV) complexes, sharing the same carrier and 
equatorial leaving groups as cisplatin, and bearing carboxylato ligands of different length in 
axial position. The investigated complexes were: 6 (cis,cis,trans-diaminedichlorobisacetate-
platinum(IV)), 7 (cis, cis, trans-diaminedichlorobisbutanoate-platinum(IV)), 8 (trans,cis, cis-
diaminedichlorobisesanoate-platinum(IV)), 9 (cis, cis, trans-diaminedichlorobisoctanoate-
platinum(IV)). 
Assuming the activation by reduction theory, these Pt(IV) complexes series have to be 
regarded as pro-drugs of cisplatin, reduced by biological antioxidants in the intracellular 
compartments. 
 
In order to check their anticancer activity against MPM, complexes 6-9 were tested both on 
the four MPM cell lines and on the healthy human mesothelial cells, as outlined in Table 9. 
Moreover, their antiproliferative ability exerted against MPM was compared to that observed 
against other cell lines, representative of most common tumoral forms, namely: A2780 
(ovarian), HCT-116 (colon), A549 (lung) and MCF-7 (breast).  
As expected, A2780 cells resulted the most responsive to cisplatin, whereas the MPM cell 
lines proved to be the less sensitive ones, confirming their intrinsic chemoresistance. 
A2780 cells appeared the most sensitive cells to complexes 6-9, in parallel with the 
responsiveness to their Pt(II) cognate, i.e. cisplatin. 
Complex 6 appeared dramatically ineffective on MPM, as it was around 20 times less active 
than cisplatin. 
At a glance, complex 7 was as nearly potent as cisplatin, except for epithelioid and mixed 
MPM  phenotypes and mesothelial cells, that were less sensitive than sarcomatoid cells. 
Complex 8 resulted more active than cisplatin on all cell lines, being the former around one 
and two orders of magnitude more active than the latter in non-MPM and MPM cells, 
respectively. 
Complex 9 showed the best performance, revealing an activity around three orders of 
magnitude higher than cisplatin.  
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Interestingly, the longer the axial chain is, more the cisplatin cross-resistance is bypassed, 
reaching a drop of cross-resistance (RF = 1.3) for complex 9.  
Intriguingly, both 8 and 9 acted in a selective way against malignant cells, as pointed out by 
selective index (SI, i.e., the ratio between IC50 (HMC) and the IC50 on the tumor MPM cell 
line) value, ranging between 3-6. 
 
 Cisplatin 6 7 8 9 
A2780 0.5±0.1 ×10
-6
 12.1±5.2×10
-6
 0.5±0.1×10
-6
 1.5±0.7×10
-8
 2.3±0.6×10
-9
 
HCT-116 2.3±0.3×10
-6
 55.3±1.7×10
-6
 1.8±0.3×10
-6
 4.2±1.0×10
-8
 9.0±0.5×10
-9
 
A549 3.8±0.7×10
-6
 78.0±17.7×10
-6
 5.6±3.2×10
-6
 20.7±0.8×10
-8
 14.7±3.2×10
-9
 
MCF-7 6.5±0.9×10
-6
 >100×10
-6
 8.0±1.9×10
-6
 33.5±16.3×10
-8
 16.5±4.8×10
-9
 
HMC 6.7±1.2×10
-6
 >100×10
-6
 38.6±8.8×10
-6
 2.7±0.4×10
-6
 91.7±2.8×10
-9
 
BR95 6.2±0.9×10
-6 
(1.1) 
>100×10
-6 
(-) 
34.1±6.0×10
-6 
(1.1) 
0.9±0.1×10
-6 
(2.9) 
64.3±19.2×10
-9
 
(2.0) 
MG06 4.1±1.5×10
-6  
(1.6) 
>100×10
-6 
(-) 
23.1±6.2×10
-6 
(1.7) 
0.9±0.2×10
-6 
(3.1) 
41.3±11.0×10
-
9
 (2.6) 
MM98 3.2±1.0×10
-6 
(2.1) 
>100×10
-6 
(-) 
7.4±2.3×10
-6 
(5.2) 
0.3±0.1×10
-6 
(11.0) 
17.0±3.9×10
-9
 
(5.9) 
MM98R 19.4±2.8×10
-6  
(-) 
>100×10
-6 
(-) 
18.7±0.5×10
-6 
(2.1) 
0.8±0.1×10
-6 
(3.5) 
22.0±3.3×10
-9
 
(5.7) 
a
RF 6.1 - 2.5 3.2 1.3 
TABLE 9. IC50 values (M) obtained after 72 h CT.  
Data in brackets reports the selectivity index, SI, i.e., the ratio between IC50 (HMC) and the IC50 on the tumor MPM cell 
line.  
a 
Resistance Factor, RF = IC50 MM98R / IC50 MM98. 
The prolonged antitumoral effects of complexes 6-9, compared with that of cisplatin, the 
reference compound, was investigated. Since the microplate-based (2D) methods are limited 
by cellular confluence to 3 days of treatment, we employed in vitro MCTS (obtained with the 
method described in the previous section) of BR95 and HCT-116 cells. 
Spheroids were challenged for 72 h (3 days), the drug was removed and fresh medium was 
added (recovery), replacing it twice a week. We adopted this procedure for two reason: i) 
first, by monitoring the changes in their volume it is possible to discriminate more accurately 
if the compounds act as cytostatic (stabilizing spheroids volume) or cytotoxic (leading to 
volume decrease); ii) second, drug removal mimics the in vivo blood clearance and so, the 
recovery period allow to establish whether the spheroids resume proliferation. It should be 
noted that a similarity exists between the in vitro experimental approach that we carried out 
and the in vivo procedure that assess tumor regression, which measure the change in the tumor 
mass volume for prolonged times. 
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First of all, we challenged MCTS  with cisplatin. Spheroids were followed in vitro up to one 
month for BR95 (Figure 57a), whereas up to 10 days for HCT-116 cells (Figure 57b).  
 
 
FIGURE 57. a) BR95 spheroids; b) HCT 116 spheroids. Spheroids were treated with increasing concentrations of cisplatin 
(reported in the legends) from day 0 to day 3, then the recovery lasted to the maximal control growth. The time zero 
volume was used for normalization of the fold increase. 
 
In the initial phase of recovery (from 3 to 7 days), we observed that low concentration was 
initially stopped the growth, which restarted after 14 days and 7 days for BR95 and HCT 116 
spheroids, respectively. The growth was arrested suggesting that cisplatin elicited a cytostatic 
effect, with concentration similar to the IC50 values. Higher concentrations exerted a cytotoxic 
effect, leading to the loss of spheroids. 
Then, platinum(IV) complexes were tested on BR95 spheroids only in order to check their 
activity in MPM. 
Complexes 6 and 7 showed a behavior comparable to that of cisplatin, since the growth was 
curbed at low concentration (Figure 58a, 58b) . Lastly, both 8 and 9 showed the most 
promising results, since also at low concentration cytotoxic effect was observed (leading to a 
drop of spheroid volume) (Figure 58c, 58d). Moreover, high concentration sometimes induced 
an initial swelling (due to loss of intracellular contacts and consequently, spheroids integrity), 
followed by the  spheroid disintegration. 
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FIGURE 58. BR95 spheroids treated with increasing concentrations (reported in the legends)of complexes 6, 7, 8 and 9 from 
day 0 to day 3, then the recovery lasted to the maximal control growth. The time zero volume was used for normalization of 
the fold increase. 
Since the lipophilicity of the compounds increased in the following order:  cisplatin < 6 < 7 < 
8 < 9 (Table 9) the antiproliferative activity of Pt(IV) complexes correlates with their 
lipophilicity. 
Compound tR (min) LogK’90 LogPo/w Solubility (mM) 
6 2.598 -0.404 -1.922 0.598 ± 0.008 
7 2.732 -0.331 0.388 0.138 ± 0.048 
8 3.044 0.198 1.142 0.002 ± 0.001 
9 3.744 0.004 4.1425 (from 
LogK’90) 
< 0.00008 
TABLE 9. Lipophilicity and water solubility. Data are means ± standard deviation of at least 3 replicates. The logPo/w  values 
and  logK’90  values of complexes 6-8 were correlated with a linear equation that was used to calculated the logPo/w  values 
of compound 9 starting from its logK’90. 
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Pt(IV) complexes with aromatic carboxylate as axial ligands 
It was reported that the introduction of aryl groups as axial ligands can improve the 
intracellular uptake of the compounds, since they confer higher lipophilicity and facilitate the 
transport across the cell membrane [200]. 
Based of this rationale, we studied two series of Pt(IV) complexes, with different carrier 
groups. Both series had aromatic carboxylate ligands of increasing length (benzoate, phenyl-
acetate and dihydrocinnamate). 
The first series included Pt(IV) complexes sharing cisplatin as Pt(II) common precursor, 
namely complex 10 (trans,cis,cis-[Pt(C6H5COO)2Cl2(NH3)2]), 11 (trans,cis,cis-
[Pt(C6H5CH2COO)2Cl2(NH3)2]) and 12 (trans,cis,cis-[Pt(C6H5(CH2)2COO)2Cl2(NH3)2]) 
On the contrary, the second series consists of  Pt(IV) complexes bearing 1R,2R-
diaminecyclohexane (1R,2R-DACH) as carrier group, that is exactly the same of oxaliplatin, 
namely 13 (cis, trans, cis-(1R,2R-DACH)[Pt(C6H5COO)2Cl2]), 14 (cis, trans, cis-(1R,2R-
DACH [Pt(C6H5CH2COO)2Cl2]) and 15 (cis, trans, cis-(1R,2R-DACH) 
[Pt(C6H5(CH2)2COO)2Cl2]). 
In order to check if they retained anticancer activity against MPM, Pt(IV)complexes 10-15 
were tested both on the four MPM cell lines and on the healthy human mesothelial cells. 
 Moreover, their antiproliferative ability exerted against MPM was compared to that observed 
against other ovarian cancer (A2780 cell line), known to be high responsive to platinum-based 
chemotherapy, and against colon tumor (HCT-116 cell lines), regarded chemoresistance to 
cisplatin but sensitive to oxaliplatin.  
As expected, A2780 cells resulted the most responsive ones to both series whereas the MPM 
cell lines proved to be the less sensitive, confirming again their intrinsic chemoresistance. 
Pt(IV) complexes showed activity around three orders of magnitude higher than that of 
cisplatin,.  
On MPM, complexes 10-12  were around ten times more active than their Pt(II) analogues. 
However, complexes belonging to the same series showed a similar biological activity. This 
implies that the activity of the Pt(IV)complexes provided with aryl axial ligands does not 
considerably raise with increasing axial chain length (Table 10).    
However, it should be noted that the increase of the length of axial chain lead to a gain on 
selectivity against malignant cells.  Moreover, these complexes are able to circumvent 
cisplatin resistance, showing a resistance factor three times lower than cisplatin (Table 10).  
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 Cisplatin 10 11 12 
A2780 0.5 ± 0.1 ×10
-6
 4  ± 1×10
-9
 60 ± 3×10
-9
 5 ± 1×10
-9
 
HCT-116 2.3 ± 0.3×10
-6
 5 ± 10×10
-9
 0.21 ± 0.05×10
-6
 50 ± 0.6 ×10
-8
 
HMC 6.7 ± 1.2×10
-6
 0.32 ± 0.05×10
-6
 4.16 ± 0.8×10
-6
 0.9 ± 0.42×10
-6
 
BR95 6.2 ± 0.9×10
-6 
(1.1) 
0.33 ± 0.09×10
-6 
(0.97) 
1.97 ± 0.64×10
-6 
(2.1) 
0.53 ± 0.006×10
-6 
(1.7) 
MG06 4.1 ± 1.5×10
-6  
(1.6) 
0.48 ± 0.09×10
-6 
(0.73) 
1.24 ± 0.57×10
-6 
(3.35) 
0.71 ± 0.57×10
-6 
(1.27) 
MM98 3.2 ± 1.0×10
-6 
(2.1) 
0.12 ± 0.032×10
-6
 
(2.7) 
0.64 ± 0.028×10
-6 
(6.5) 
0.2 ± 0.073×10
-6 
(4.5) 
MM98R 19.4 ± 2.8×10
-6  
(-) 
0.47 ± 0.085×10
-6 
(0.68) 
1.23 ± 0.33×10
-6
 
(3.38) 
0.44 ± 0.12×10
-6 
(2) 
RF 6.1 3.9 1.9 2.2 
TABLE 10. IC50 values (M) obtained after 72 h CT.  
Data in brackets reports the selectivity index, SI, i.e., the ratio between IC50 (HMC) and the IC50 on the tumor MPM cell 
line.  
a 
Resistance Factor, RF = IC50 MM98R / IC50 MM98. 
A similar biological behavior was observed for the 13-15, belonging to the other series, 
corroborating previous observations: these complexes showed a similar biological activity, in 
spite of the increasing length of the axial aromatic chains.  
Further investigations of these complexes are in progress, in order to dissect the molecular 
basis of biological effect observed.  
Complexes 13-15 appeared more effective than oxaliplatin, i.e their Pt(II) counterparts used in 
clinic, and hugely by-passed cisplatin resistance, since showed a better RF than cisplatin 
(Table 11). 
 1R,2R-DACH-Cl2 Oxaliplatin 13 14 15 
A2780 0.12 ± 0.04×10
-6
 0.17 ± 0.01×10
-6
 2.2 ± 3×10-9 3.6 ± 0.9×10-9 1.3 ± 1 ×10-9 
HCT-
116 
0.275 ± 0.028×10
-6
 0.33 ± 
0.015×10
-6
 
2.6 ± 0.4×10-9 11 ± 0.1×10-8 5 ± 0.1×10-9 
HMC 0.8 ± 0.1×10
-6
 4.9 ± 0.5×10-6 0.13 ± 0.08×10-6 0.23 ± 
0.07×10-6 
0.15 ± 0.08×10-6 
BR95 1 ± 0.2×10
-6 
(0.8) 
2.4 ± 0.7×10-6 
(2) 
21 ± 0.5×10-8 
(6.2) 
20 ± 0.5×10-8 
(11.5) 
14 ± 0.7×10-8 
(10.7) 
MG06 0.8 ± 0.2×10
-6 
(1) 
3 ± 0.9×10-6 
(1.6) 
40 ± 0.2×10-8 
(3.2) 
0.9 ± 0.08×10-6 
(0.2) 
80 ± 20 ×10-8 
(1.9) 
MM98 2.2 ± 0.4×10
-6 
(0.36) 
4.4 ± 0.8×10-6 
(1.1) 
15 ± 3×10-8 
(8.6) 
60 ± 0.2×10-8 
(3.8) 
60 ± 20×10-8 
(2.5) 
MM98R 2.5 ± 0.6×10
-6 
(0.32) 
3.8 ± 0.9×10-6 
(1.29) 
20 ± 0.3×10-8 
(6.5) 
30 ± 0.1×10-8 
(7.6) 
70 ± 30×10-8 
(2.1) 
a
RF 1.1 0.9 1.3 0.5 1.7 
TABLE 11. IC50 values (M) obtained after 72 h CT.  
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Data in brackets reports the selectivity index, SI, i.e., the ratio between IC50 (HMC) and the IC50 on the tumor MPM cell 
line. 
a 
Resistance Factor, RF = IC50 MM98R / IC50 MM98. 
 
In order to verify whether the different cytotoxicity observed for complex 10 is affected by a 
different cell accumulation, the cellular uptake of complex 10 was determined on A2780 
HCT116 cell lines. The results support the activity data: the very lipophilic complex  10 
(Table 12) enters cell in a superior extent than cisplatin. Indeed, as shown in Table 13, 10 
intracellular uptake is 30 and 120 times higher than that observed with cisplatin on A2780 and 
HCT-116 cell lines, respectively. 
 
 
 
 
 
 
 
TABLE 12. logK’0 values of cisplatin and 10 
 
 
 Control Cisplatin 10 
A2780 0.09 ± 0.09 1.78 ± 0.57 54.71 ± 12.07 
HCT-116 0.05 ± 0.01 1.83 ± 0.5 214.65 ± 37.28 
TABLE 13. Uptake (ng Pt/10
6
 cells) after 4h of treatment con 10 M with each compound  
 
 
 
 
 
 
 
 
 
Compound log k0 
cisplatin -0.567 
10 3.022 
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C-Myc inhibition to enhance cisplatin-based MPM 
chemotherapy  
It has been reported that (+)-JQ1 reduce expression of c-MYC and its target genes, prompting 
to cell-cycle arrest and cell senescence in many tumoral models, with encouraging in vivo 
results [124][205]. Furthermore, JQ1 has been shown to act on solid tumour cells through  
FOS-Like antigen 1 (FOSL1) modulation, in a cell-line dependent manner [206]. c-MYC 
suppression enhanced the effectiveness of cisplatin in osteosarcoma and melanoma [207] and 
recently, it has been reported that a virus vector encoding the c-Myc repressor FIR showed 
synergistic antitumor effects in combination with cisplatin in vitro e in vivo in the treatment of 
MPM [207]. 
Thus, we hypothesized that JQ1 could enhance cisplatin-based chemotherapy in MPM. 
In accordance with the in vitro previous results, As shown in Table 14, (+)-JQ1 resulted far 
more active than is enantiomer (-)-JQ1. So, in the following investigations we considered 
only the more potent enatiomer (hereafter (+)-JQ1 was simply defined as JQ1). 
The MM98 and MM98R sarcomatous cell lines resulted more responsive to JQ1 than 
epitheliod an mixed phenotypes; in addition, it exerted a cytotoxic activity tenfold more high 
than cisplatin. On the contrary, JQ1 was threefold more potent than cisplatin in BR95 and 
MG06 cell lines. Notably, JQ1 overcame cisplatin resistance lowering the resistance factor 
value (RF = 2).  
It should be noted that JQ1 acts in a quite selective way against malignant cells. The 
selectivity is ascribed to expression of its target, c-myc, that is low in normal cells but it is 
elevated in a broad range of human cancers, including MPM [208].  
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 (-)-JQ1 (+)-JQ1 Cisplatin 
HMC 5.3 ± 0.9 3.1 ± 0.9 6.7  1.2 
BR95 3.9 ± 1.0 
(1.4) 
2.2 ± 0.6 
(1.4) 
6.2 ± 0.9 
(1.2) 
MG06 3.0 ± 0.4 
(1.8) 
1.0 ± 0.3 
(3.1) 
4.1 ± 1.5 
(1.8) 
MM98 3.8 ± 0.6 
(1.4) 
0.089 ± 0.6 
(31.6) 
3.2 ± 1.0 
(2.3) 
MM98R 2.8 ± 0.2 
(1.9) 
0.18 ± 0.08 
(17.2) 
19.4 ± 2.8 
(0.4) 
RF
a 0.7 2.0 6.1 
 
TABLE 14.  IC50 values (intended as M concentrations) obtained after 72h of treatment.  Data in brackets reports the 
selectivity index, SI, i.e., the ratio between IC50 (HMC) and the IC50 on the tumor MPM cell line.  
a 
Resistance Factor, RF = IC50 MM98R / IC50 MM98. 
Based on these encouraging data, a drug combination study was performed, in order to: i) 
reduce cisplatin dosage, ii) minimize its side effects and so, iii) improve therapeutic 
compliance (term that refers to the match between medical prescriptions and their applications 
by the patient in order to obtain the cure of an illness). 
We employed cisplatin and JQ1 given simultaneously at fixed molar ratio (10:1 on 
sarcomatous cells and 3:1 on epithelial, mixed and healthy cells, chosen according to the ratio 
of IC50 values found for cisplatin and JQ1).  
For the sake of clarity, in Table 15 only the Combination Index (CI) values obtained for the 
combination that gave 50 % growth inhibition (FA=0.5) are reported. The combination 
resulted additive on both sarcomatous and epitheliod cell lines, whereas it resulted synergistic 
on MG06 cells only. Interestingly, the pharmacological association induced a little 
antagonistic effect on non-tumoral HMC cell lines, indicating selectivity.  
 
 HMC BR95 MG06 MM98 MM98R 
Cisplatin + (+)-JQ1 1.20 ± 0.07 1.08 ± 0.19 0.38 ± 0.04 0.79 ± 0.18 1.06 ± 0.24 
TABLE 15. combination Index (CI) was obtained for the drug combination that gave 50% growth inhibition (FA=0.5). CI < 1: 
synergism; CI around 1:  additive; CI> 1: antagonism.  
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These data correlate with the activation of caspase-3. MG06, BR95 and HMC cells were 
treated with 7.5 M CDDP, 2.5 M JQ1, or both, while MM98 and MM98R cells were 
treated with 2.5 M CDDP, 0.25 M JQ1, or both. As shown in Table 16, caspase-3 activity 
was almost undetectable in HMC and MM98. In MM98R, JQ1 induced a slight activation, 
which increased in the combination with CDDP. A similar behavior was observed in BR95, 
but with higher caspase-3 activities. In MG06, both CDDP and JQ1 induced caspase-3 
activation, with the latter giving similar values as in the combination. CDDP alone induced a 
strong caspase-3 activation in the positive control (A2780). 
 
 
TABLE 16. Caspase-3 activity (arbitrary units/min) ± standard deviation after 24h of treatment. The human ovaric carcinoma 
cell line A2780, treated with 10 M cisplatin, was used as positive control. After cell lysis, the caspase-3 fluorescent 
substrate Ac-DEVD-AFC was followed for 1 h, normalized over the blank and fitted with a linear kinetic. The slope, standing 
for the caspase-3 activity is the average from duplicate experiments. The caspase-3 inhibitor Ac-DEVD-CHO  suppressed 
every signal (for the sake of clarity, data are not shown). 
Since JQ1 is known to exert its cytostatic effect by means of senescence induction [205], 
which could be also initiated by cisplatin [209], the analysis of senescent cells after the same 
combination protocol was performed. It should be recall that an increasing number of reports 
indicate that senescence could be a potential therapeutic treatment to overcome drug 
resistance in solid tumors [210] [211].  
Interestingly, cisplatin did not trigger senescence on HMC cells (within this experimental 
range of concentrations) and slightly decreased senescence induction due to JQ1 (Figure 59a). 
Thus, the antagonistic effect between JQ1 and cisplatin in antiproliferative activity on these 
healthy cells could be ascribed to an antagonistic effect in senescence induction. Accordingly,  
high concentrations of cisplatin, exerted a cytostatic effect on this cell line. 
Cells Control CDDP JQ1  JQ1+CDDP 
HMC  8.4±3.1 3.0±0.7 24.3±4.4 23.1±18.4 
BR95 48.9±18.0 55.5±1.4 194.2±5.0 336.4±50.3 
MG06 40.0±5.9 172.0±40.2 358.7±52.7 384.0±27.3 
MM98 0.8±0.3 10.6±3.4 14.4±10.4 32.7±20.7 
MM98R 3.6±2.5 10.0±9.1 48.3±1.8 60.0±9.0 
A2780 24.2±8.9 709.5±51.4 - - 
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In MG06 (Figure 59b), a bumpy fall in the number of remaining  cells was observed in the 
same experimental conditions, thus confirming the strong synergistic effect.  On BR95 
(Figure 59c), MM98 (Figure 59d) and MM98R cells (Figure 59e), the combination seemed to 
be the orthogonal sum of the effects observed for cisplatin and JQ1 in single treatments 
(higher level of senescent cells, top right corner of each plot). Thus, the additive effect 
correlated once again with senescence induction. 
These data indicate that senescence is the main mechanism of action underlying the 
effectiveness of the combination between cisplatin and JQ1.  
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FIGURE 59. Contour plots of % of SA--gal positive (senescent) cells after 3 days of treatment, indicated by the legend 
located on the right of each graph. From top to bottom: a)HMC; b) MG06; c)BR95; d) MM98 and e)MM98R. 
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We further investigated the trend of senescence after three days of continuous treatment 
(3CT) and four more days of recovery (4R) in drug-free medium, to check if cells are able to 
revert their quiescence to a proliferant/viable state after drugs removal.  
Once again, a cell line-specific behaviour was observed: senescence level remained stable 
only in the non-tumor cell line (HMC, Figure 60a), while on MG06 cells (Figure 60b) high 
levels of senescence were observed as far as the recovery partially restored cellular viability. 
The percentage of senescent cells clearly decreased in BR95 (Figure 60c), MM98 (Figure 
60d), and MM8R (Figure 60e) cell lines, which means that the additive effect  in senescence 
induction is maintained until cells are challenged with the drugs.  
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FIGURE 60. Contour plots of % of SA--gal positive (senescent) cells after 3 days of treatment+ 4 days of recovery. From top 
to bottom: a)HMC; b) MG06; c)BR95; d) MM98 and e)MM98R. 
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Based on these observations, we checked if a sequential treatment of cisplatin, followed by 
repeated treatments with JQ1 should be beneficial.  We explored if the combination would be 
effective after prolonged exposure, the multicellular tumor spheroids (MCTS) of BR95 were 
employed. 
We treated BR95 spheroids with cisplatin (for 1 day) at the same concentrations as for the 
senescence experiments, followed by 3+3 days of treatment with JQ1 given at 1/3 
concentration in according to the dose ratio. As shown in Figure 60, while cisplatin alone (1 
CT + 3R+3R) induced the reduction of the spheroid volume with the higher concentration  (3 
M and 7.5 M) (Figure 61a), JQ1 (1R+ 3 CT+ 3 CT) simply counteracted the tumor growth 
(Figure 61b). Thus, cisplatin exerted cytostatic effect, while JQ1 resulted in cytostatic effect. 
The combination of the two drugs (1 CT + 3 CT JQ1 + 3 CT JQ1) gave better outcomes, 
showing the strongest volume decrease even at lower cisplatin concentration (Figure 61c). 
Thus, the sequential order of treatment give the better therapeutic outcomes and allows to 
reduce cisplatin concentration. 
Mannava et al. reported that  myc- depleted melanoma  cells undergo extensive DNA damage  
that is caused by the unexpression of thymidylate synthase (TS) and ribonucleotide reductase 
(RR)  and subsequent depletion of deoxyribonucleoside triphosphate (dNTPs) pools, leading 
to senescent phenotype [212]. These evidence might explain the strong cytotoxic effect 
induced by cisplatin-JQ1 sequential treatment:  it is likely that DNA-damage induced by 
cisplatin couldn’t be efficiently repaired because of  JQ1 ability to counteract TS  and RR 
activity  by means of c-myc inhibition. 
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Figure 61. BR95 spheroids fold volume.  a) treatment with cisplatin for 1 day, followed by drug-free medium for 3 days, and 
drug-free medium again for further 3 days; b) treatment with cisplatin for 1 day, followed by JQ1 for 3 days, and JQ1 again 
for further 3 days; c) treatment with drug-free medium for 1 day, followed by JQ1 for 3 days, and J JQ1 again for further 3 
days. 
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Evaluation of a Cobalt-based complex as candidate drug 
for MPM treatment 
Malignant pleural mesothelioma (MPM) is a fatal malignancy related to previous asbestos 
exposure. Asbestos generates  a prolonged state of inflammation  that enhances the expression 
of inducible enzymes causing, inter alia, up-regulation of cyclooxigenase-2 (COX-2) [158].  
It is known that prostaglandin E2 (PGE2), the main COX-2 metabolite,  impacts several 
pathways involved in carcinogenesis. Celecoxib, a COX-2 inhibitors, showed to have 
antineoplastic efficacy against MPM both in vitro and in vivo [213].  
Therefore, The aspirin derivative Co-Ass, [2-acetoxy-(2-
propynyl)benzoate]hexacarbonyldicobalt (Co-Co), was investigated as potential drug against 
MPM, and its biological properties was compared to those of both its analogue Co-EPM, 
hexacarbonyl[-(2-ethylphenyl)-methanol]dicobalt (Co-Co) and acetyl salicilic acid (aspirin 
or ASA). Co-EPM is deprived of its COX inhibition ability (that lie in acetyl group), whereas 
ASA is a well-know COX-2 inhibitor. 
First of all the antitumoral activity of the investigated compounds was explored on the MPM 
cell lines. As expected, ASA showed IC50 values 2-3 orders of magnitude higher than Co-ASS 
in all cell lines (Table 17). 
We found that Co-ASS was more active than the metal-reference drug cisplatin on cells 
having  sarcomatous phenotype, whereas it was 10 fold less potent on cells having epitheliod 
phenotype that showed equal sensitivity to both Co-Ass and Co-EPM. Moreover, both cobalt-
complexes were able to circumvent-cisplatin chemoresistance in MM98R cell lines, as proved 
by low RF values. 
Thus, Co-ASS acted in a selective way against the responsive sarcomatous phenotype MM98, 
while the opposite is true for the less sensitive BR95 and MG06 cell lines. Our data are in line 
with previous results, which highlighted that Co-Ass antiproliferative activity is highly 
dependent on the peculiarities of each tumoral cell line [214]. In order to  examine the weight 
of COX-2 inhibition on the different antiproliferative ability, Co-ASS and Co-EPM were also 
tested on two other tumor model cell lines: the human colon carcinoma HCT-116 (non-
expressing COX-2), and human lung cancer A549 (expressing COX-2). As predicted, the 
HCT-116 cells were less sensitive to Co-ASS than A549, but this difference in activity (IC50 
ratio = 1.9) was lower than that observed between BR95 and MM98 (IC50 ratio = 8.9) and 
MG06 and MM98 (IC50 ratio = 7.7). Moreover, Co-EPM showed a similar IC50 ratio in  HCT-
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116 and A549 of (1.4).  These data suggested that COX-2 inhibition might not the only 
mechanisms involved in the antiproliferative of Co-Ass on MPM (Table 17). 
 
 
 Co-ASS (M) 
(SI) 
Co-EPM (M) 
(SI) 
ASA (mM) 
(SI) 
Cisplatin (M) 
(SI) 
HCT-116 7.5  0.5 43  5 3.8  0.2 2.3  0.3 
A549 4.8  2.2 30.2  2.7 2.01  0.9 3.7  0.8 
BR95 15.1  2.6 
(0.4) 
 
25.7  5.6 
(2.1) 
0.6  0.3 
(4.5) 
6.2  0.9 
(1.2) 
MG06 24.7  4.8 
(0.3) 
19.7  3.2 
(2.7) 
1.5  0.4 
(1.8) 
4.1  1.5 
(1.8) 
MM98 1.7  0.7 
(3.6) 
25.2  5.2 
(2.1) 
4.6  0.4 
(0.6) 
3.2  1.0 
(2.3) 
MM98R 3.2  0.8 
(1.9) 
25.1  7.4 
(2.1) 
2.8  0.2 
(1) 
19.4  2.8 
(0.4) 
HMC 6.2  1.3 53.4  3.4 2.7  0.7 6.7  1.2 
RFa 1.9 1 0.6 6.1 
 
TABLE 17. IC50 values calculated after 72 h continuous treatment. 
a 
Resistance factor (RF)= IC50 (MM98R)/IC50 (MM98) 
b 
Selectivity Index (SI)= IC50 (HMC)/ IC50 malignant cell line 
These observations correlated with PGE2 levels, the main metabolite of COX-2, that pointed 
out that there wasn’t a reduction of enzyme activity (Figure 62). In particular, we observed a 
huge increase of PGE2 levels in BR95 cells  after exposure to both cobalt-complexes and 
ASA; this event should be conceived as a defense response operated by the cells to abrogate 
pro-death mechanisms. On the contrary, PGE2 levels remained stable on the more responsive 
MM98 cell lines, except after ASA treatment, that reduced them. 
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FIGURE 62. PGE2 levels in extracellular medium of BR95  and MM98 detected after 24h of CT with Co-ASS, Co-EPM, ASA at 
concentration around IC50. 
In order to explain if the cobalt-based complexes have a cytotoxic or cytostatic effect, their 
antiproliferative activity was compared by means of clonogenic assay employing the BR95 
and MM98 cell lines. As shown in Table 18,Co-ASS and Co-EPM gave more or less the same 
IC50 value as that obtained from the viability assay on both cell lines, indicating that its 
growth inhibition corresponds to a cytostatic effect on both phenotypes. On the contrary, Co-
Ass was far more active than Co-EPM in MM98 cells, standing for a strong cytotoxic activity.  
 Co-ASS (M) Co-EPM (M) 
BR95 28.0  2.3 28.6  0.9 
MM98 0.050  0.001 19.7  4.6 
TABLE 18. IC50 values obtained by clonogenic assay of BR95 and MM98 cell lines, challenged with 3 days CT and then 1 week 
recovery. 
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As previously reported, Co-ASS exert its cytotoxic effect inducing apoptosis: indeed,  
activated caspase-3, the main effector  caspase, was detected in MM98 cells only (Figure 63). 
The opposite  is true for BR95, for which we didn’t reveal caspase-3 activation, confirming 
the results of  clonogenic assay. 
 
 
 
 
 
 
 
 
 
 
FIGURE 63.  Percentage of caspase-3 activity in MM98 (dark grey) and BR95 (light grey) after 24h CT with increasing 
concentration of Co-Ass.  The corresponding data in the presence of the specific inhibitor Ac-DEVD-CHO are reported 
(empty symbols, dashed lines). 
 
Co-Ass induced apoptosis in MM98 through the intrinsic pathway, mitochondrial potential 
gradient () was affected by the treatment, as reported in Figure 64. Absence of  
dissipation in BR95 confirm again the reluctance of this cell lines to undergo cell death. 
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FIGURE 64.  Mitochondrial potential gradient () of BR95 (top, grey bars) and MM98 (bottom, dark bars), reported as 
percentage of the signal. Cells were treated for 24 h with increasing concentration of Co-ASS. 
 
The only common effect to both cell lines following a short treatment (2 h) with equitoxic 
cobalt-complexes  was the reduction of ROS/NOS levels (for sake of clarity, it must be 
pointed out that the fluorophore probe used, the dichlorofluoresceine-diacetate, H2DCF-DA, 
is able to detect both species), as shown in Figure 65.  ROS levels were assessed in order to 
verify if apoptosis induction was mediated by ROS/NOS generation, in a similar manner as 
the cobalt-salt CoCl2 [215]. Surprisingly, CoCl2 induced a significant ROS increase in in 
MM98 cells only that could be stopped by pre-treatment with N-acetylcysteine (NAC, an 
amino-acid derivative with antioxidant properties), but no change in ROS levels were 
observed in BR95 cells, showing that also the response to CoCl2 was cell-type specific.  
ASA induced a ROS increase in both cell lines, while the pre-treatment with NAC was not 
able to abrogate its ROS generation (Figure 65). Therefore, the ASA-moiety could not be  
responsible for the observed of antioxidant effect of Co-ASS, shared with Co-EPM. Thus, the 
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dicobalthexacarbonyl moiety and its decomposition products were the only remaining 
candidates responsible for such an antioxidant behavior. While the Co salts are excluded since 
they produce the opposite effect, while the released gaseous CO is the candidate for such a 
biochemical pathway. Interestingly, ROS decrease was also observed in chondrocytes treated 
with CO-releasing molecules (CO-RMs), leading to an overall inflammation decrease by 
decreasing oxidative stress and NO2 levels [216]. CO-RMs is a family of transition metal-
carbonyl complexes designed to release CO on decomposition in a controlled fashion, that 
includes the alkynehexacarbonyldicobalt (Co-Co) complexes. Thus, we be supposed that both 
the hexacarbonyldicobalt (Co-Co) derivatives, namely Co-ASS and Co-EPM, deliver CO into 
the cells exerting anti-inflammatory activity and causing ROS level drop [217].  
 
 
 
 
 
 
 
 
 
 
 
FIGURE 65. ROS levels of BR95 (light grey) and MM98 (dark grey); % DCF fluorescence was normalized upon % viability after 
2 h of treatment at equitoxic concentration, and reported as normalized mean fluorescence intensity (MFI). H2O2 was used 
as positive control. 
 
The  released CO inhibits with heme proteins, such as NOS, the enzyme that produces NO 
along with citrulline from arginine. NO and CO are two gaseous mediators that interplay in a 
intricate way, since NO counteracts CO generation and in turn, CO inhibits NOS activity, as 
simplified in Figure 66 [218].  
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FIGURE  66. CO is produced physiologically through the degradation of heme catalyzed by heme oxygenase (HO). The 
inducible isoform of the enzyme, HO-1, is activated in stressing conditions, as in various inflammatory  diseases. Gaseous 
CO inhibits NOS by binding to the NOS-heme moiety, leading to a fall of NO levels. 
 
Thus, CO would lead to reduced RNS, the more stable derivatives of NO .Therefore, the 
nitrite levels have been measured.  
HL-60 cells were stimulated byinterleukin-1 (IL-) to increase the production of NO and 
then treated with increasing concentration of Co-Ass and Co-EPM.  
As show in Figure 67, both cobalt-complexes prompted to nitrite levels fall to a similar extent 
(20 % and 25 % with Co-EPM and Co-ASS, respectively), confirming their CO-RM activity. 
 
 
 
FIGURE 67. Nitrite levels of HL-60 cells after 24 h of treatment with 5 mM, 10 mM and 20 mM of Co-EPM (white triangles) 
and Co-ASS (black filled circles). 
COX-2 is a heme proteins too. It explain how complexes with  Co2 (CO)6   cluster  could 
inhibit  COX activity, as it was previously reported [219].  
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ROS, COX-2 and NOS-dependent signaling converge in the nuclear transcription factor NF-
B, which has a central role in both inflammation and cancer, regulating the expression of 
proteins involved in cell survival and proliferation. The levels of NF-κB activity are ruled by 
ROS [220]. Therefore, the activity of NF-B was analyzed by means of its nuclear 
translocation. On BR95 cells, Co-ASS induced a huge jump of NF-B activity, while Co-
EPM and ASA did not affect its nuclear translocation. We supposed  that NF-B is 
responsible for the PGE2 increase, since it rules COX-2 expression [221].  
On the contrary, all drug treatments in the Co-ASS-sensitive MM98 decreased the NF-κB 
activity, with the strongest inhibition exerted by Co-ASS.  The decrease of  NF-κB activity 
induced by Co-ASS on MM98 explains its strong cytotoxic effect (Figure 68).  
Thus, Co-ASS modulates NF-κB positively or negatively in cell-specific way. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68.  activity of NF-κB was analyzed by means of its nuclear translocation after 24 h CT with the tested compounds 
ASA (light grey bars, upright lines), Co-EPM (grey bars, horizontal lines) and Co-ASS (dark grey bars, vertical lines). 
While the cytotoxic effect of Co-ASS on MM98 corresponds to apoptotic cell death, its 
cytostatic effect on BR95 had to be still explained. Cancer cells treated with 
chemotherapeutics can trigger senescence as a survival strategy or as an intermediate step 
towards cell death by means of a permanent growth inhibition. Senescence limits the 
propagation of cells with damaged DNA. Indeed, as NF-kB is activated, many cellular fates 
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occur ranging from cell survival to cell death or senescence [33]. Therefore, we supposed that 
senescence induction in BR95 cell lines should be responsible of biological responses 
triggered by alkynehexacarbonyldicobalt (Co-Co) complexes. Indeed, NOS inhibition can 
trigger cell senescence [222]. So, we checked the activity of the marker senescence-associated 
(SA) -galactosidase, after a prolonged treatment (one week), as shown in Figure 69. BR95 
cells resulted more prone to senescence, when challenged with each compound under study 
with respect to MM98. It should be noted that concentrations of Co-ASS above 10 M killed 
all MM98 cells, in accordance with its cytotoxic property. Cisplatin caused the highest level 
of senescent cells, followed by Co-EPM, Co-ASS, and ASA. The prolonged treatment with 
Co-EPM gave a significant amount of positive cells, as expected from its CO-RM, and 
consequent NOS-inhibiting activity (Figure 69). On the contrary, in both cell lines Co-ASS 
produced only few senescent cells. Therefore we hypothesized that the lack of senescence 
caused by Co-ASS should be rather ascribed to its ASA-portion. Indeed, it has been 
previously reported that ASA reduces cell senescence, even a low concentration (within the 
M range, as in the case of Co-ASS), triggering lipoxin synthesis by means of acetylation of 
COX-2 active site, which induce the restoration of the basal NOS activity [223].  
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FIGURE 69. SA β-galactosidase percentage of positive cells after one week of treatment with increasing concentrations of 
cisplatin (black filled circles), Co-EPM (light grey filled triangles), Co-EPM+ASA (light grey empty triangles, dashed line), Co-
ASS (grey filled squares) and ASA (black filled squares). Top: MM98, bottom: BR95. 
 
 
In order to verify if the ASA-like portion of Co-ASS counteracted the CORM-induced 
senescence, BR95 cells were challenged simultaneously with equimolar concentration of Co-
EPM and ASA. As shown in Figure  69, we observed a net reduction of senescent cells. Thus, 
the reduced senescence rate observed for Co-ASS treatment could be ascribed to the action of 
its ASA-like portion, counteracting the initial NO-inhibiting activity. 
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In perspective, Co-ASS would be better considered as aCO-NSAID agent (a CO-releasing 
molecule retaining the NSAID properties similar to NO [224] and H2S-NSAIDs [225]) than 
as an antitumor drug candidate. 
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Conclusions 
A microplate-based coating-free method to generate multicellular spheroids (MCTS) in vitro 
was optimized for drug screening purposes. The spheroid growth was easily obtained by 
simple seeding in round-bottomed polypropylene plates placed on orbital mixer within a CO2
 
incubator. Spheroids allowed to discriminate between the cytostatic and cytotoxic effect of the 
drugs that we investigated. 
We realized that targeting the GSH system for therapeutic purposes could be both a boon and 
a curse. Bi-functional complexes targeted to GST were an unsuccessful attempt, since GST 
inhibition by EA is not synergistic with cisplatin per se. 
On the contrary, picoplatin-based Pt(IV)complexes represented a more successful strategy. 
On one hand, GSH promotes the reduction of Pt(IV) to Pt(II), activating the pro-drugs in the 
cells, and on the other hand the presence of a bulky moiety hinders the GSH inactivation of 
the reduced Pt(II) metabolite. 
Good results were obtained from a series of dicarboxylateplatinum(IV) complexes, sharing 
the same carrier and equatorial leaving groups as cisplatin (i.e. the same equatorial structure), 
and bearing carboxylate ligands of different length in axial position. On the contrary, Pt(IV) 
complexes provided of aromatic carboxylate chains as axial ligands did not show a vastly gain 
of antitumor  activity compared to that of cisplatin. Analogues Pt(IV)complexes series, that 
differ for the presence of (1R,2R-DACH) moiety as carrier group, showed better performance.  
So, platinum(IV) complexes represent a quite promising strategy for malignant pleural 
mesothelioma and although we observed a correlation  between the antiproliferative activity 
of Pt(IV) complexes in vitro and their lipophilicity, a rational choice of the axial carboxylate 
ligands is needed.  
Furthermore, an innovative approach for MPM was explored, based on the hypothesis that 
targeting c-myc expression with JQ1 could enhance cisplatin activity. The combination 
resulted additive to synergistic on all MPM cell lines, and antagonistic on the healthy cells, 
showing selectivity towards the tumor. Although the mechanism of action underlying the 
effectiveness of the combination deserves for further investigations, our data showed that 
apoptosis and senescence are the main cell death pathways involved in the antitumor activity. 
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